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Background. Crohn’s disease (CD) is associated with multifactorial insult to the 
muscle-bone unit. The independent and combined effects of chronic 
inflammation, undernutrition, and exposure to glucocorticoids adversely affect 
bone and muscle mass accrual and maintenance in paediatric and adult CD, 
respectively.  
Aim. The overall aims of this thesis were to assess the muscle-bone unit in children 
and adults with CD and investigate the potential role for exercise to improve 
musculoskeletal outcomes. High-resolution MRI was used to comprehensively 
assess muscle-bone outcomes in paediatric and young adult with childhood onset 
CD managed with contemporary treatment strategies. Associations between CD 
and IBD with adverse musculoskeletal outcomes, in particular the risk of falls, 
were explored in a large population-based cohort of middle-aged and older adults 
using data from the UK Biobank research study. Subsequently, to explore the 
potential utility of exercise in CD and IBD, a systematic review was performed. 
Finally, the feasibility of jumping based exercise in CD was explored via an online 
survey followed by a short-term jumping-based exercise intervention in paediatric 
CD.  
Results. The primary results highlight persistent muscle-bone deficits in CD across 
different age groups, despite currently well controlled disease and contemporary 
management. High-resolution MRI revealed deficits in trabecular 
microarchitecture in paediatric but not young adult CD. Paediatric and young adult 
with childhood onset CD were both associated with poor muscle function, and 
young adults had around 20% lower muscle area, compared to healthy populations. 
Older adults with CD also displayed higher likelihood of pathological muscle 
weakness and falls compared to age-matched controls. Systematic review 
revealed little evidence on the utility of exercise for managing muscle-bone 
deficits in CD, although some studies identified a benefit of exercise to muscle 
function and bone mass and mild improvements in HRQoL. Particularly, the 
evidence for exercise in young or paediatric CD was almost non-existent. The 
feasibility survey suggested jumping exercise to be an acceptable and feasible 
intervention in adolescents and young adults with CD, with most respondents 
stating a willingness to exercise and intentions to participate in future exercise 
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research. In feasibility study of jumping exercise, the recruitment rate was lower 
than expected from survey. Still, jumping exercise appeared feasible as the small 
number who participated achieved high adherence to the protocol.  
Conclusions. This research provides valuable insight into the muscle-bone unit in 
CD across different age groups. Even in well controlled disease and under 
contemporary management, CD remains associated with adverse musculoskeletal 
outcomes, including low trabecular bone volume in paediatrics and low muscle 
mass in young adults. Poor muscle function was characteristic in these cohorts and 
was linked to increased risk of falls in early old adults with CD. These data further 
highlight the adverse muscle-bone unit in CD and emphasise the need for effective 
non-pharmacological strategies to address this. Preliminary data suggests exercise 
to be a feasible strategy for targeting muscle-bone outcomes in CD and future 
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1.1 Crohn’s Disease 
1.1.1 Overview 
Crohn’s disease (CD) is a chronic immune related disorder characterised by 
cyclical remitting and relapsing inflammation of the gastrointestinal (GI) tract. 
CD, alongside ulcerative colitis (UC), comprise the two main sub-types of 
inflammatory bowel disease (IBD). IBD is classified as either CD or UC based on 
endoscopic, histological, and radiological investigations, in line with 
accompanying clinical context. While CD and UC have some overlapping clinical 
characteristics, they have distinct differences which facilitate differential 
diagnoses and appropriate clinical response. Continuous inflammation of the 
mucosa and sub-mucosa that is confined to the colon is confirmatory of UC 1. 
Transmural inflammation localized to any region of the GI tract from mouth to 
anus, together with distinct characteristics such as cobblestone appearance, skip 
lesions, stricturing, or fistulae, are suggestive of CD 1,2. A third sub-type of IBD 
known as IBD-unclassified (IBDU) may be diagnosed based on pathology that is 
indeterminable as CD or UC. Classification of CD on the bases of age at diagnosis, 
disease location, and disease behaviour, is conducted according to the Paris 
disease classification 3. 
1.1.2 Aetiology and pathogenesis 
The aetiology of CD is complex, and the mechanisms not fully understood. 
Consensual understanding of CD pathogenesis suggests a major role and 
interaction between genetic and environmental factors, leading to intestinal 
dysbiosis 2. Genetic influence on CD pathogenesis is recognised by common 
familial aggregation 4 and the identification of multiple susceptibility loci 5. Most 
of the disease risk, however, is thought to be through exposure to specific 
environmental risk factors. A recent umbrella review of meta-analyses reported 
positive associations between onset of CD and multiple environmental risk factors. 
These included smoking, antibiotic exposure, vitamin D deficiency, and physical 
inactivity 6. The adverse associations between smoking 7 and antibiotic exposure 
8 with CD onset could be linked to negative alterations in gut microbiota. 
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Conversely, PA may promote positive changes in the microbiome 9 and is 
associated with reduced circulating pro-inflammatory cytokines 10,11, which could 
potentially confer protective effects against the onset of CD. Direct causal links 
between these factors and risk of CD, however, have not been established. 
Disease pathogenesis occurs when epithelial barrier function becomes degraded, 
allowing the translocation of luminal antigens into the intestinal wall 2. This 
triggers immune cell activation and expression of pro-inflammatory cytokines 12. 
Anti-inflammatory and regulatory mechanisms are inhibited in CD, resulting in an 
inability to adequately resolve acute inflammatory episodes. Activated immune 
cells thus become dysregulated and produce excessive levels of pro-inflammatory 
cytokines, leading to chronic inflammation and tissue destruction 12. Cytokines 
play a key role in CD pathogenesis and have been identified as contributory to 
intestinal inflammation, including tumour necrosis factor-α (TNF-α), interleukin 
(IL) -1β and IL-6 13. Furthermore, abundant pro-inflammatory cytokines also 
influence systemic effects and extra-intestinal manifestations of disease, such as 
musculoskeletal insult and growth failure in paediatric patients. The specific 
actions of pro-inflammatory cytokines on bone and muscle are discussed in Section 
1.4.2.1. 
1.1.3 Epidemiology 
The epidemiology of CD lends further insight into the influence of genetic and 
environmental factors on disease pathogenesis. Disease prevalence is highest in 
industrialised regions such as Europe (250 - 320 per 100,000 in Norway, UK, & 
Germany) and North America (~300 per 100,000 in Canada) 14,15. Recent estimates 
suggest a population prevalence of approximately 0.8% for IBD in Scotland, which 
is projected to increase to ~1.2% within the next decade 16. This increasing 
prevalence is due to low mortality and stable disease incidence rates, as observed 
in other high-income countries. Low-income countries have experienced a rapid 
increase in IBD incidence that parallels their rate of industrialisation and adoption 
of a ‘westernised’ lifestyle. For example, Brazil and Taiwan experienced annual 
percentage increase in CD incidence of +11% and +4%, respectively, across 
approximately two decades (1990 - 2010) 14. The emergence of IBD as a global 
disease highlights the need for cost-effective management strategies that will 
help alleviate the burden of disease independently of, or in conjunction with, 
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costly pharmacological therapies. The peak age of diagnosis occurs between the 
second and fourth decade of life, with a further spike in incidence between 50 to 
60 years 2. Approximately 25% of all new cases of CD are diagnosed in the 
paediatric age (age <17 years) with a peak age of onset between 10-14 years, 
concordant with a critical period of growth and pubertal development 17.  
1.1.4 Clinical characteristics 
Presenting symptoms of CD can vary widely, however the classic triad of symptoms 
are unsolicited weight loss, abdominal pain, and chronic diarrhoea 18. These 
symptoms alone are not definitive of CD and are often mistaken as infective 
pathology. The onset of CD is insidious, resulting in prolonged period of symptoms 
prior to diagnosis.  Diagnostic delay in CD has been associated with poorer disease 
outcomes, including increased need for surgery in adults 19, and more complicated 
disease and associated growth disturbance in paediatric patients 20. In children 
with CD, active inflammation can disrupt growth and pubertal development, and 
these can often be presenting clinical features prior to the onset of any 
gastrointestinal symptoms. Extra-intestinal manifestations are very common in 
CD, occurring in up to 50% of patients 21. These can be present at diagnosis or can 
develop later in the disease course. The most common secondary complications 
include arthralgia, osteopenia/osteoporosis, cutaneous involvement, and growth 
disturbance and pubertal delay in children 21. 
1.1.5 Assessment of disease activity 
Ongoing assessment of disease activity is a critical component in CD management 
and is conducted through various subjective and objective measures. In clinical 
practice, patients are routinely assessed using the validated Crohn’s disease 
activity index (CDAI; aged ≥18 years) 22 or its paediatric equivalent (PCDAI; aged 
<18 years) 23. These provide an assessment of disease activity based on seven-day 
history of symptoms, a physical examination, biochemical parameters, and extra-
intestinal manifestations. Disease activity is categorised as clinical remission 
(CDAI <150; PCDAI <12.5), mildly active (150 – 220; 12.5 – 40), moderately active 
(221 – 450; >40 – 57.5) or severe (>450; >57.5). A mathematically weighted PCDAI 
(wPCDAI) was developed that better discriminates between disease activity 
categories than the original and is a more feasible tool in clinical practice 24. The 
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threshold for a clinically meaningful response in CDAI has been reported as a 
reduction >100 points, whereas for the wPCDAI it is defined as a reduction of >17.5 
points. These indexes have an important role in clinical practice as they provide 
rapid feedback on current symptoms. Despite this, the subjectivity of reporting 
means they correlate poorly with objective measures of disease such as endoscopy 
25. However, endoscopic assessment is highly invasive and administered only when 
disease reassessment is clinically indicated.  
Faecal calprotectin has recently emerged as a useful objective marker of disease 
activity in CD for both diagnostic and monitoring purposes 26. Inflammatory insult 
to the intestines causes leakage of neutrophils into the lumen, of which 
calprotectin accounts for ~60% of the cytosolic protein 27. Faecal calprotectin can 
detect subclinical inflammation not picked up by CDAI 27 and can be used to 
predict response to therapy. Resultantly, calprotectin assessment has become 
routine in clinical practice and is used in conjunction with disease indexes to 
navigate clinical management. 
1.1.6 Disease management 
Management of CD prioritises effective symptom control through two core phases 
of treatment. At diagnosis, or during active disease flare, induction therapy is 
used to rapidly treat active inflammation and achieve remission 28. Maintenance 
therapy is then introduced to sustain remission for as long as possible, avoiding 
subsequent disease flares. Beyond symptom control, therapeutic goals are to 
improve intestinal healing, optimise nutritional status, and optimise growth and 
development in paediatric patients 29. Choice of pharmacological therapy is 
directed by national and international guidelines, dependant on disease location 
and phenotype 29. Response to therapy varies widely among patients and should 
be tailored to the individual. Individuals who fail to respond to conventional 
therapies may advance to surgical intervention.  
Historically, glucocorticoids (GC) have been first line induction therapy for severe 
CD. GC are highly effective, achieving a therapeutic response in up to 80% of 
patients 30,31. Despite high levels of clinical response, GC therapy is associated 
with a significant side-effect profile including mood disturbances, weight gain, 
and increased cardiovascular risk 32. Particularly, GC also have profound and 
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devastating effects in bone and muscle 33. The specific actions of GC in bone and 
muscle are highlighted in section 1.4.2.3. Briefly, they are associated with rapid 
and sustained bone loss 34, catabolism and fat infiltration of skeletal muscle 35, 
and contribute to growth and pubertal delays in children 36,37. The systemic 
toxicity of GC led to incorporation of GC free remission as a primary treatment 
outcome in CD research and clinical management. GC are not suitable as 
maintenance therapy and their use is closely monitored and tapered as quickly as 
is clinically viable to reduce risk of adverse effects.  
Exclusive enteral nutrition (EEN) has become preferred first line induction therapy 
for paediatric CD patients in the UK and other regions 29. This therapy consists of 
an eight-week, exclusively liquid diet and requires ongoing dietetic support to 
promote adherence. EEN has similarly high efficacy compared to GC, with up to 
80% achieving clinical remission 38. EEN, however, has few adverse side-effects 
and is associated with greater mucosal healing 39 and improved nutritional profile 
40 compared to GC. Adults with CD are not routinely treated with EEN as it was 
associated with significantly lower likelihood of clinical remission compared to GC 
in meta-analysis (Pooled OR: 0.65 [95% CI: 0.52, 0.82]) 41. These data were almost 
certainly influenced by non-adherence to therapy, with up to 40% of participants 
in some studies withdrawing from EEN due to issues with palatability. The 
restrictive nature of EEN means it is not a viable maintenance therapy, although 
research is ongoing to replicate the nutritional profile of EEN in a solid food-based 
diet. Preliminary data are promising, showing improved intestinal inflammation, 
good palatability, and positive influence on the gut microbiome 42. 
The advent of cytokine-targeting biological therapies has transformed care in CD 
and IBD. Antibodies targeting tumour necrosis factor alpha (TNF-α) and other 
cytokines have become cornerstone treatments in IBD. Early use of anti-TNF-α 
biologics in paediatric CD was around 15-20%, whereas now their use is seen in 
>50% of patients 43. Biologics are used as both induction and maintenance therapy 
in CD, often with concurrent immunosuppression from thiopurines or 
methotrexate 28,29,44. Combination therapy has been shown to improve drug levels 
while reducing formation of antibodies, thus delaying loss of response 45. Early 
introduction of anti-TNF-α has been associated with higher steroid- and surgery-
free remission in children at one year, and lower rates of osteoporosis, reduced 
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risk of bowel stenosis, and fewer healthcare consultations in adults 46. In 
paediatric patients, anti-TNF-α are associated with improvements in linear growth 
and biomarkers of muscle-bone 47-49, and reduced resection rates 50, although 
there is limited data on their long-term effects. Older adults with CD are less 
likely to be prescribed anti-TNF-α due to increased risk of opportunistic infections 
and issues with polypharmacy 51. 
There is currently a lack of data regarding the utility of non-pharmacological 
interventions in the management of CD. Interventions that can be implemented 
alongside pharmacological therapy warrant investigation as a way of potentially 




1.2 The muscle-bone unit 
1.2.1 Overview 
Bone and skeletal muscle are intricately linked across the lifespan, evidenced by 
their closely paralleled development, maintenance, and subsequent degradation. 
The mechanical relationship between bone and muscle is long established; 
however, bone and muscle have been also observed as important reciprocal 
regulators of one another through numerous crosstalk mechanisms. From this 
knowledge, the concept of a combined ‘muscle-bone unit’ has been developed, 
whereby their inherently linked physiology suggests one cannot be considered 
independently of the other. This section will briefly summarise the independent 
anatomy and functions of bone and skeletal muscle and review the mechanical 
and physiological relationships that underpin the muscle-bone unit. Adiposity of 
skeletal muscle and bone marrow will be reviewed, and regulators of the muscle-
bone unit across the lifespan will also be discussed. Finally, the topic of 
osteoporosis will be introduced. 
1.2.2 Bone 
1.2.2.1 Bone: function and anatomy 
Bone tissue is highly dynamic and serves multiple physiological functions. The 
skeleton provides physical apparatus for movement and protection of organs, 
contributes to haematopoiesis, regulates mineral homeostasis, and conducts 
important metabolic and endocrine functions. 
Bone is a composite material with structures hierarchically arranged from micro- 
to macroscopic level. Approximately 25% and 65% of bone mass is organic and 
inorganic material, respectively; with the remaining ~10% being water 52. The 
organic phase is predominantly (90%) type I collagen and non-collagenous proteins 
(10%). The inorganic phase is composed primarily of impure hydroxyapatite 
crystals. Microscopically, bone is comprised of an abundant network of type I 
collagen fibrils strengthened by the mineralised hydroxyapatite. These material 
properties provide the mechanical foundation of bone strength and any 
abnormalities in organic or inorganic structure can have marked effects on 
skeletal integrity 52.   
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Bone has two macrostructural compartments: cortical bone and trabecular bone. 
Cortical bone is a compact structure that constitutes the outer shell of most bones 
and the diaphyseal shaft of long bones. Cortical bone is characterised by the 
appearance of concentric lamellar bone organised as osteons around a central 
Haversian canal, through which vascular and neural networks travel (Figure 1-1). 
Cortical bone accounts for approximately 80% of total bone mass and has low 
porosity, thus providing great stiffness and high resistance to stress but low 
resistance to strain 53. 
 
Figure 1-1 Structural arrangement of cortical bone. 
Cortical bone structure is comprised of a network of osteons, each of which contain several layers 
of concentric lamellar bone formed around a central haversian canal. Created with BioRender.com.  
Trabecular bone, conversely, is a highly cancellous structure which occupies the 
metaphysis of long bones, plus the vertebrae and ribs. Trabecular bone is 
comprised of a lattice microarchitecture of plate and rod like struts anywhere 
from 50-800m thick (Figure 1-2). The high porosity and interconnected 
architecture of trabecular bone provides better elasticity compared to cortical 
bone 53. This improves resistance to strain and the ability to distribute mechanical 
loading effectively. Additionally, trabeculae preferentially orientate along the 
axis from which they experience the greatest mechanical strains (Figure 1-2), 




Figure 1-2 Trabecular bone structure. 
Trabecular bone structure within the (A) vertebrae and (B) proximal femur. (A) Trabecular plates are 
thicker and more mechanically efficient compared to trabecular rods [Adapted from Mosekilde 56]. 
(B) The organised orientation of trabeculae parallel to the axis of greatest mechanical strain is clear 
within the proximal femur [Adapted from Wolff 55]. 
1.2.2.2 Bone cells 
Bone cells, namely osteoblasts, osteoclasts, and osteocytes, each have distinct 
functions within bone. 
Osteoblasts are bone forming cells derived from the same bone marrow 
mesenchymal stem cells (MSCs) as adipocytes. MSCs are committed to osteoblast 
lineage under direction of key transcription factors such as Runx2 57. Mature 
osteoblasts make organic bone matrix (osteoid) by secreting large volumes of type 
I collagen together with other non-collagenous proteins 58. These cells have a short 
lifespan and undergo apoptosis after cessation of bone formation. Some, however, 
become embedded in the mineralised matrix and terminally differentiate into 
osteocytes. Osteoblasts partly regulate bone turnover through the relative 
expression of receptor activator of nuclear factor κB ligand (RANKL) and 
osteoprotegerin (OPG), which promote and inhibit osteoclastogenesis, 
respectively 59. 
Osteoclasts are multinucleated bone resorbing cells derived from the monocyte-
macrophage lineage (Figure 1-3). Pre-osteoclasts differentiate and fuse together 
under the influence of RANKL and macrophage colony stimulating factor 1 (M-CSF) 
60. These are the only cells capable of resorbing bone and do so by secreting 
Trabecular plates 
Trabecular rods A B 
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protons which acidify the hydroxyapatite in bone. Osteoclasts undergo apoptosis 
after bone resorption; however, their lifespan can be prolonged in the presence 
of GC excess or elevated pro-inflammatory cytokines 34,61. 
Osteocytes are the predominant cells in bone, accounting for 90 - 95% of all 
skeletal cells in adults 62. These cells are terminally differentiated osteoblasts 
that have become embedded in the mineralised matrix. Osteocytes develop a 
dendritic morphology which creates a neural like network in bone through which 
signalling molecules can be transmitted (Figure 1-3). Osteocytes are the 
mechanosensory cells within bone and are regarded as the master regulators of 
bone turnover, expressing various molecules, and activating signalling pathways 
in the context or absence of mechanical loading 63. Mechanical loading 
downregulates osteocyte derived production of the osteoblast inhibitor sclerostin 
and increases production of the decoy RANKL receptor OPG, resulting in net 
formation activity 64. Conversely, mechanical disuse is associated with increased 
osteocyte expression of sclerostin and RANKL, and reduced OPG expression, 
leading to net bone resorption activity 64. 
 
Figure 1-3 Lineage of osteoblasts, osteoclasts, and osteocytes. 
Illustration of bone cell lineage. MSCs differentiate into pre-osteoblasts under direction of Runx2 and 
some eventually terminally differentiate into osteocytes. Osteocytes develop their dendritic 
morphology post-differentiation to create a neural network and facilitate transfer of signalling 
molecules. Osteoclasts are from monocyte-macrophage lineage and differentiate under direction of 
RANKL and M-CSF into large, multinucleated cells.  
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1.2.2.3 Bone growth and modelling 
Osteogenesis begins at around week seven of embryonic development and 
continues throughout the lifespan. Bone modelling refers to the independent and 
uncoupled processes of osteoblastic bone formation (i.e. ‘formation modelling’) 
or osteoclastic bone resorption (i.e. ‘resorption modelling’), each of which are 
critical during bone growth. Longitudinal growth occurs at the epiphyseal growth 
plates in the long bones of the axial and appendicular skeleton via endochondral 
ossification. The growth plate is delineated into morphologically distinct zones 
that are classified based on their primary cellular processes (Figure 1-4). 
Chondrocytes rapidly proliferate and hypertrophy, which creates longitudinal 
growth in the bone. The chondrocytes then signal adjacent blood vessels to begin 
vascularisation of the area before undergoing apoptosis and releasing vesicles that 
promote mineralisation of the extracellular matrix. Finally, bone tissue is formed 
at the zone of ossification by newly recruited osteoblasts 65. As bones grow 
longitudinally, formation modelling creates new metaphyseal trabeculae while 
older trabeculae undergo resorption modelling. This resorption modelling is 
necessary to remove trabeculae from the expanding diaphyseal shaft and create 
greater capacity for marrow storage. In humans, epiphyseal growth plates 
eventually fuse and become ossified, shortly after which linear growth ceases. 
 
Figure 1-4 Histology of the epiphyseal growth plate. 





Zone of ossification 
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To maintain mechanical integrity, bones must increase their width as they 
increase their length. Failure of bones to grow radially proportionate to length 
would increase susceptibility to bending stresses and ultimately fracture 67. Radial 
growth occurs via intramembranous ossification and is carefully coordinated to 
maintain the mechanical strength of bone. At the diaphysis, osteoblasts add bone 
tissue to the inner layer of the periosteum, known as periosteal apposition. 
Concurrently, endocortical resorption modelling takes place to increase the 
diameter of the marrow cavity 68 (Figure 1-5). This has the overall effect of 
increasing the diaphyseal width. Periosteal apposition also exceeds endocortical 
resorption, thus increasing cortical thickness and strength 69. At the metaphysis, 
endocortical apposition modelling and periosteal resorption modelling occur, 
ultimately reducing the diameter of the metaphysis to fit the expanding diaphysis 
(Figure 1-5). Radial growth occurs much more slowly than longitudinal growth, 
especially during periods of rapid linear growth. This may create a transient 
mechanical deficit that is thought to contribute to the increased incidence of 
fractures observed in early pubertal children 70. Unlike longitudinal growth, 
periosteal apposition continues throughout the adult lifespan, although at a much-
reduced rate. Longitudinal and radial growth and their effects on bone strength 
are regulated by several physiological and mechanical factors (discussed in section 
1.2.5).  
 
Figure 1-5 Bone growth and modelling at the diaphysis and metaphysis. 
(I) Longitudinal growth occurs via endochondral ossification. (II) Periosteal resorption occurs to fit 
the old metaphysis with the diaphysis (metaphyseal in-wasting). (III) Central metaphyseal resorption 
modelling occurs to create space for marrow storage in the newly formed diaphysis. (IV & V) 
Periosteal apposition and endocortical resorption modelling occur simultaneously to expand the 
medullary cavity [From Rauch, 2012 71]. 
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1.2.2.4 Bone remodelling 
Bone remodelling relates to the coordinated and coupled activity of osteoblasts 
and osteoclasts at a single site, whereby old bone is resorbed and replaced by new 
tissue. The remodelling cycle occurs within a bone multicellular unit (BMU), 
controlled by the RANKL/OPG system and other factors 59. Remodelling occurs in 
five distinct phases (Figure 1-6). First, osteoclast precursors are recruited, then 
differentiate and fuse to become mature multinucleated osteoclasts (Activation 
phase). Osteoclasts then bind to the bone surface and begin actively dissolving 
mineral and detaching collagen fragments (Resorption phase). Resorption 
eventually ceases and osteoblasts are recruited to begin bone formation under the 
direction of several growth factors including IGF-1 and transforming growth factor 
beta (TGF-β) 72 (Reversal phase). Osteoblasts subsequently lay new type I collagen 
rich organic matrix within the resorption cavity for the deposit of inorganic 
hydroxyapatite (Formation phase). Finally, bone formation ceases, and the bone 
surface is covered with bone lining cells (Quiescent phase). In healthy individuals 
a typical bone remodelling cycle is thought to take approximately 3-4 months, 
although mineralisation of newly formed matrix continues for several months 
thereafter 73. 
 
Figure 1-6 Bone remodelling cycle. 
Illustration of sequential bone remodelling cycle in trabeculae. Osteocytes sense microdamage in 
canaliculi and signal osteoblast lineage cells to express RANKL and M-CSF to activate 
osteoclastogenesis (activation). Activated osteoclasts bind to and resorb the bone matrix 
(resorption). Osteoclasts undergo apoptosis and osteoblast precursors are recruited by growth 
factors (reversal). Precursors mature into active osteoblasts and synthesize new bone matrix 
(formation) which become mineralised over the proceeding several months (quiescent). [Adapted 
from Seeman and Delmas, 2006 72]. 
Activation Resorption Reversal Formation Quiescent 
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Bone remodelling is independent of skeletal growth and occurs across the entire 
lifespan. It is a critical mechanism for the maintenance and repair of bone mass, 
as well as mineral homeostasis. Targeted bone remodelling occurs in response to 
local events such as osteocyte apoptosis or microdamage 74. Stochastic 
remodelling is linked to calcium homeostasis 74. Remodelling activity is tightly 
regulated to ensure that resorption and formation activity are closely coupled. In 
growing children, remodelling is balanced towards slightly increased formation 
activity and thus net bone formation. In older adults the opposite is true, where 
resorption exceeds formation resulting in net bone loss 72. Disordered bone 
remodelling can be pathological and lead to metabolic bone diseases such as 
osteoporosis. Bone remodelling is highly sensitive and influenced by various 
hormones, growth factors, and cytokines, as well as disease status and the 
mechanical environment. These regulators are discussed in section 1.2.5. 
1.2.2.5 Bone turnover markers 
The protracted timescale for an entire bone remodelling cycle makes short term 
investigation of material changes in bone difficult to assess. Assessing bone 
turnover through biochemical markers has become a useful method of assessing 
metabolic activity in bone. Bone formation activity can be assessed via bone 
specific alkaline phosphatase (BAP) or osteocalcin (OC). BAP is expressed by 
osteoblasts in very high quantities during the formation phase of bone remodelling 
and is regarded as a sensitive marker of formation activity 58,75. OC is the most 
abundant non-collagenous protein in bone. OC primarily binds with calcium in 
bone after post-transcriptional carboxylation and may represent activity of 
mature osteoblasts 76. The preferred marker of bone resorption activity is C-
terminal cross-linked telopeptide of type I collagen (CTX-1). CTX-1 contains 
collagen fragments and is highly specific to bone as osteoclasts do not participate 
in degradation of other bodily sources of collagen 77. Markers of bone turnover 
display large circadian variations and are sensitive to nutritional status and other 
factors. In children with delayed growth and puberty, like those with chronic 
diseases such as CD, it may not be acceptable to simply compare values with age 
and gender matched controls. 
15 
 
1.2.3 Bone marrow 
1.2.3.1 Overview 
Bone marrow is a multicellular tissue occupying approximately 80% of the 
medullary cavity in bone. Bone marrow consists of mainly red haematopoietic 
tissue in neonates that experiences rapid infiltration of adipocytes during 
childhood. This conversion to yellow, fatty tissue continues more gradually across 
adulthood 78. As the primary site of haematopoiesis, red marrow is preserved in 
adults mainly within the axial skeleton (including the proximal femur), while 
yellow marrow accumulates in the appendicular skeleton in a centripetal manner 
79. Bone marrow is the common origin of both haematopoietic stem cells (HSCs) 
and pluripotent MSCs. 
1.2.3.2 Mesenchymal stem cells (MSCs) 
Pluripotent MSCs have the capacity to proliferate in undifferentiated form prior 
to their commitment into tissue specific progenitors. In response to signalling 
factors and/or gene expression, MSCs may commit to several different cell 
lineages, including osteogenic and adipogenic cells. Differentiation to osteoblast 
or adipocyte lineage depends on two vital transcription factors, Runx2 and 
peroxisome proliferator-activated receptor γ (PPARγ), respectively. Runx2 and 
PPARγ are reciprocally regulated and the upregulation of one tends to occur with 
downregulation of the other 80. Evidence suggests that MSC commitment to 
osteogenic lineage occurs at the expense of adipogenesis and vice versa 81.  
1.2.3.3 Bone marrow adiposity 
The reciprocal regulation of osteoblast and adipocyte progenitors has led to 
increased exploration of the role of bone marrow adiposity (BMA) in skeletal 
health. MSCs are thought to develop an increased propensity for adipogenic 
differentiation under various conditions include aging and inflammation. This shift 
is thought to be one of the main factors associated with BMA accumulation 79. The 
physiology of BMA is not entirely understood and may depend on its location and 
relative composition. Indeed, the metabolic function and genetic expression of 
BMA has been found to differ depending on its location 78. This may be due to the 
relative haematopoietic capacity of proximal bone marrow in comparison to distal 
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fatty marrow 82. BMA has been positively associated with bone mineral content 
(BMC) in growing children, suggesting a potential role in skeletal development 83. 
Another study, however, found a negative relationship between BMA and cortical 
bone in children after adjusting for weight and body fat 84. The association 
between BMA and BMC is therefore likely mediated by weight or total body 
adiposity and may represent a negative marker of bone health when adjusted for 
these factors in children 85. In healthy adolescents and young adults, BMA of the 
lumbar spine is estimated at between 10-30% 86. BMA is generally higher in males 
until menopausal age, after which rapid accumulation occurs in females, 
potentially due to the loss of oestrogen. The utility of BMA as a potential marker 
of skeletal fragility has been demonstrated by its negative associations with 
volumetric bone mineral density (vBMD) and trabecular bone volume in both 
children and adults 85,87. Furthermore, BMA is elevated in conditions with 
associated skeletal morbidity, such as obesity, anorexia nervosa (AN), type 2 
diabetes mellitus (T2D), and endogenous GC excess 88-90. The paradoxical 
relationship between BMA and adiposity observed in AN suggest that BMA is 
metabolically distinct from other fat depots. It is currently unclear whether BMA 
plays a role in inflammatory mediated bone loss or whether its accumulation is 




1.2.4 Skeletal muscle 
1.2.4.1 Skeletal muscle: function and anatomy 
Skeletal muscle is a highly plastic tissue that contributes to many homeostatic 
functions. The primary mechanical function of muscle is to generate force for 
movement. Physiologically, skeletal muscle contributes to basal metabolic rate 
and maintenance of core temperature 91, is the primary site of glucose storage 
and metabolism 92 and stores amino acids 93. Skeletal muscle has also been 
identified as an endocrine organ through its release of so called ‘myokines’, which 
exert autocrine, paracrine, and endocrine functions – including within bone 94,95. 
Accounting for approximately 40% of total body mass, skeletal muscle is the most 
abundant tissue in humans. Muscle tissue is primarily composed of water (~75%) 
and protein (~20%) with a small amount of carbohydrates, lipids, and minerals. 
The size and orientation of individual skeletal muscles is dependent on their innate 
mechanical function. Anatomically, however, skeletal muscles share a common 
underlying structure. Muscles are arranged hierarchically into subunits of muscle 
cells (known as myofibers) and layers of connective tissue. This arrangement 
allows selective activation of specific regions or myofibers within a single muscle 
96. The connective tissue layers are rich in collagen that is ultimately entwined 
with the collagen in the muscle tendons. This facilitates near frictionless muscle 
contraction while maintaining the mechanical integrity of myofibers under large 
contractile forces. 
Myofibers are multinucleated cells with a long, cylindrical morphology (~10-100µm 
diameter, ~1-30cm length). During development, these cells form through the 
fusion of myoblasts. Myofibers have a surrounding plasma membrane 
(‘sarcolemma’) and contain several cellular organelles including mitochondria; a 
T tubule system responsible for conduction of action potentials to the interior of 
the cell; and sarcoplasmic reticulum responsible for the storage, release, and 
reuptake of calcium ions post-activation 96. Myofibers are comprised of many 
myofibrils, each of which contain millions of myofilaments (proteins) 97 (Figure 
1-7). These myofilaments are highly organized into successive units known 
sarcomeres, which form the basic contractile unit of skeletal muscle. Sarcomeres 
are arranged into alternating thick (myosin) and thin (actin) filaments that are 
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anchored between cytoskeletal structures known as Z-lines. Sarcomeres arrange 
consecutively along the length of myofibrils. Sarcomeres generate force via 
excitation-contraction coupling in what is known as the sliding filament theory 
(Figure 1-8). 
Skeletal muscle also contains specialized myogenic precursors known as satellite 
cells, located between the sarcolemma and basal lamina of terminally 
differentiated myofibers. Satellite cells are the adult stem cells of skeletal muscle 
and play a critical role in the plasticity and regenerative capacity of muscle tissue 
98. Under the influence of myogenic factors, satellite cells fuse to damaged 
myofibers for repair, or fuse to each other to form new myofibers 99. The pool of 
available satellite cells reduces with age, leading to poorer muscle regeneration 
in older adults 100.  
 
Figure 1-7 Anatomy of skeletal muscle. 




Figure 1-8 Sliding filament theory of muscular contraction in a sarcomere. 
Illustration of the sliding filament theory of muscular contraction in a single sarcomere. Action 
potentials are received at the neuromuscular junction and transported into the myofiber through the 
T tubules. The following chain of molecular events results in the release of calcium ions into the 
sarcoplasm. These ultimately bind to troponin, altering the troponin-tropomyosin complex and 
exposing binding sites on actin filaments. Hydrolyzed myosin heads then bind to the actin filaments, 
creating new cross-bridges. Myosin releases its energy which pulls the actin filaments toward the 
centre of the sarcomere. During contraction, the A-band remains the same width, while the I-bands 
become smaller. This process happens concurrently in many thousands of consecutive sarcomeres, 
resulting in muscular contraction. (Created in BioRender.com). 
1.2.4.2 Muscle adiposity 
Infiltration of skeletal muscle with adipocytes is a common hallmark of aging 102 
and neuromuscular disease 103. Accumulation of adipocytes within muscle is 
positively associated with insulin resistance, which impairs the capacity for 
protein synthesis, ultimately leading to poor muscle mass and function 104. Muscle 
adiposity also expresses pro-inflammatory adipokines that could contribute to 
systemic inflammation and is associated with reduced bone strength in children 
and adults 105. 
Several mechanisms may contribute to the accumulation of adipocytes in skeletal 
muscle. In aging or chronic disease, chronically elevated pro-inflammatory 
cytokines may reduce the regenerative capacity of skeletal muscle. Excessive TNF-
α has been found to epigenetically alter muscle satellite cells via p38 mitogen 
activated protein kinase (MAPK) signalling, inhibiting myogenesis 106. A second 
population of stem cells located within muscle known as fibro/adipogenic 
progenitors (FAPs) can differentiate into adipocytes under conditions of injury or 
20 
 
GC excess 107. Sex steroid deficiency has been implicated in muscle fat 
accumulation in both men with prostate cancer undergoing androgen deprivation 
therapy 108 and ovariectomised rodents 109. The effects of sex steroid deficiency 
due to delayed puberty on muscle fat accumulation in children has not been 
established but appears biologically plausible. Disuse is also strongly associated 
with muscle fat infiltration as has been established in populations with immobility 
secondary to neuromuscular disease 103. Conversely, exercise intervention can 
effectively decrease muscle fat accumulation in older adults 102. The long-term 
implications of muscle fat infiltration and its contribution to systemic 
inflammation in CD is currently unknown; however, increased muscle fat has been 
associated with longer post-operative hospital stay in IBD patients 110. 
1.2.5 Regulators of the muscle-bone unit 
1.2.5.1 The mechanical muscle-bone unit 
Mechanical loading is a critical regulator of bone mass. Bone tissue is sensitive to 
its biomechanical environment and adapts accordingly to mechanical loading or 
disuse. This mechanical relationship is well described by Frost’s Mechanostat 
theory 111. Bone adaptation occurs secondary to mechanical loading to optimize 
bone mass and geometry in relation to functional demands. Bone experiences 
varying types of deformation when placed under mechanical loading from 
compressive, tensile and shear strains from muscle contraction and external 
forces. The mechanostat exists to ensure deformation remains within an 
acceptable physiological range to avoid spontaneous fracture, while meeting 
functional demands.  
The magnitude of strain experienced within bone from mechanical loading is 
perhaps the most important regulator of skeletal mass. The mechanostat 
mechanism functions as a non-linear continuum between the magnitude of strain 
and the resorptive, regenerative or formative activity within bone 53. A minimum 
effective strain is required to maintain current bone mass 112. If habitual 
mechanical loading falls below the minimum effective strain threshold, then 
osteoclast mediated bone resorption becomes upregulated to remove excess 
tissue 113. In the absence of mechanical loading, bone loss occurs rapidly in adults 
and bone fails to develop in children, leading to a markedly increased risk of 
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skeletal fragility. This has been clearly evidenced in studies of hindlimb suspension 
in animals 114 and in children with neuromuscular disorders associated with 
impaired mobility such as cerebral palsy 115 and Duchenne muscular dystrophy 
(DMD) 116. Mechanical loading within the normal physiological range results in 
maintenance of bone mass and structure, with similar levels of bone formation 
and resorption. Chronic exposure to mild supraphysiological mechanical loading, 
such as that experienced during resistance training or impact exercise, signals 
upregulation of bone formation activity which can lead to long term structural 
adaptations and improvements in bone strength 117-119. Adaptations to mechanical 
loading include increases in cortical thickness, cortical and trabecular vBMD, and 
trabecular bone volume. For example, the dominant arm of elite youth tennis 
players had 40% [ 12%] greater cortical bone cross sectional area of the humerus 
compared to the contralateral limb 120, highlighting the large site-specific effects 
of repeated exposure to various high-magnitude strains. Skeletal gains made 
through exercise can also confer a lifelong benefit to bone strength, as highlighted 
by the persistence of elevated cortical bone mass in the throwing arm of retired 
baseball players 121. The mechanostat model is highly dependent on other, non-
mechanical influences such as nutrition, hormonal, and disease status and cannot 
override the contribution of these factors. For example, the loss of bone 
protective estrogen in post-menopausal women causes rapid bone loss despite no 
changes in their habitual loading patterns 122. 
In growing children, increasing body mass and skeletal muscle mass results in 
higher magnitude of habitual loading of the skeleton from contracting muscle and 
gravitational forces. The increasing mechanical loads are sensed by 
mechanoreceptive osteocytes which subsequently signal osteoblasts to upregulate 
bone formation in areas where new bone is required to meet mechanical demands. 
This was nicely illustrated in a study of adolescents in whom peak velocity of lean 
body mass accretion was temporally followed by peak velocity in BMC accretion 
approximately 0.5 and 0.4 years later in girls and boys, respectively 123. As stated, 
this mechanism is sensitive to other factors including pubertal development and 
disease status, which have specific implications in the growing child. Children who 
fail to accrue muscle mass secondary to chronic disease may subsequently fail to 
accrue bone mass due to inadequate mechanical loading. Peak bone mass is one 
of the most important predictors of skeletal fragility later in life, therefore poor 
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muscle and bone accretion during growth may predispose these individuals to 
increased risk of sarcopenia, osteoporosis, and fractures as adults. 
1.2.5.2 Biochemical interaction between bone and muscle 
Muscle and bone express myokines and osteokines, respectively, that exert 
endocrine functions in the opposing tissue. Myostatin, the first myokine identified, 
is a potent negative regulator of skeletal muscle mass that is upregulated during 
periods of chronic inflammation and GC excess 124. In bone, myostatin promotes 
resorption, potentially through its actions in osteocytes, in which it has been 
demonstrated to upregulate expression of sclerostin and RANKL 125. Myostatin has 
also been found to inhibit bone regeneration after injury, whereas its inhibition 
promoted improved bone healing in models of T2D 126. 
Exercise induced IL-6 expression in skeletal muscle stimulates osteoclastogenesis 
by inducing RANKL expression in osteoblasts and osteocytes 127. This IL-6 mediated 
bone resorption pathway facilitates physiological adaptation to exercise, rather 
than acting as a pathological mechanism 128. Resorption releases uncarboxylated 
osteocalcin from the bone matrix, an osteokine with endocrine functions in 
skeletal muscle and other tissues 129. Osteocalcin increases insulin sensitivity and 
mediates nutrient uptake into myofibers in a dose dependent manner 128. 
Osteocalcin may also partly regulate muscle mass, as osteocalcin null mice 
displayed reduced muscle mass and exogenous osteocalcin administration 
increased muscle in older animals 130. This is indicative of a muscle-bone biological 
crosstalk mechanism that moderates the physiological responses to exercise. 
Muscle and bone specific expression of growth factors such as IGF-1 may have 
regulatory effects in the opposing tissue. Muscle derived IGF-1 is expressed after 
exercise and stimulates bone formation in local osteoblasts 131. Local skeletal IGF-
1 expression may also have anabolic effects in adjacent muscle, although to date 
no studies have assessed this. 
1.2.5.3 Regulators of bone and muscle 
The reciprocal regulatory relationship between bone and muscle is accompanied 
by their individual and combined regulation via systemic, local, and environmental 
factors. Bone and muscle development are primarily regulated by genetics, with 
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an estimated heritability of 50-80% for peak bone and muscle mass 132,133. The 
remaining variability in bone and muscle development and maintenance are 
regulated by physiological and environmental factors. 
1.2.5.3.1 Puberty 
Puberty is a critical period for the accrual of bone and muscle mass 134. Bone mass 
approximately doubles between the pre-pubertal and young adult age while true 
volumetric density is relatively unchanged. By late adolescence, approximately 
90% of peak adult bone mass will be attained. The effects of puberty on bone and 
muscle are mainly moderated by a surge in sex steroid production 135. Increased 
oestrogen expression is pivotal for the maturation and mineralisation of bone in 
both boys and girls during puberty 136, more so than testosterone. In early puberty, 
oestrogen may reduce the remodelling threshold of the bones mechanostat 
mechanisms, requiring lower mechanical loading to induce skeletal adaptation 137. 
This potentially explains the more rapid accrual of bone mass in girls in the pre-
pubertal years in comparison to boys, despite similar loading patterns. 
Testosterone expression upregulates androgen receptors in growth plate 
osteoblasts 138; however, the bone promoting effects of testosterone may also be 
mediated by greater mechanical strain due to increasing muscle mass. Sex steroids 
also play an important role in bone and muscle maintenance during adulthood, 
and their eventual declines are associated with significant loss in both tissues 136. 
Children with delayed onset or progression of puberty may fail to accrue adequate 
bone and muscle mass as a direct result of sex steroid deficiency, leading to 
persistent musculoskeletal deficits in adulthood. 
1.2.5.3.2 GH/IGF-1 axis 
The GH/IGF-1 axis is one of the primary regulators of linear skeletal growth and 
muscle accrual during childhood and puberty 139. GH and IGF-1 promote bone 
growth through endocrine effects and local action at the growth plate. GH 
supports proliferation of osteoblasts and chondrocytes and triggers bone formation 
in mature osteoblasts 140,141. GH also induces local IGF-1 expression and action at 
the growth plate, which stimulates linear growth 139,142. In skeletal muscle, the 
anabolic actions of GH are mediated by systemic and local IGF-1, which stimulate 
protein synthesis and reduces protein degradation 143. During puberty, the surge 
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in sex steroid production increases spontaneous GH secretion which further 
upregulates systemic and local IGF-1 production 144, leading to accelerated growth 
of bone and muscle. Children and adults with chronic inflammatory disease may 
display abnormalities in GH/IGF-1 axis including relative GH insufficiency or 
GH/IGF-1 resistance, which can inhibit anabolic processes in muscle and bone 145.  
1.2.5.3.3 Nutrition 
Nutritional status plays a central role in the development and maintenance of 
bone and muscle. Mechanisms affected by poor nutritional status include bone 
mineralisation, muscle protein synthesis, and GH/IGF-1 axis. The skeleton stores 
almost the entire bodily reserve of calcium, which is critical for accrual of bone 
mass and bone mineralisation 146. Calcium also acts as a signalling molecule and is 
essential for healthy muscular contraction. Calcium is not produced endogenously 
and is entirely obtained through nutritional consumption. As such, poor intake is 
associated with low bone mass in children and adults 147. Poor nutrition also 
adversely affects the GH/IGF-1 axis, inhibiting bone and muscle development 148. 
In human studies, poor nutritional status is associated with increased systemic GH, 
potentially due to downregulation of hepatic GH receptors 148,149. The onset of 
puberty is linked to nutritional status through the actions of leptin, an adipocyte-
derived hormone that is reduced in the context of undernutrition 150. Chronic 
undernutrition and low adiposity stores are therefore thought to be key regulators 
of delayed puberty and growth failure in children with chronic inflammatory 
disease. 
1.2.5.3.4 Physical activity & exercise 
The importance of PA as a regulator of muscle and bone is largely mediated by 
the influence of mechanical loading on these tissues (discussed in section 1.2.5.1). 
Observational data highlights that children and adults who participate in greater 
levels of moderate to vigorous PA (MVPA) have favourable bone mass compared to 
active and inactive peers 151. Individuals who participate in high-impact activities 
such as gymnastics are routinely reported as having higher bone mass than inactive 
controls or other active cohorts 152-155. As mentioned, skeletal adaptations are 
highly site-specific, as demonstrated by the large within-person variability in bone 
mass between dominant and non-dominant limbs of elite level athletes 120,121. The 
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long-term benefits of exercise induced gains in bone mass highlight the potential 
for exercise as an effective strategy for augmenting muscle-bone development 
and reducing risk of future musculoskeletal morbidity. The enhanced 
mechanosensitivity of bone in children and young people may provide an optimal 
window for the application of strategies to improve bone mass and strength via 
PA and exercise. Jumping based exercise interventions generating ground reaction 
forces in the range of three to five times bodyweight have been demonstrated to 
effectively increase bone mass in paediatric cohorts 117-119. Independently of gains 
in aBMD, chronic exposure to highly strenuous activity (i.e. military training) can 
lead to structural adaptations and improved bone strength in young women 156. 
Even in older adults, maintenance of a physically active lifestyle is associated with 
an attenuation in the rate of bone loss 157. 
Similarly, in skeletal muscle, PA and exercise are associated with better muscle 
mass, quality, and function across all ages 158,159. The structural and functional 
adaptations within skeletal muscle are highly dependent on the mode and 
intensity of PA and exercise. Resistance exercise is highly effective for inducing 
muscle hypertrophy and strength gains, primarily through its actions in stimulating 
muscle protein synthesis 160,161. A recent systematic review also suggested that 
plyometric training may be as effective at inducing gains in muscle mass when 
compared to traditional resistance training in previously untrained individuals, 
although this requires further investigation 162. Aside from improvements in muscle 
mass, PA and exercise also indirectly stimulate lipolysis via expression of myokines 
which inhibits the accumulation of muscle fat infiltration and maintains muscle 





Osteoporosis is a systemic disorder characterised by low bone mass and 
deterioration of bone microarchitecture (i.e. bone quality) which leads to 
compromised skeletal strength and increased risk of fracture 163. Osteoporosis is 
primarily an age-related disease of abnormal bone metabolism, whereby excessive 
bone resorption results in net bone loss 164. Secondary osteoporosis relates to bone 
loss that occurs because of other factors, such as chronic inflammatory disease, 
GC exposure, or impaired mobility 165. Secondary osteoporosis can occur at any 
age and can be caused by inadequate skeletal development in children, rather 
than bone loss per se 166.  
In adults, a clinical diagnosis of osteoporosis is based on DXA derived 
measurements of areal bone mineral density (aBMD). As an age-related disease, 
osteoporosis is typically diagnosed in older adults, in whom DXA aBMD T-score is 
strongly predictive of fracture risk. A clinical diagnosis of osteoporosis is 
confirmed by a DXA aBMD T-score < -2.5 SDS, compared to a healthy young adult. 
This threshold is used for the initiation of bone protective therapies such as 
bisphosphonates or anti-RANKL antibodies 164. Osteopenia, low bone mass that is 
not as pronounced as in osteoporosis, is characterised by an aBMD T-score of > -
2.5 < -1.0 SDS in adults. In these individuals, the calculation of fracture risk 
algorithm (FRAX) score may be used to guide clinical management of bone. This 
tool uses several demographic and environmental risk factors to calculate the ten-
year probability of a major osteoporotic fracture in adults aged >40 years 167. At 
present, there is no robust data linking aBMD with fracture risk in young adults, 
as fracture risk is generally very low. This means, however, that there is currently 
a lack of clinical guidelines for the management of osteoporosis in this cohort, 
including young adults who may have aBMD deficits secondary to chronic disease. 
In children, DXA aBMD is also not a useful predictor of fracture risk and paediatric 
osteoporosis is not clinically diagnosed by densitometry alone. Fractures occur in 
up to 50% of children 166, therefore the identification of fractures resultant of 
intrinsic skeletal fragility rather than typical childhood activities is necessary 168. 
The fracture centric approach to the clinical diagnosis of osteoporosis in 
paediatrics also considers the type of trauma required for fracture, with low 
trauma fracture or fragility fracture defined as fracture from standing, sitting or 
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no faster than walking pace. Paediatric osteoporosis can be diagnosed in a child 
with ≥1 nontraumatic vertebral compression fracture (VF), independently of aBMD 
assessment, as nontraumatic VF are associated with skeletal pathology 168. 
Alternatively, osteoporosis can be diagnosed in a child with an age- and body size-
adjusted aBMD Z-score < -2.0 SDS plus a clinical history of long bone fractures (≥2 
by age 10 years or ≥3 by age 19 years) 168. These guidelines seek to avoid 
overdiagnosis of skeletal fragility in otherwise healthy children who happen to 
experience multiple fractures. On the other hand, the lack of clinical context or 
mechanistic insight into long bone fractures in the updated ISCD guidelines may 
underdiagnose skeletal fragility in children with underlying associated risk factors 
or pathology 166. For example, children with CD, who have risk factors including 
chronic inflammation, nutritional deficits, and GC exposure, may benefit from a 
comprehensive skeletal evaluation after the occurrence of one long bone low 
trauma fracture. Yet, under current guidelines, this is not recommended; 
potentially delaying the identification of skeletal fragility until the occurrence of 
further fractures.  
These clinical definitions of osteoporosis in the elderly and young are developed 
to target those at the highest risk of fragility fractures, or who have already 
sustained fragility fractures, for treatment with bone protective therapies. Whilst 
such definitions may be useful in clinical practice to limit unnecessary bone 
protective therapies, these definitions and DXA densitometry-based evaluation do 
not provide detailed information on skeletal abnormalities. Subsequently, more 
advanced imaging methods are required for the detailed assessment of bone in 




1.3 Muscle-bone assessment methods 
1.3.1 Overview 
Collective evaluation of bone and muscle as an integrated unit in vivo is vital to 
our understanding of their close relationship across the lifespan in both health and 
disease. Currently, micro-computed tomography (µCT) and histomorphometry of 
bone biopsy is the ‘gold standard’ skeletal assessment. This is a highly invasive 
procedure that requires general anaesthetic in children and cannot concurrently 
evaluate muscle. Several non-invasive imaging methods for the assessment of the 
muscle-bone unit have been developed. Quantitative ultrasound (QUS), dual x-ray 
absorptiometry (DXA), peripheral quantitative computed tomography (pQCT) and 
advances in high-resolution magnetic resonance imaging (MRI) and spectroscopy 
(MRS) each have value in muscle-bone assessment. Several simple functional 
assessments are also available that may complement the use of imaging in 
assessing the muscle-bone unit. The application, suitability, and limitations of 
these methods for assessing muscle-bone will be discussed in the subsequent 
sections. 
1.3.2 Muscle-bone imaging 
1.3.2.1 Dual energy x-ray absorptiometry (DXA) 
1.3.2.1.1 Overview 
Dual energy x-ray absorptiometry (DXA) is the most widely used method of 
assessing bone health in both clinical and research settings. DXA scanners are 
widely available and thus routinely employed for assessment of body composition 
and bone monitoring. Indeed, DXA is the current ‘gold standard’ for clinical 
assessment of skeletal health and DXA derived areal bone mineral density (aBMD) 
is the primary outcome used in the assessment of osteoporosis 164. DXA can also 
be implemented for the assessment of total body or appendicular muscle mass 169. 
1.3.2.1.2 Technology 
DXA is used to assess body composition based on a three-compartment model – 
bone mineral content (BMC), fat mass (FM) and lean mass (LM). During scanning, 
the individual lies in a supine position on the bed. In modern scanners the x-ray 
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source generates a narrow fan beam containing high and low energy photons that 
are passed through the individual in the posterior-anterior direction towards a 
scanning arm containing a scintillation detector. Tissue dependent photon 
attenuation occurs with high density materials (i.e. bone) allowing fewer photons 
through than low density materials (i.e. lean and fat mass). The ratio of 
attenuation coefficient between the two energy peaks is subsequently calculated 
for each tissue compartment and algorithmically computed into appropriate 
values for BMC, FM and LM.  
1.3.2.1.3 Strengths and limitations 
The advantages of DXA include quick scan time, low cost, and wide availability at 
medical facilities. Due to the large-scale application of DXA over recent decades, 
there are vast reference datasets available for paediatric and adult populations, 
thus allowing like-for-like comparisons - important due to the variability in bone 
and body composition based on age, sex, ethnicity, and other factors 170. 
Additionally, reproducibility of aBMD and lean mass measurements are high (CVs 
~1 to 3%), allowing small changes to be assessed with confidence. Skeletal muscle 
assessed by DXA also correlates strongly with the gold standard methods of MRI (r 
> 0.8) and CT (r > 0.9) in cross-sectional studies 171,172.  
Despite the above, the technique also has several known limitations. Although in 
a relatively small dose per scan, DXA involves exposure to ionizing radiation. This 
may become problematic for people who require routine scanning and thus 
repeated radiation exposure, including children with chronic diseases associated 
with poor bone development or in those treated with chronic GC. DXA is also 
unable to delineate cortical and trabecular bone, each of which are important 
determinants of bone strength that can be independently affected by pathology. 
Indeed, only approximately 60-70% of bone strength variability is accounted for 
by DXA, meaning it fails to capture important contributors to overall mechanical 
strength. DXA alone is insensitive at identifying most individuals who would 
benefit from bone protective therapy or intervention as the greatest incidence of 
fractures occur in people who do not meet the diagnostic threshold for 
osteoporosis 173. Instead, most fractures occur in individuals with low bone mass 
and other associated clinical risk factors as many more people fall into this 
category 173.  
30 
 
DXA measures are also inherently linked to bone size. DXA uses a two-dimensional 
projection of bone area to calculate BMC (g) and aBMD (g/cm2) in a three-
dimensional structure, without accounting for bone thickness in the anterior-
posterior direction. This does not accurately reflective volumetric BMD ([mg 
hydroxyapatite/cm3]) and results in systematic underestimation of bone density 
in children with small bones secondary to skeletal delay or pathology, as has been 
observed in CD 174. Several methods of adjustment have been suggested including 
for bone area 175, bone age 176, and lean mass 177 alleviate concerns of 
underestimation. Bone mineral apparent density of the lumbar spine (LS BMAD) 
can also be calculated using the vertebral width based on an assumed cylindrical 
volume of the vertebra and is used as a surrogate measure of vBMD. LS BMAD is 
the preferred adjustment method used in local clinical practice. 
1.3.2.2 Quantitative computed tomography (QCT) 
1.3.2.2.1 Overview 
Advances in quantitative computed tomography (QCT) techniques have facilitated 
improved measurement of skeletal density, structure, and strength in comparison 
with DXA. Peripheral QCT (pQCT) scanners allow the measurement of bone, 
muscle, and fat at the distal limbs at a fraction of the cost or radiation burden of 
traditional whole-body CT scanning 169.  
1.3.2.2.2 Technology 
Like DXA, pQCT technology is based on the physics of photoelectric absorption. 
The scanner contains a rotating gantry that houses an x-ray tube and adjacent 
detector. During scanning, the individual’s limb is fixed within the rotating gantry 
to aid immobilisation. As the gantry rotates, the x-ray tube emits a fan beam of 
photons through the individual’s limb and towards the detector. Tissue dependent 
x-ray attenuation allows the independent assessment of bone, muscle, and fat at 
the region of interest using an in-plane voxel size of 200µm – 800µm 178. 
Attenuation data are reconstructed into a single two-dimensional tomographic 
slice for subsequent analyses. The assessment of trabecular bone occurs at the 
metaphysis, whereas cortical bone and muscle and fat cross-sectional area are 
measured at the diaphyseal shaft 179.  
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1.3.2.2.3 Strengths and limitations 
Unlike DXA, pQCT independently evaluates trabecular and cortical bone 
compartments, providing a true vBMD for each that is independent of bone size. 
Bone size and geometry can also be quantified and estimated mechanical 
properties calculated from pQCT 179. Skeletal muscle area assessed by pQCT 
correlates almost perfectly (r = 0.97) with the gold standard MRI when a strong 
image filter is applied 180. Additionally, pQCT can assess intermuscular fat 
distribution, providing insight into overall limb composition and muscle quality, 
not available via DXA 169,179. Mid-thigh measures of skeletal muscle adiposity also 
correlated very closely between pQCT and MRI (r2 = 0.82) 181, highlighting the 
validity of this method for multicompartment assessment.  
Standard pQCT resolution precludes direct assessment of trabecular 
microarchitecture; however, newer high-resolution pQCT (HR-pQCT) scanners 
have improved spatial resolution (82µm) that can more accurately quantify these 
minute structures. HR-pQCT outcomes associate closely with micro-CT analyses of 
bone biopsies 182. A primary limitation of pQCT techniques is the inability to scan 
more proximal anatomical locations due to the relatively small gantry size and 
scanner setup. Availability of scanners is also low, and they are highly expensive, 
especially for HR-pQCT. Furthermore, the various scanning protocols in pQCT 
make comparisons between studies difficult.  
1.3.2.3 Quantitative ultrasound 
1.3.2.3.1 Overview 
Quantitative ultrasound (QUS) provides a useful alternative to conventional 
imaging methods for the assessment of bone and muscle. QUS provides outcomes 
associated with bone mineralisation and trabecular structure and can also provide 
detailed visualisation of muscle thickness, area, fascicle length and pennation 
angle. Currently, the only accepted measurement site for assessing bone health 
using QUS is the heel. QUS is not a currently accepted method of assessing muscle 
mass clinically, although cross sectionally QUS measures of muscle thickness have 
correlated well with MRI muscle area (r = 0.82) 183. In the absence of DXA imaging, 
heel QUS may be used in conjunction with other risk factors for the initiation of 




Ultrasound waves are mechanical vibrations that are altered in shape, intensity 
and speed by the medium through which they are travelling. QUS assesses the 
interaction and propagation of these waves across bone tissue 179. Parameters 
derived from QUS are therefore based on physical interactions between ultrasound 
waves and bone tissue. The signal velocity and attenuation are dependent on the 
characteristics of bone tissue and allow deduction of the mechanical properties 
and structural anisotropy of bone including density, trabecular structure, and 
elasticity 185. Velocity is measured as speed of sound (SoS [m/s]) and attenuation 
measured by broadband ultrasound attenuation (BUA [dB/MHz]). Variations of 
scanning technique exist, depending on the device used. Nevertheless, 
fundamentally, a scan consists of a transmitter producing ultrasound waves 
through the calcaneus towards a receiver located on the other side. A coupling 
medium is used, either gel or water immersion, to ensure correct coupling of the 
wave into the skin.  
1.3.2.3.3 Strengths and limitations 
The low-cost, quickness, and portability of QUS measurements are the primary 
advantages, particularly for use in neonates or population-based research where 
the application of DXA or other imaging may be impractical 186,187. Despite this, 
QUS is hampered by many limitations. Measurement is limited to superficial sites 
and the only currently validated measurement site in osteoporosis management is 
the calcaneus. Inter-operator variability can be very high and differing technology 
and calibration methods precludes accurate comparisons between devices 179. The 
utility of QUS for fracture prediction is controversial, although validated devices 
have been found to predict fracture in post-menopausal women and elderly men, 
independent of DXA aBMD 184. While QUS measures of muscle mass show good 




1.3.2.4 Magnetic resonance imaging 
1.3.2.4.1 Overview 
Magnetic resonance imaging (MRI) has emerged as a useful tool for 
comprehensively assessing the musculoskeletal apparatus. Advances in high-field 
(≥3-Tesla) scanners have facilitated high-resolution imaging of bone at the macro- 
and microarchitectural level. MRI is also the gold standard imaging method for 
assessment of skeletal muscle. Previous research has found MRI assessment of 
trabecular microarchitecture to be sensitive at identifying individuals with prior 
fragility fractures who do not meet DXA aBMD criteria of osteoporosis 188. Despite 
this, MRI is not a currently accepted clinical method of assessing skeletal fragility 
as the field is still in its relative infancy. 
1.3.2.4.2 Technology 
MRI physics is founded on the magnetic properties of atomic nuclei. Hydrogen 
nuclei, together with others that contain odd numbers of protons and neutrons, 
produce a small magnetic field due to the spinning of their positive magnetic 
moment around an axis. Hydrogen constitutes most tissue within the human body 
and generates the greatest magnetic signal, hence its use in MRI. During MRI, when 
a patient enters the scanner the magnetic moments of the hydrogen nuclei align 
parallel or anti-parallel with the external magnetic field (B0), with a slightly larger 
number aligning parallel as this is a lower energy state (Figure 1-9) 189.  
 
Figure 1-9 Alignment of magnetic moments relative to external magnetic field. 
A slightly higher number of magnetic moments align parallel with B0 as this is a lower energy state. 
This creates a net magnetic vector along the same direction as B0. NMV – net magnetic vector; B0 – 
external magnetic field. (From Westbrook [2018] 190) 
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The magnetic moments of these nuclei spin around the axis of B0 at a frequency 
known as the Larmor Frequency, which is directly proportional to scanner field 
strength. The individual is then exposed to radio frequency (RF) pulses at precisely 
the value of the Larmor frequency. This causes excitation of the hydrogen nuclei 
as they absorb energy from the emitted RF pulses - known as resonance. Low 
energy nuclei begin to join the high-energy group and re-align anti-parallel to B0. 
When enough energy is applied this shifts the net magnetic vector away from B0 
towards the transverse plane (Figure 1-10). Resonance also causes the magnetic 
moments of nuclei to move in phase with each other, meaning they spin at the 
same position on the precessional path around B0 as each other 190. The MR signal 
is generated when in phase transverse magnetisation crosses a receiver coil. 
 
Figure 1-10 Excitation and flip-angle generation. 
The NMV moves towards the transverse plane when enough energy is supplied by the RF as more 
moments align anti-parallel to B0.  
After removing the RF pulse the net magnetic vector returns to alignment with B0 
- causing magnetization in the longitudinal and transverse planes to increase (T1 
recovery) and decrease (T2 decay), respectively. T1 recovery occurs when nuclei 
release their energy into the surrounding environment (spin lattice relaxation), 
whereas T2 decay occurs when the magnetic fields of adjacent nuclei interact 
with each other (spin-spin relaxation). These phenomena are both exponential 
processes with their relaxation times measured as the time taken for 63% of 
longitudinal magnetization to recover and 63% of transverse magnetization to be 
lost for T1 and T2, respectively (Figure 1-11 A & B). The different compositions of 
body tissues mean that they have differing T1 and T2 relaxation times. Each tissue 
therefore generates a different signal intensity at any given time, allowing clear 
distinction on the generated MRI image. Water, due to its high inherent energy 
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state, does not freely release energy to the surrounding lattice and has long T1 
and T2 relaxation times. Conversely, fat, due to its low energy state and tightly 
packed lipid molecules, has shorter T1 and T2 relaxation times. These times are 
shorter again in muscle tissue 190 (Figure 1-11 C & D). 
 
Figure 1-11 T1 and T2 relaxation times. 
Illustration of exponential relaxation times for (A) T1 and (B) T2 magnetisation. Relaxation times 
differ depending on the specific tissue (C & D). (Adapted from Westbrook & Ridgway [2010] 191) 
A pulse sequence constitutes carefully designed patterns of RF pulses designed to 
achieve the desired image contrast and quality. The time between two RF pulses 
(repetition time [TR]) dictates the level of T1 relaxation allowed prior to the next 
excitation. The time between applying the RF pulse to the peak signal induced in 
the receiver coil (echo time [TE]) determines the amount of T2 relaxation allowed 
prior to reading the signal. The MRI signal is retrieved by a receiver coil from the 
energy released during relaxation. To transform this signal into a comprehendible 
three-dimensional image a field of view (FOV) must be placed over the desired 
anatomical location for imaging. This FOV is divided into individual volumetric 
pixels known as voxels, which, together with slice thickness, determines the 
spatial resolution of the image.  
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The excellent contrast generation between tissues in MRI depends on both intrinsic 
and extrinsic factors. Intrinsic factors such as the T1 or T2 relaxation time of a 
tissue cannot be changed, whereas extrinsic factors can, such as pulse sequence 
parameters. Images are ‘weighted’, meaning the pulse sequence parameters are 
designed so that either T1 or T2 predominates over the other. T1-weighted images 
have a short TR and are characterised by hyperintense (bright) signal in fat and 
hypointense (dark) signal in water. T2-weighted images are the reverse, fat is 
hypointense and water hyperintense. In bone imaging, contrast is generated 
between the hypointense signal of bone and the hyperintense signal of adjacent 
fatty marrow, muscle, and subcutaneous fat. 
Several factors influence the quality of MRI images, including spatial resolution, 
signal to noise ratio (SNR) and scan time. Increased spatial resolution improves 
image quality by allowing accurate differentiation between minute structures, 
whereas in large voxels signal intensities are averaged creating partial volume 
effects. SNR increases proportionately with scanner field strength but is negatively 
associated with spatial resolution. Scan time should be kept as short as possible 
to reduce movement artefacts that may negatively affect image quality, however 
high-resolution requires longer scan times. These factors must be carefully 
considered based on the tissue and structures being imaged to optimise image 
quality. 
1.3.2.4.3 Strengths and limitations 
The advantages of MRI over other imaging techniques when assessing muscle and 
bone are manifold. These include widespread availability at medical research 
facilities, lack of radiation exposure, and ability to scan more proximal anatomical 
locations compared to pQCT. The excellent tissue contrast that can be generated 
by MRI makes it the gold standard imaging method for assessment of skeletal 
muscle and fat 169. The utility of MRI in assessing multiple facets of bone, muscle, 
and adiposity from a single series of imaging is another key advantage. The 
improved SNR and spatial resolution of high-field scanners has facilitated the study 
of trabecular bone microarchitecture, with results that correlate highly with 
micro-CT of bone biopsy (r2 = 0.82 for trabecular bone volume) 192. Three-
dimensional reconstructions can be generated from a series of contiguous scans, 
allowing analysis of trabecular anisotropy as well as simulated stress testing 193. 
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Interscan repeatability in our centre for trabecular parameters was high with CVs 
of <3.5% for all outcomes 194. Single slice MRI at the mid-thigh has been reported 
as an acceptable surrogate for total body skeletal muscle 195 and the assessment 
of intramuscular fat infiltration provides insight into muscle quality that is not 
achievable with pQCT or DXA.  
Nevertheless, several limitations of MRI must also be considered. MRI scanning is 
expensive, requires specialist operators, and is time consuming in comparison to 
DXA or pQCT. The currently available spatial resolution of MRI (~100µm – 200µm) 
precludes accurate delineation of individual trabeculae, which is achievable for 
larger trabeculae using the improved resolution of HR-pQCT (82µm). MRI-derived 
trabecular microarchitecture measurements are therefore subject to partial 
volume effects, although have been found to perform equally as well as HR-pQCT 
in this regard 196. Current scan times required to assess trabecular 
microarchitecture are relatively long (~9-12 minutes), resulting in increased 
susceptibility for movement artefacts. Even very slight movement can influence 
image quality due to the relative size of the structures being assessed, although 
the application of immobilisation methods or image filtering may alleviate this. 
Finally, no standardised MRI protocols for the assessment of bone exist, meaning 
custom pulse sequences and regions of interest are implemented, limiting 
comparisons between centres. 
1.3.3 Magnetic resonance spectroscopy (MRS) 
1.3.3.1.1 Overview 
Magnetic resonance spectroscopy (MRS) allows the additional assessment of 
metabolites of interest in conjunction with MRI. Proton MRS (1H-MRS) is regarded 
as the gold standard for quantification of BMA 197. Recently, BMA has emerged as 
an indicator of skeletal health and its assessment in conjunction with muscle-bone 
MRI provides comprehensive data not available using other imaging techniques. 
BMA quantification is typically conducted in the lumbar spine, pelvis, and hip. 
1.3.3.1.2 Technology 
1H-MRS is also founded on the magnetic properties of hydrogen atomic nuclei. 
When assessing BMA, point-resolved spectroscopy (PRESS) or stimulated echo 
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acquisition mode (STEAM) pulse sequences are used to measure the abundance of 
hydrogen nuclei within different elements of tissue (i.e. water and fat). This 
generates adiposity spectra within the region of interest. This spectrum plots 
signal intensity against chemical shift, measured in unit parts per million (ppm) 
(Figure 1-12). Chemical shift is caused by the shielding of an atoms electrons which 
results in identical nuclei resonating at different frequencies depending on their 
environment. In 1H-MRS, the signal is separated into a lipid and water peak, from 
which the area under the curve is used to quantify the water-fat composition of 
the marrow and calculate BMA fat fraction 198. 
 
Figure 1-12 1H-MRS of the lumbar spine. 
Representative water and lipid peaks from single voxel 1H-MRS. 
1.3.3.1.3 Strengths and limitations 
The use of 1H-MRS has many advantages, particularly when used in conjunction 
with MRI assessment of bone and muscle. These techniques provide the best 
overall assessment of bone, muscle, and marrow fat from a single series of scans. 
1H-MRS is the gold standard non-invasive assessment of BMA and closely correlates 
with marrow adiposity measured by biopsy 199. Repeat imaging variability has been 
reported as <2% highlighting the reproducibility of the technique 200. The primary 
limitations of 1H-MRS are the lack of available reference data and careful 
consideration is required when selecting reference groups as controls, as BMA is 






1.3.4 Muscle-bone functional assessments 
1.3.4.1 Jumping mechanography 
1.3.4.1.1 Overview 
Jumping mechanography has emerged as a useful tool for the functional 
assessment of the muscle-bone unit in both health and disease. This tool benefits 
from providing dynamic assessment of several aspects neuromuscular function. 
Functional assessments can be implemented in a range of populations, from 
children and adults with chronic diseases to athletic populations. 
1.3.4.1.2 Technology 
Jumping mechanography utilises a battery of functional tests of the lower limbs, 
using a portable force plate (Leonardo Mechanograph Ground Reaction Force 
Plate, Novotec Medical GmbH, Pforzheim, Germany).  This force plate contains 
eight strain gauge force sensors, used to measure the vertical ground reaction 
forces (GRFs) applied during various physical tests. Force sensors sample at a 
frequency of 800Hz and data is transferred and analysed in specialist software 
(Leonardo Mechanography v4.4 Research Edition Software, Novotec Medical 
GmbH, Pforzheim, Germany). The two most common assessments performed are 
the single two-legged jump (S2LJ) and multiple one-legged hopping (M1LH) tests. 
Other tests simulating activities of daily living like the timed-up-and-go test can 
be implemented in older populations. S2LJ is used to assess dynamic function and 
anaerobic power of the lower limbs through a single countermovement jump for 
maximum height. Force plate data is sampled and analysed providing outputs for 
multiple aspects of neuromuscular function and jump performance. The primary 
outcomes assessed from S2LJ are maximum power (kilowatts [kW]) and maximum 
power relative to body mass (watts per kilogram [W/kg]) generated during the 
take-off phase, and maximum jump height achieved. M1LH is designed as an 
assessment of the functional muscle-bone unit by aiming to achieve the maximum 
possible GRF to the tibia during stiff-legged hopping. The primary outcomes of this 
test are the maximum applicable force (kN) and the maximum force as a multiple 
of bodyweight experienced during the landing phase of a single hop. 
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1.3.4.1.3 Strengths and limitations 
Jumping mechanography benefits from providing dynamic assessments of the 
muscle-bone unit that provide insight into several aspects of neuromuscular 
function. Mechanography provides insight into the site-specific muscle-bone 
relationship that is not available from standard isometric dynamometry. The tests 
are accessible and representative of habitual movement of children and 
adolescents meaning they can be easily implemented without any learning effect. 
Further, the portability of the device means the tests can be applied in research 
or clinical settings, particularly compared to methods such as isokinetic 
dynamometry. Test-retest reliability is good in healthy children and adults, with 
CVs of approximately 5% for S2LJ and 4% for M1LH parameters, respectively 201.  
A potential limitation of mechanography, applicable to most muscle assessments, 
is a reliance on participant motivation to achieve accurate results. Participants 
are asked to perform maximal effort physical tests and low motivation may 
confound results. Inter-operator reliability may vary depending on how tests are 
introduced and described to participants. For example, during M1LH, asking 
participants to hop as quickly as possible and as high as possible have both been 
reported, each producing markedly different results 202,203. Standardisation of test 
technique is required to ensure results can be appropriately compared between 
studies and with the relevant reference data. Jumping mechanography may not 
be suitable for individuals with impaired mobility or those with neuromuscular 
disease, although it has been safely implemented in both children with 
osteogenesis imperfecta 204 and elderly adults 205, highlighting its safety. 
1.3.4.2 Grip strength 
1.3.4.2.1 Overview 
Maximum isometric grip force, generally termed ‘grip strength’, is the most widely 
applied method of muscle function assessment. Grip strength provides a rapid 
assessment of isometric muscle force that has been reported as a useful prognostic 




Grip strength is assessed using a handheld analogue or digital dynamometer. The 
Jamar hydraulic dynamometer is most widely used and generally considered the 
gold standard for comparison. This very simple test involves holding the 
dynamometer in one hand and performing a single, maximal effort contraction of 
the musculature of the hand and forearm. Dynamometers are adaptable to ensure 
optimum positioning of the hand that may facilitate a maximum effort. The 
resultant output is a measure of force (Newtons [N]) that is generally converted 
to kilograms (kg) prior to reporting.  
1.3.4.2.3 Strengths and limitations 
Grip strength dynamometry is cheap can be very easily implemented in research 
or clinical practice settings. Test-retest reliability of grip dynamometry is very 
good 207 and grip strength is considered a reasonable marker of overall muscle 
function. Potential limitations include the dependence of grip strength on growth 
characteristics such as height and bodyweight. This limits the use of grip strength 
among children unless suitably age, sex, and size-adjusted Z-scores are available. 
The variability in techniques employed precludes direct comparisons between 
studies as different dynamometers, hand dominance, or posture may produce 
systematically different results. Finally, grip strength is a static assessment that 
does not represent typical muscular function. Nevertheless, grip strength is a 
reasonable indicator of muscle function that may be useful in the rapid assessment 




1.4 Muscle-bone health in Crohn’s disease 
1.4.1 Overview 
As discussed, bone and muscle are tightly regulated by many mechanical and non-
mechanical factors. Chronic inflammatory diseases such as CD present several 
challenges to pathways involved in the growth and maintenance of bone and 
muscle. This section will present a brief overview of prior research into bone and 
muscle health in paediatric and adult CD, followed by discussion of the potential 
pathogenic factors associated with muscle-bone deficits in these populations. 
1.4.2 Pathophysiology of muscle-bone deficits in Crohn’s disease 
The pathophysiology of muscle-bone deficit in CD is multifactorial and may be 
attributed to specific physiological actions of disease, lifestyle factors associated 
with disease, or adverse side effects of therapy.  
1.4.2.1 Pro-inflammatory cytokines 
Pro-inflammatory cytokines perpetuate gastrointestinal inflammation and tissue 
destruction in CD while also regulating some extra-intestinal manifestations and 
systemic effects of disease - including within bone and muscle. Pathological 
inflammation leads to the disordered development or loss of bone and muscle in 
children and adults with CD, respectively. The effects of chronic inflammation on 
bone and muscle in CD may predispose these patients to increased risk of adverse 
musculoskeletal events such as falls, fractures, and osteoporosis. 
The role of inflammation in pathogenesis of skeletal deficits in CD has been 
highlighted by reduced bone mass in newly diagnosed cohorts of treatment naïve 
CD patients 208,209. The serum of treatment naïve CD patients was also found to 
inhibit osteoblast function in vitro, indicating a biochemical component of CD that 
negatively regulates bone formation - most likely due to the pro-inflammatory 
milieu 208,210. Several cytokines known to be elevated in CD such as TNF-α, IL-1β, 
and IL-6 inhibit osteoblast function and promote osteoclastogenesis 61,211-213. TNF-
α may be the master regulator of bone loss in CD as it promotes expression of 
RANKL from osteogenic cells and independently interacts with RANKL as a potent 
stimulator of osteoclastogenesis, via the nuclear factor kappa B (NF-κB) signalling 
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pathway 214,215. The decoy RANK receptor, OPG, is upregulated in an apparent 
attempt to maintain bone homeostasis in CD; however, this mechanism appears 
insufficient to reverse RANKL and TNF-α mediated bone resorption 216. During a 
disease flare, CD patients were found to have elevated serum RANKL compared to 
active UC and controls, highlighting the influence of ongoing inflammation on this 
pathway 213. The influence of TNF-α on bone turnover in CD is evidenced by the 
rapid improvement in bone formation markers in individuals treated with TNFα 
neutralizing antibodies 49,217. Despite improved markers of bone turnover, 
however, the long-term effects of anti-TNFα therapy on bone mass are unclear. 
Children with CD treated with up to 12 months of anti-TNF therapy had persistent 
deficits in bone and muscle 49,217, despite mild improvements 49. Whether long 
term treatment with anti-TNF-α or other cytokine targeting therapies is associated 
with improvements in skeletal structure and normalisation of BMD in paediatric 
CD remains unclear. The current data suggests that suppression of TNF-α may only 
facilitate skeletal improvements and other factors must be involved. 
TNF-α and IL-6 are also key regulators of muscle loss in CD, a pathway shared with 
aging. Circulating TNF-α and IL-6 are increased in healthy elderly adults and are 
negatively associated with muscle mass and function 218. These cytokines are 
elevated in the serum of CD 210,211 and have been found by some 219, but not others 
220, to correlate with clinical disease activity. While cytokines play a key role in 
muscle homeostasis and regeneration, in the context of dysregulated immune 
function as that in CD, they mediate and contribute to skeletal muscle loss. TNF-
α and IL-1β mediated activation of NF-κB accelerate protein degradation 221 and 
decrease expression of pro-myogenic factor, MyoD 222. TNF-α may also inhibit the 
regenerative capacity of satellite cells through epigenetic silencing of the Notch 
1 gene 223. These pathways can lead to inflammatory muscle loss in CD with 
reduced muscle mass and function. A prospective study of 19 adults with active 
CD treated with anti-TNF-α induction therapy observed a significant increase in 
quadriceps muscle volume at week 25, accompanied by reduced serum IL-6 levels, 
suggesting suppression of cytokines by anti-TNF-α facilitates the reversal of 
inflammatory muscle loss in CD 224. In paediatric CD, anti-TNF-α and EEN have both 
been associated with short term improvements in biomarkers but not complete 
normalisation of muscle deficits 49,225. 
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1.4.2.2 Nutritional deficit 
The aetiology of nutritional deficit in CD is multifactorial. Rapid weight loss is 
typically a key presenting characteristic of CD both at diagnosis and during 
relapse, indicative of nutritional deficiency. Severe malnutrition, arbitrarily 
classified as a BMI Z-score < -2 SDS, was observed in approximately 30% of 
paediatric CD patients at diagnosis in one prospective study, reducing to 15% at 
long term follow up 226. Other studies have estimated malnutrition to affect 60 - 
80% of patients at diagnosis 227-229.  
Individuals with CD often develop food aversions or may follow exclusionary diets 
to prevent exacerbation of symptoms 230, leading to inadequate nutritional intake. 
Pro-inflammatory cytokines also directly interfere with appetite hormones and 
reduce hunger 231. Dietary intake has been reported as lower than nutritional 
recommendations in both active and inactive disease 232-234. During active disease, 
protein turnover may be increased, thus compounding nutritional deficit. 
Malabsorption of nutrients such as vitamin D and calcium may also adversely affect 
bone and muscle health in CD. Vitamin D deficiency has been reported in up to 
60% of children and adults with CD 235-237. Still, no direct link between vitamin D 
status and musculoskeletal outcomes have been established in CD. Low calcium 
intake, however, was recently associated with reduced femoral neck aBMD in a 
cohort of young adults with CD, although around half of this cohort had active 
disease at time of assessment which may have contributed to bone loss 238.  
Contrary to the typical low weight and BMI observed in CD, a large proportion of 
patients now present with overweight and obesity, in line with the increasing 
prevalence of obesity in the general population. This creates a separate issue of 
nutrition that may contribute to bone and muscle defects. The prevalence of 
obesity among adults with CD is estimated at 20-50% 239,240. Obesity is associated 
with poor bone microarchitecture relative to bodyweight 241 and increased BMA 
and muscle fat infiltration 242, risk factors for poor muscle function and skeletal 
fragility. In the absence of obesity, however, CD remains associated with 
increased visceral adiposity or ‘creeping fat’. This visceral adiposity expresses 
pro-inflammatory adipokines such as TNF-α, IL-1β, and IL-6 that may perpetuate 
systemic inflammation and contribute to bone and muscle loss in CD 12.  
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1.4.2.3 Glucocorticoids (GC) 
GC are routinely administered as first line induction therapy for moderate to 
severe CD in adult and paediatric patients, although EEN is now preferred first 
line therapy for paediatrics. Despite the highly effective immunosuppressing 
properties of GC, they are associated with profound and devastating effects on 
musculoskeletal health. Chronic GC exposure can lead to muscle atrophy, GC 
induced osteoporosis (GIO), and a markedly increased risk of fractures 33,35,36. In 
children, GC exposure can lead to delayed pubertal development and inhibition 
of linear growth 36,243.  
In adults, GC induced bone and muscle loss occurs in a rapid, dose-dependent 
manner. GC induce preferential loss of metabolically active trabecular bone 244, 
highlighted by the high incidence of vertebral fractures in GC treated populations. 
Primarily, GC induced bone loss occurs via protracted reduction of bone 
formation, as GC inhibit osteoblast function 33. They have also been observed to 
induce osteoblast and osteocyte apoptosis 245. An initial increase in bone 
resorption is also observed as GC stimulates increased expression of RANKL from 
osteoblastic cells while downregulating OPG expression 246. Additionally, GC 
reduce the capacity of mature osteoblasts to synthesize type I collagen, leading 
to a reduced volume of bone matrix for mineralisation 247. Extra-skeletal effects 
of GC include impaired intestinal absorption of calcium and phosphate, impaired 
vitamin D metabolism, and increased renal calcium excretion, which may lead to 
secondary hyperparathyroidism 33.  
In children, GC directly inhibit growth via peripheral and central mechanisms. GC 
cause local GH/IGF-1 insensitivity at the growth plate by disrupting GH/IGF-1 
receptors in chondrocytes 144. They also inhibit IGF-1 signalling which impedes 
proliferation and upregulates apoptosis in chondrocytes 248,249. Chronic exposure 
to GC in children can also contribute to delayed puberty via hypogonadotropic 
hypogonadism due to suppression of gonadotrophic releasing hormone (GnRH) 250. 
The use of GC in paediatric patients is therefore avoided if possible, or very closely 




The catabolic effects of GC within muscle may also negatively influence bone. The 
muscle wasting properties of GC can be observed as little as 7 days after initiation 
of therapy 251. GC inhibit protein synthesis, potentially via reductions in circulating 
and muscle IGF-1, which typically promotes activation of protein synthesis 
pathways. Myofibers also experience increased protein degradation via 
upregulation of atrophy related genes including muscle RING finger 1 (MuRF1) and 
muscle atrophy F-box (MAFbx) 252,253, leading to muscle weakness. These GC 
induced muscle mass and function deficits may increase the risk of 
musculoskeletal morbidity, including sarcopenia, falls, and fractures. 
The effects of GC, independent of inflammation, on musculoskeletal health in CD 
are difficult to establish. Active disease is an indication for GC therapy that is 
itself known to disrupt bone and muscle as discussed above (Section 1.4.2.1). In a 
prospective study of newly diagnosed paediatric CD who received subsequent GC 
therapy, cortical vBMD was normal whereas cortical area and trabecular vBMD 
were reduced at baseline 37. At follow up, those with lower exposure to GC and 
inflammation had the greatest improvements in cortical area and linear growth, 
although they remained low compared to reference values. In a recent cross-
sectional study of young adults with CD, all individuals who were currently on GC 
therapy (n = 14) had low aBMD assessed by DXA, while the majority (87%) not on 
GC had normal aBMD 238.  
1.4.2.4 Pubertal delay 
The insidious onset of CD in children typically manifests in the pre- or early 
pubertal age and can significantly delay the timing of puberty. Delayed pubertal 
development has extensive implications for muscle-bone health. The pubertal 
growth spurt is a critical period of muscle and bone accrual, and any disturbance 
can result in poor linear growth and sub-optimal bone and muscle accretion. 
Studies have used various maturational markers to assess pubertal delay, including 
bone age 254, age at menarche 255, and age at pubertal growth spurt 256. Age at 
initiation of pubertal growth spurt was delayed by a median 0.8 (1.7, -0.4) and 
0.5 (2.1, -1.5) years in girls and boys, respectively, compared to healthy controls 
256. Radiographic bone age was delayed by 1.3 and 0.7 years in girls and boys, 
respectively, compared to reference values 254. In the menarcheal age cohort, 
median age at menarche was delayed by nearly two years in CD 255. 
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Nutritional deficits and inflammatory cytokines are implicated in the pathogenesis 
of pubertal delay in CD. Chronic undernutrition is associated with reduced fat 
mass and low circulating levels of leptin 257, which is an essential hormone for the 
advent of puberty. Animal models, however, have suggested that reduced leptin 
is not the sole regulator of delayed puberty in CD and that pro-inflammatory 
cytokines have a role, likely through their inhibitory actions on gonadotropin 
secretion 258,259. This hypothesis is supported by a recent study in children with 
active CD who were treated with anti-TNF-α induction therapy. Pro-inflammatory 
cytokines were reduced and circulating sex hormones and gonadotropins 
improved, independently of body composition 260. The role of inflammation in 
pubertal delay is also supported by evidence of pubertal progression after 
intestinal resection in refractory active disease 261. While contemporary therapies 
have reduced the prevalence and severity of pubertal delay in paediatric CD, 
children with diagnostic delays or who fail to respond to current therapies remain 
at risk. Whether maturation delay shortens the proposed window of opportunity 
for skeletal growth is unclear. One study reported that continued linear growth 
past the expected timeframe was common in young people with CD and bone age 
delay, potentially due to delayed fusion of epiphyseal growth plates 262. Expected 
epiphyseal fusion, however, was estimated based on chronological age in this 
study and bone age was not directly evaluated 262. Nevertheless, these authors 
suggested that if inflammation can be well controlled, young people with CD may 
experience an extended period growth that could facilitate recovery of any 
skeletal deficits encountered earlier in the disease course. 
1.4.2.5 GH/IGF-1 abnormalities 
In paediatric CD, failure of linear growth is a concern that often precedes 
gastrointestinal symptoms, potentially caused by abnormalities in the GH/IGF-1 
axis. Studies have generally reported normal levels of GH secretion with reduced 
IGF-1 and IGFBPs in CD, although a range of different abnormalities in GH/IGF-1 
have been observed 263 Systemic inflammation inhibits multiple aspects of the 
GH/IGF-1 axis 264. Pro-inflammatory cytokines such as IL-6 and TNF-α reduce IGF-
1 through inhibition of GH signal transduction 265 in hepatocytes. IL-6 also 
increases proteolysis of IGFBP3, which inhibits IGF-1/IGFBP3 complex formation 
and increases IGF-1 clearance 266. Anti-TNF-α therapy has been shown to improve 
IGF-1 in murine models of colitis 267 and adults with CD 268. In two prospective 
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studies in paediatric CD, anti-TNF-α therapy was associated with a rapid 
improvement in IGF-1 Z-score after 10 weeks in one study (-0.4 SDS vs -1.0 SDS, p 
< 0.001) 48 but no change in another 217, although IGF-1 Z-scores were normal at 
baseline in the latter. Both studies reported persistent muscle-bone deficits at 12 
months follow up, with serum IGF-1 levels comparable to baseline despite 
sustained improvements in disease activity 48,217. Muscle mass and function deficits 
were also associated with reduced capacity for muscle protein synthesis in young 
adults with CD, potentially linked to reduced IGF-1 activation of hypertrophy 
pathways 269. 
1.4.2.6 Physical inactivity 
The important role of PA as a regulator of bone and muscle mass through 
mechanical and molecular pathways is clear (Section 1.2.5). Observational data 
highlight low levels of habitual PA and exercise in self-reported 270-272 and 
accelerometry 273,274 studies. Only 6% of adolescents with IBD achieved the 
recommended guidelines of 60 minutes per day of MVPA, while >50% had BMD Z-
scores of < -1 SDS 273. In the same study, MVPA was positively associated with BMD 
independently of pubertal status and BMI. Physical inactivity could potentially 
contribute to the systemic effects of CD independently of the lack of mechanical 
loading. The expression of myokines from skeletal muscle is downregulated during 
periods of inactivity. As myokines perform several anti-inflammatory functions, 
their absence leads to a pro-inflammatory state. This, plus increased 
accumulation of adipocytes within inactive muscle, could perpetuate local and 
systemic inflammation in CD. It has been suggested that low PA may contribute a 
physical component to the chronic fatigue observed in individuals with CD/IBD 274.  
1.4.3 Bone health in CD 
As discussed, the potentially adverse effects of CD and its associated risk factors 
on bone are multifactorial. A summary of major imaging studies assessing bone 
mass, geometry, and microarchitecture in paediatric and adult CD is available in 
Table 1-1. Imaging studies in paediatric CD have reported more consistent findings 
than those in adults.  
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The currently understood skeletal phenotype in paediatric CD is characterised by 
deficits in cortical bone geometry with low aBMD and trabecular vBMD but 
maintained cortical vBMD (Table 1-1). Abnormalities are evident at diagnosis in 
paediatric CD, with deficits in trabecular vBMD 275-277, cortical thickness 209,275-277, 
and muscle CSA 225,275-277 observed in pQCT studies. These highlight the role of 
uncontrolled inflammation on muscle-bone outcomes in paediatric patients which 
can lead to growth arrest or pubertal delay, often characterised by short stature 
209,225,276,277. Adverse skeletal outcomes have been demonstrated independently of 
linear growth or pubertal delay in studies that reported low DXA and pQCT Z-
scores in CD when adjusted for height 277,278, bone size 174,276, or bone age delay 
279,280. Prospective studies have failed to report normalisation of bone deficits 
after long term follow up in paediatric CD patients 276,280 or in those treated with 
EEN 225 or anti-TNF-α 49,217,281, suggesting factors other than disease control are 
important. These results could also suggest that current methods of evaluating 
disease severity may not be sensitive enough to detect milder degrees of chronic 
inflammation. Currently, little is known regarding microarchitectural parameters 
in paediatric CD, as no in vivo high-resolution imaging studies have been 
performed exclusively in this population. One study analysed trans-iliac biopsies 
in a small cohort of newly diagnosed CD patients (n = 20) and found maintained 
trabecular bone volume despite cortical deficits, inhibited bone turnover activity, 
and low BMAD 209. 
In adults with CD, imaging studies of bone health have been almost exclusively 
conducted using DXA, excluding two HR-pQCT studies 282,283. The skeletal 
phenotype in adults with CD is less clear, as some conflicting data exists between 
studies. Additionally, several studies report data for CD and UC collectively under 
the umbrella of IBD, despite suggestions bone health is more adversely impacted 
in CD than UC. Nonetheless, the skeletal phenotype in adults with CD appears to 
be one of low aBMD, particularly at the lumbar spine and hip regions 284-287. This 
was further highlighted in a recent meta-analysis that reported mean difference 
in aBMD Z-scores of -0.52 (95%CI: -0.71, -0.32) and -0.45 (95%CI: -0.62, -0.29) at 
the lumbar spine and femoral neck, respectively, in adults with IBD 288. One 
population-based study reported a higher likelihood of osteoporosis in IBD 
compared to healthy age and sex matched controls (OR: 1.47 [95%CI: 1.2, 1.78]) 
287. In studies that report no overall group deficits in aBMD T-scores or Z-scores, 
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the prevalence of osteopenia remains high at up to 35% 286,289,290; highlighting how 
the diagnosis of CD itself may not be the primary determining factor of low bone 
mass. Imaging assessment of skeletal macro and microstructure is less common in 
adults with CD. Two HR-pQCT studies reported deficits in trabecular 
microarchitecture and vBMD, and cortical geometry, in young 283 and middle-aged 
282 adults with IBD. Most published studies represent patients of a previous era in 
terms of disease management and imaging technology. Further high-resolution 
imaging studies are required to understand the micro and macrostructural 
























pQCT ND Radius & 
Tibia 
 
DXA TB & LS 
(Lunar Prodigy) 
47% GC at 
baseline. 
 
11% at follow 
up. 
↓ Trabecular vBMD 
↔ Cortical vBMD 
↓ Cortical Thickness & Muscle CSA 
(Radius only) 
 
↓ TB & LS aBMD 
No improvement in bone or muscle outcomes after 12 
months anti-TNF-α. Linear growth improved in subgroup 
w/ growth potential. IGF-1 improved only in those with 













pQCT Left Tibia 
 









↓ Trabecular vBMD 
↑ Endo & ↓ Peri Circ. 
↓ Cortical thickness & Muscle CSA 
↓ LS aBMD, BMAD & TB BMC 
1 VF 
Incident cohort <35 days of initial therapy. Moderate-to-
severe disease in 90%. Jumping mechanography muscle 























↓ Trabecular vBMD 
↓ Cortical Thickness 
↑ Cortical vBMD & SSI 
1 VF; ↓ vertebral height in 27%. 
 
Height adjusted pQCT Z-scores. Remission or mild 
disease. Jumping mechanography muscle function 
assessments were not different to reference data (sex 











pQCT Left Tibia 32% GC at 
baseline. 
 
7% at follow 
up. 
↓ Trabecular vBMD 
↔ Cortical vBMD (base) 
↓ Muscle CSA 
↑ Endo & ↓ Peri Circ. 
 
Infliximab induction cohort. 50% severe disease at 
baseline. Trabecular vBMD improved but still low at 12 
months. Cortical vBMD low at follow up, endo circ. 
Improved. Improvements in younger and those with best 









Retrospective DXA LS  
(Lunar Prodigy) 




↓ LS aBMD & BMAD DXA aBMD Z-score not adjusted for body size. No change 
in aBMD or BMAD after one-year adalimumab. 14/18 





















↓ TB & LS aBMD 
↔ TH aBMD 
Abnormal vertebrae in 9 IBD (total 
16 VF) 
All IBD vs controls, although no differences between CD 
and UC.  
DXA Z-scores adjusted for chronological age and bone 






















pQCT ND Radius GC naïve. No 
GC during 
follow up. 
↔ Trabecular & cortical vBMD 
↓ Muscle CSA 
 
After 12 weeks: Trabecular vBMD & 
Muscle CSA ↑, cortical vBMD ↓. No 
further changes at 52 weeks. 
Incident cohort. Height SDS low. Height adjusted pQCT 
Z-scores. Short term improvements in bone turnover and 




















GC naïve  ↔ Trabecular bone volume 
↑ Trabecular number 
↓ Cortical thickness 
↓ LS aBMD & BMAD 
↓ TB lean mass & BMC 
No evidence of VF 
 
Incident cohort. Bone age ↑ vs CA. 
DXA BMC & lean mass Z-scores adjusted for height. 
BMC:lean mass ratio normal for height. Conflicting 
biopsy data – osteoclast surface was low but eroded 






143 IBD (98 CD) 
 
I: 13 ± 3.3 












↓ Trabecular vBMD 
↑ Cortical vBMD 
↓ Bone & Muscle CSA  
 
All IBD vs controls, CD not reported separately. 
Muscle CSA SDS lower in newly diagnosed vs prevalent 












pQCT Left Tibia 62% GC, 0 to 6 
months. 
 
31% GC, 6 to 
12 months 
↓ Trabecular vBMD 
↔ Cortical vBMD 
↓ Muscle & Fat CSA 
↑ Endo & ↓ Peri Circ. 
↓ Section modulus (Zp) 
pQCT geometry Z-scores adjusted for tibia length. 
Incident cohort <2 weeks of diagnosis. 84% with growth 
failure. Mild improvements after 12 months follow up 












DXA TB & LS  
(Lunar DPX) 
56% GC during 
follow up. 
↓ TB & LS aBMD. 
No change in Z-scores at 2 years 
follow up. 
 
Incident cohort. Bone age delay ~1 year in CD. 
DXA adjusted for bone age. Elevated serum IL-6 
associated with low aBMD in CD. TB aBMD positively 
















11% current GC 
(enemas) 
↓ TB BMC in sex, height and 
puberty adjusted models.  
↔ TB BMC when + adjustment for 
lean mass. 
DXA adjusted for bone size. Log-transformed models for 
BMC relative to height. Age & pubertal status of CD and 
controls different. Low BMI Z-score associated with low 






















Not reported ↓ LS BMD at baseline 
No change in Z-scores at follow up 
of between 3 – 9 years (n = 25) 
Incident cohort. 
Age adjusted DXA Z-scores. Not adjusted for body size.  
Locally recruited controls also had slightly low Z-scores 






102 IBD (75 CD) 
 




HR-pQCT ND Distal 
Radius & Tibia 
 




↓ aBMD at all sites in IBD vs control 
↓ Total & Trabecular vBMD 
↓ TbN & Cortical thickness at Tibia. 
↑ TbSp at Radius & Tibia 
5 VF 
Includes paediatric & adult patients but data not 
presented separately. Fractured IBD had lower total and 
trabecular vBMD & TbTh, and higher TbSp & Tb 












DXA TB, LS, FN, SMI 
(Lunar DPX) 
93% current or 
previous GC. 
Unclear. 
↓ TB, LS, FN aBMD & SMI Z-scores in 
male CD (n=20) 
↔ TB, LS, FN aBMD & SMI Z-scores 
in female CD (n=9) 
 
Childhood onset cohort. DXA not adjusted for body size. 
Males lower height & weight compared to controls. 
Higher myopenia (24% vs 15%) & myopenic-obesity (9% vs 
2%) in IBD vs controls. Myopenia & myopenic-obesity 





98 IBD (59 CD) 
 
42.8  










↓ Total, Trabecular & Cortical 
vBMD 
↓ Trabecular BV & TbTh 
↓ Cortical thickness & area 
Poorer vBMD and structural outcomes in CD vs UC. 72% 
current biologics use. 45% current/previous smokers. 
54% history of chronic high-dose GC. Low BMD, female 










(IQR 38, 57) 
Retrospective DXA LS, FN, TH 
(Lunar DPX/Prodigy) 
23% GC @ DXA ↓ aBMD T-scores at all sites 
↓ aBMD T-scores vs controls 
(n=44500) in adj. regression. 
 
Increased risk of osteoporosis for CD vs controls in 
adjusted regression (OR: 1.47 [1.2, 1.78]). aBMD T-





101 IBD (56 CD) 
 





DXA TB, LS & TH 
(Hologic) 
60% prior GC. 
Current GC not 
reported. 
↓ LS & TH aBMD T-scores 
↔ TB aBMD T-scores 
↔ TB, LS & TH aBMD Z-scores 
Mean LS aBMD T-score at lower end of normal (-0.76 ± 
1.2). Young IBD (aged <50) lower BMD Z-scores vs older 





70 IBD (58 CD) 
 








GC for >1 
month 
↔ aBMD T-scores at all sites 
25/70 (36%) osteopenic T-scores at 
≥1 site. 
 
All premenopausal women. ‘Early onset’ IBD (diagnosed 
<20 years). CD & UC presented together. Manufacturer 
reference data. Low BMD associated with recent 














68 IBD (24 CD) 
 








↔ aBMD Z-scores at all sites 
18/68 (26%) osteopenic T-scores at 
≥1 site. 
Incident cohort <6 months from diagnosis. Mean T-scores 
not reported. 12.5% active disease at time of DXA. Local 











DXA LS, PF 
(Lunar DPX) 
22% current 
GC. 86% ever 
GC. 
↔ aBMD Z-scores at all sites 
34/117 (29%) osteopenic, 14/117 
(12%) osteoporotic [Z-scores] 
DXA age- and sex-adjusted Z-scores (Not T-score). aBMD 





30 IBD (15 CD) 
 
24 (14, 83) 
Prospective 
cohort 




↓ LS & Arm aBMD Z-scores in CD Incident cohort <3 weeks of diagnosis. Age- and sex-
adjusted Z-scores from manufacturer. No change in Z-
scores after 12 months. 
CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis; N, number; GC, glucocorticoids; aBMD, areal bone mineral density; vBMD, volumetric 
bone mineral density; DXA, dual energy x-ray absorptiometry; pQCT, peripheral quantitative computed tomography; BV, bone volume; TbN, trabecular number; TbSp, 
trabecular separation; endo., endosteal; peri., periosteal; circ., circumference; TbTh, trabecular thickness; TB, total body; TH, total hip; LS, lumbar spine; PF, proximal 




1.4.4 Muscle health in CD 
Despite sharing common risk factors, the assessment of muscle mass and 
particularly muscle function have received notably less attention than bone health 
in children and adults with CD. Recently, investigations of muscle in CD have 
increased as the relationship of muscle with bone and clinical outcomes has 
become more apparent. Many adult bone imaging studies in CD failed to report 
muscle outcomes (Table 1-1). Others have employed arbitrary definitions of 
sarcopenia, primarily based on muscle mass, in their assessment of skeletal muscle 
in CD. Low muscle mass was observed in 51% and 58% of CD patients at diagnosis 
293 and during an acute flare 294, respectively, when assessed by abdominal CT. 
Similarly, using DXA, 60% of CD patients in remission were observed to have low 
muscle mass, 91% of which also had osteopenic BMD T-scores 295. Combined low 
muscle mass and function was also associated with six-fold higher likelihood (OR: 
6.3) of osteopenia in another cohort 296, highlighting the close relationship 
between muscle and bone intact in individuals with CD. Muscle function may be 
low in adults with CD compared to controls even when matched by BMI 297-299; 
however, BMI can be reassuringly normal in the context of low muscle mass in CD 
292. Poor muscle function is associated with subjective fatigue 298, again suggesting 
that muscle fatigue might contribute to general fatigue in adults with CD 274. Other 
studies have noted an association between low muscle mass and clinical outcomes 
in CD, including early failure of anti-TNF-α therapy 300 and post-surgical morbidity 
294, although these were retrospective in design and require validation in 
prospective assessment. 
The related development of muscle and bone during growth may explain the more 
consistent reporting of muscle outcomes in primarily bone focused research in 
paediatric CD. Studies using pQCT have observed significant deficits in muscle CSA 
at the tibia and radius in children with newly diagnosed 225,275-277 and established 
49,217,275 CD. Newly diagnosed CD was associated with lower muscle CSA Z-scores 
vs prevalent disease in one study, suggesting recent inflammatory activity may be 
a key contributor to muscle deficits 275. Deficits in lean and muscle mass were 
evident when adjusted for height 209,225,276 although the ratio of BMC to lean mass 
was maintained, highlighting no discordance in the muscle-bone relationship 209. 
As with bone, muscle deficits have been found to improve slightly, but remain 
low, after long term follow up 49,217,225,276. Two studies reported on dynamic muscle 
  56 
 
function in CD using jumping mechanography, with conflicting results. No deficits 
were found for muscle function in a cohort of adolescents with mild prevalent IBD 
(N = 70, 53 CD) 278, whereas newly diagnosed CD (n = 73) was associated with 
significantly reduced muscle power compared to reference data 277. The influence 
of active disease is an obvious confounder in the comparison between these 
studies, however they also used different methods of mechanography testing, 
compared to different reference datasets, and only one used Z-scores that were 
adjusted to body size 278. Others using hand dynamometry have reported low age 
and sex-adjusted Z-scores for grip strength in CD, which is also likely to have been 
confounded by poor growth in these cohorts 225,275. It is currently unclear if muscle 
function deficit in paediatric CD is a product of purely reduced muscle mass, or 
whether intrinsic deficits in muscle function exist that may be targeted for future 
interventions. 
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1.5 The potential role for exercise in CD 
1.5.1 Overview 
PA and exercise are critical determinants of physical and psychological wellbeing 
across the lifespan. A clear dose-dependent relationship exists between PA and 
the risk of morbidity and mortality from several chronic disease, with higher levels 
conferring the greatest protection. The utility of exercise as an adjunctive therapy 
in chronic disease is also well established. Despite this, current evidence for the 
role of PA and exercise in the management of CD and IBD is lacking. This section 
will discuss the potential mechanisms by which PA and exercise may alleviate the 
burden of IBD and its associated symptoms and briefly discuss research into the 
role of exercise in experimental models of IBD. 
1.5.2 Exercise in CD: potential beneficial mechanisms 
1.5.2.1 Inflammation 
Exercise upregulates expression of skeletal muscle myokines that exert several 
anti-inflammatory functions 301. These anti-inflammatory properties have 
potential to alleviate chronic low-grade inflammation, which remains elevated in 
CD even during periods of remission. The primary myokine expressed during 
exercise is IL-6, the expression of which is dose-dependently related to exercise 
intensity and duration 302. Typically, elevated IL-6 is associated with pro-
inflammatory mechanisms, and contributes to bone, muscle, and intestinal tissue 
destruction in CD. Muscle expressed IL-6, however, has direct and indirect anti-
inflammatory actions. It stimulates expression of anti-inflammatory cytokines IL-
10 and IL-1 receptor antagonist (IL-1ra), which inhibit the actions and expression 
of TNF- and IL-1 303. Myocyte expressed IL-6 also induces lipolysis and increases 
systemic fat oxidation 94, indirectly contributing to reduced inflammation. Regular 
exercise can also inhibit the infiltration of macrophages into adipocytes 304, which 
are known to be abundant in the creeping fat of individuals with IBD and 
contributors to intestinal and systemic inflammation. Exercise has also been 
shown to downregulate the surface expression of toll like receptors (TLRs) in 
monocytes, effectively desensitising them to pro-inflammatory stimulus and 
helping generate an anti-inflammatory phenotype 301. 
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The cumulative anti-inflammatory effects of individual bouts of PA or exercise 
leads to long term reduction in low-grade inflammation. This has been highlighted 
in studies reporting inverse associations between habitual PA and inflammatory 
markers in both adolescents 305,306 and adults 307. The association between IL-6 and 
systemic inflammation in CD suggests an exercise induced spike in circulating 
levels could potentially exacerbate disease; however, the demonstrable anti-
inflammatory actions of muscle derived IL-6 suggest any exacerbation of disease 
is unlikely. 
1.5.2.2 Fatigue 
Fatigue is one of the most reported clinical problems in CD. Up to 50% of 
individuals with CD in clinical remission and 80% of those with active disease report 
chronic fatigue 308. The anti-inflammatory effects of exercise may play a role in 
reduction of fatigue in CD, as inflammation has been implicated in the 
pathogenesis of fatigue in IBD 308. Reduced PA and exercise capacity have been 
reported in a small study (n = 10) of fatigued compared to non-fatigued individuals 
with IBD 274, suggesting poor muscle function may be a contributor to overall 
fatigue. Similarly, severe fatigue was more prevalent among CD patients who self-
reported being physically inactive compared to active peers (34% vs 19%) 272. PA 
and fatigue likely exist in a negative feedback mechanism in CD, whereby a lack 
of activity leads to poorer physical function and increased feelings of fatigue, 
subsequently leading to less activity. The potential for exercise in combating 
fatigue in CD remains relatively unexplored and fatigue is commonly cited as one 
of the primary barriers to exercise participation in CD and IBD 271,272,309. On the 
other hand, much research has been conducted into the effects of exercise in 
cancer related fatigue, which is also thought to be at least partly mediated by 
elevated circulating pro-inflammatory cytokines 310. Exercise has been 
demonstrated as an effective intervention in the treatment of cancer related 
fatigue, both during and post treatment 311. The mechanisms involved may 
therefore be beneficial to individuals with CD and this should be included as a 
primary outcome in future research, owing to the high fatigue burden in these 
patients. 
  59 
 
1.5.2.3 Psychological wellbeing 
The many facets and unpredictability of CD can lead to poor health related quality 
of life (HRQoL) and psychological wellbeing. The prevalence of anxiety and 
depression in adults with IBD is approximately double that of the healthy 
population 312. Additionally, in adolescents with IBD, disturbances in physical 
maturation contribute to poor HRQoL. The association between PA and 
psychological wellbeing has been reported in health 313,314 and other inflammatory 
diseases 315. The mechanisms that mediate the effects of PA on improved 
psychological wellbeing are not clear but may occur secondary to improved 
physical function, self-efficacy, or inflammation. The available data in CD and IBD 
is limited to self-reported studies. One study found self-reported PA to be 
negatively associated with depression after adjustment for potential confounders 
272. Another reported no associations between walking or MVPA with mental 
wellbeing 316. These studies employed the same PA assessment tool but neither 
used an IBD-specific assessment of HRQoL, therefore failing to report on disease 
specific aspects of psychological wellbeing. Studies with directly measured PA and 
disease specific indices of HRQoL are needed to understand the potential role for 
PA and exercise in the psychological wellbeing of individuals with CD and IBD. 
1.5.2.4 Bone 
The potential benefits of PA and exercise on bone mass and architecture are mode 
and intensity dependent. As discussed, primary adaptations in bone occur due to 
its mechanosensitivity to external loading patterns (section 1.2.5.1). Skeletal 
adaptation to PA or exercise is therefore highly dependent on the type and 
chronicity of the activity. For example, significantly greater aBMD, bone CSA, and 
bone section modulus have been observed in women participating in high-impact 
(e.g., volleyball, football, sprinting) compared to low or non-impact (e.g., cycling, 
swimming) sports after adjusting for age, height, and weight 152. High-impact 
loading exercise is an effective strategy for improving bone mass in school-aged 
children 317 and pre-menopausal women 318. Self-reported bone loading activities 
during adolescence and young adulthood also positively associated with HR-pQCT 
measured cortical geometry and trabecular microarchitecture outcomes in young 
adults 319. Studies of young women undergoing chronic strenuous activities (i.e. 
military training) have also reported 3-5% increases in micro and macrostructural 
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parameters of the tibia, independently of changes in aBMD 156. However, the 
extremely high volumes associated with this training was also associated with a 
threefold increased risk of stress fractures, suggesting the optimal intensity for 
skeletal adaptation is likely to be lower. 
Observational data suggest low-impact activities such as walking are most popular 
among individuals with CD and IBD 272,309, however these are likely to be 
ineffective for improving bone mass. One study assessed the effects of 12 months 
of daily low magnitude mechanical stimulation in children with CD and low tibia 
vBMD, observing no benefit to DXA or pQCT measured bone parameters 320. The 
low strain magnitude may have been insufficient to stimulate bone adaptation in 
children with normal ambulation, suggesting higher mechanical loads are 
required. Agreeably, a recent observational study noted a positive association 
between accelerometer measured MVPA and bone mass in adolescents with IBD 
273. Contemporary disease management improves bone metabolism in CD but does 
not appear to normalise bone mass deficits. The promotion of impact-based 
activities may stimulate greater bone mass accretion and bone strength in 
paediatric and adult CD, respectively, and warrants investigation as an adjunctive 
intervention. 
1.5.2.5 Muscle 
The skeletal muscle wasting in CD may be counteracted by PA and exercise. 
Particularly, resistance training promotes muscle hypertrophy by activation of 
muscle protein synthesis pathways 160,161, which were found to be impaired in a 
cohort of young adults with CD 269. This impaired activation of the IGF-1/Akt 
muscle protein synthesis pathway was associated with lower muscle mass and 
habitual PA. The rate of protein turnover is increased during active CD and can be 
alleviated by effective disease control 321,322. However, therapies may alleviate 
protein degradation while concurrently reducing protein synthesis, with minimal 
effect on net protein balance. This may partly explain the persistence of muscle 
mass deficits in remissive CD 295,299. For example, paediatric CD patients treated 
with EEN or anti-TNF-α therapy experience modest short-term improvements in 
muscle mass that parallel the induction of disease remission, but muscle mass 
deficits persist after long term follow up 49,217,225. The addition of exercise as an 
adjunct to pharmacological therapy may promote muscle hypertrophy in the 
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context of reduced inflammation. Habitual PA and exercise may also indirectly 
reduce proteolysis in muscle through anti-inflammatory mechanisms that 
ultimately inhibit the actions and expression of pro-inflammatory cytokines like 
TNF-α 94. The association between low muscle mass and poor clinical outcomes in 
CD suggests that increasing muscle could lead to improved disease status and help 
alleviate other complications such as fatigue or osteopenia. 
1.5.3 Exercise in CD: summary 
This section has highlighted the potential ways in which exercise may be an 
effective strategy for counteracting the secondary complications of CD, including 
musculoskeletal deficits. Currently, no disease specific guidelines exist for PA and 
exercise in CD or IBD, and the overall utility of exercise as a management tool in 
IBD is unknown. In Chapter 5, a systematic review of the current literature was 
performed to assess the potential role of exercise in both children and adults with 
IBD. 
  
  62 
 
1.6 Rationale summary and aims of the present work 
The muscle-bone unit is highly dynamic, and its development and maintenance 
are tightly regulated by multiple intrinsic and extrinsic factors. Here, it has been 
discussed how Crohn’s disease is associated with multifactorial insult to the 
muscle-bone unit, including chronic inflammation, nutritional deficit, and 
prolonged exposure to GC. These factors directly and indirectly inhibit bone and 
muscle accrual in paediatric CD and can cause accelerated bone and muscle 
degradation in adult CD. Subsequently, individuals with CD may be at increased 
risk of musculoskeletal morbidity and adverse events such as falls and fractures. 
Advanced imaging techniques allow high-resolution assessment of the 
musculoskeletal apparatus that was previously unavailable and has not been 
extensively carried out in paediatric or young adults with CD. These detailed 
assessments may identify specific facets of the musculoskeletal apparatus that 
can be targeted in future interventions. Further, despite extensive knowledge of 
the positive effects of exercise on bone and muscle health, the potential role for 
exercise in alleviating musculoskeletal burden in CD remains relatively 
unexplored. Therefore, the overall aims of this study were to characterise the 
muscle-bone unit in young people with CD and to explore the potential role that 
exercise may play in the management of any associated muscle-bone deficits. 
The specific aims of each chapter are as follows: 
Chapter 2: MRI assessment of the muscle-bone unit in paediatric Crohn’s 
disease. Aim – Investigate the muscle-bone unit in paediatric CD using high-
resolution MRI imaging, MRS, and functional assessment of muscle-bone. 
Chapter 3: MRI assessment of the muscle-bone unit in young adults with 
childhood onset Crohn’s disease. Aim - Investigate the muscle-bone unit in 
paediatric CD using high-resolution MRI imaging, MRS, and functional and 
biochemical assessment of muscle-bone. 
Chapter 4: 3 Associations between IBD and adverse musculoskeletal outcomes 
in middle-aged and older adults. Aim – Investigate the associations between a 
diagnosis of IBD, and its subtypes CD and UC, and musculoskeletal outcomes 
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including falls and fractures using data from a large, population-based cohort 
study. 
Chapter 5: Systematic review of exercise in inflammatory bowel disease. Aim 
– Assess the available evidence for the potential role of exercise in the 
management of IBD and its associated complications. 
Chapter 6: Feasibility of jumping based exercise as complementary therapy in 
adolescents and adults with Crohn’s disease: a questionnaire study. Aim – 
Investigate the attitudes of adolescents and adults towards the exploration of 
jumping based exercise as an adjunctive therapy for the treatment of muscle-
bone deficits in CD. 
Chapter 7: Feasibility of jumping based exercise in children and adolescents 
with Crohn’s disease. Aim – Assess the feasibility and safety of a short-term, 
jumping based exercise intervention in children and adolescents with CD. 
 
 
2 MRI assessment of the muscle-bone unit in 
paediatric Crohn’s disease 
2.1 Abstract 
Background. Paediatric CD is associated with multiple risk factors for adverse 
muscle-bone development. Prior studies have reported deficits in bone and muscle 
mass but evidence regarding bone microstructure is lacking, particularly in cohorts 
managed with contemporary therapies. 
Aim. Investigate the muscle-bone unit in a cohort of paediatric CD in comparison 
with healthy age- and sex-matched controls. 
Methods. High-resolution MRI was used to image trabecular microarchitecture, 
cortical geometry, and skeletal muscle area and adiposity at the distal femur in 
CD and controls. Bone marrow adiposity of the lumbar spine (L3) was measured 
using MRS. Muscle function was assessed using grip strength dynamometry and 
jumping mechanography in CD and compared to previously published normative 
datasets. A sub-cohort of CD participants also underwent full body DXA scans to 
measure TBLH-BMC and lumbar spine BMAD. 
Results. Twenty-one children and adolescents (11 female) with CD with median 
age 14.5 (10.6, 16.4) years and 21 age- and sex-matched controls were included. 
Median age at CD diagnosis was 8 (5, 14) years. Sixteen of the 21 CD participants 
were in clinical remission and five had mildly active disease. Paediatric CD was 
associated with lower trabecular bone volume (0.55 [0.44, 0.62] vs 0.58 [0.53, 
0.62], p = 0.003) and higher trabecular separation (0.24 mm [0.21, 0.39] vs 0.22 
mm [0.20, 0.28], p = 0.002) than controls. No differences were observed between 
CD and controls for MRI assessed cortical geometry, or muscle area and adiposity; 
or for BMA assessed by MRS. Compared to previously published normative data, 
jumping mechanography Z-scores adjusted for age and weight, respectively, were 
consistently lower than zero (all p<0.05). In the sub-cohort with available DXA (n 
= 14), LS BMAD (Z-score: -0.6 [-2.1, 1.1], p = 0.01) was lower than zero but TBLH-
BMC (Z-score: -0.1 [-0.9, 2.2], p = 0.49) was not. In CD, trabecular bone volume 
was higher in those with no prior exposure to GC. Self-reported PA was positively 
associated with trabecular bone volume (r = 0.57, p = 0.01) and negatively 
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associated with muscle fat fraction (r = -0.73, p < 0.001) and BMA (r = -0.63, p = 
0.002) in CD. 
Conclusions. Paediatric CD was associated with deficits in trabecular bone volume 
and separation compared to healthy controls, despite well controlled disease. 
These deficits appeared to be associated with prior GC exposure or disease 
severity. No differences were observed between CD and control groups for cortical 
geometry, muscle mass and adiposity, or BMA. CD was, however, associated with 
low muscle function compared to published reference data. Self-reported PA was 
also associated with several musculoskeletal outcomes in CD, suggesting it may 
play a role in any observed deficits. 
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2.2 Introduction 
The onset of CD in childhood has adverse implications for bone and muscle 
development. Risk factors for poor bone and muscle in paediatric CD include 
chronic elevation of circulating pro-inflammatory cytokines, exposure to GC 
therapy, and nutritional deficits. These factors cause systemic and local 
disruptions in mechanisms of bone and muscle development, including GH/IGF-1 
abnormalities 144, impaired bone formation 208,247, muscle catabolism, and delayed 
puberty 254,255. Disturbed pubertal development of bone and muscle in CD 
predisposes these patients to poor peak muscle and bone mass 323. In turn, these 
individuals are at increased risk of future adverse musculoskeletal events. This 
was highlighted in a recent population-based study that reported an elevated risk 
of hip fracture in adults with paediatric onset CD (HR: 1.7 [95% CI: 1.2, 2.5]) 324. 
Assessing the muscle-bone unit in paediatric CD may identify deficits that can be 
targeted to augment development of bone and muscle mass. 
Previous pQCT studies have identified deficits in muscle, cortical bone geometry, 
and trabecular vBMD, both in previously treated 49,217 and newly diagnosed 
paediatric CD patients 276,277. These studies were primarily conducted in patients 
with active disease, potentially highlighting the adverse effects of underlying 
inflammation on bone and muscle. However, muscle-bone deficits persisted at 12-
24 months follow up despite successful induction and maintenance of remission in 
most patients 49,217,276. These studies may represent slightly older treatment 
paradigms as treatment practises have changed in the last 5-10 years. Little 
research has been conducted in cohorts with established paediatric CD under 
contemporary management. Additionally, no studies have employed high-
resolution imaging in paediatric CD, meaning detailed evaluations of bone and 
muscle microstructure are lacking. 
Advances in high-resolution MRI have facilitated its use as an assessment tool for 
bone microstructure 193, in addition to its known capacity as the gold standard 
imaging assessment of muscle area. Furthermore, when combined with MRS, the 
additional capacity to assess adiposity provides a comprehensive assessment of 
bone, muscle, and fat not possible with other imaging methods. BMA is an 
emerging marker of skeletal health that can be measured by proton MRS. 
Osteoblast and marrow adipocyte precursors share a common origin in 
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mesenchymal stem cells and differentiation is competitive between tissue specific 
lineages 80. BMA has been found to be elevated in several populations with 
associated skeletal deficits and may negatively associate with bone mass 88,90. To 
date, the role of BMA in skeletal health of paediatric CD has not been investigated 
in any published study. This study therefore aimed to provide a comprehensive 
assessment of the muscle-bone unit in paediatric CD using high-resolution MRI and 
MRS, in comparison to healthy age and sex matched controls. 
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2.3 Methods 
2.3.1 Study population and design 
This study adopted a cross-sectional, case control design. From September 2018 
to October 2020, children diagnosed with CD who were managed by the paediatric 
gastroenterology team at the Royal Hospital for Children (RHC), Glasgow, were 
recruited. Study activity was suspended for a period of approximately 6 months 
during the period of March to September 2020 due to Covid-19. Potential recruits 
were identified by the gastroenterology team at RHC and contacted by mail or 
signposted to a member of the research team at outpatient clinic appointments. 
A total of 89 individuals were invited and 21 consented to participate in this study. 
Inclusion criteria were a confirmed diagnosis of CD at least 12 months prior to 
study involvement, a current age of between 8 and 17 years (inclusive), and no 
changes in medication for four weeks prior to the study (excluding dosage 
optimisations). Exclusion criteria were any significant comorbidity affecting 
musculoskeletal health, the use of medications known to affect bone health 
(excluding GC for the treatment of CD), and any contraindication to MRI. Prior to 
enrolment, all participants provided written informed consent or assent, and their 
respective legal guardian also provided written consent. This study was approved 
by the South Yorkshire Research Ethics Committee (REC Ref: 18/YH/0229). 
2.3.2 Data collection 
Disease specific data including age at CD diagnosis, current medication use, 
surgical history, and history of GC exposure were self-reported and validated in 
participants’ electronic medical records. Disease phenotype at diagnosis 
according to the Paris classification 3 was also verified in participants’ medical 
records. Disease activity was calculated according to the weighted paediatric 
Crohn’s disease activity index (wPCDAI) 24 and categorised as in remission (<12.5), 
mildly active (12.5 – 40), moderately active (42.5 – 57.5), or severe (>57.5).  
Height was measured to the nearest 0.1mm using a wall mounted stadiometer and 
weight was measured to the nearest 0.1kg. BMI (kg/m2) was calculated using 
height and weight measurements. Height, weight, and BMI were transformed into 
age- and sex-adjusted Z-scores according to UK population reference data. 
Pubertal status was self-assessed by participants and categorised according to 
  69 
 
Tanner. For analysis, Tanner stages were categorised as pre-pubertal (Stage 1), 
early pubertal (Stages 2 & 3), and late pubertal (Stages 4 & 5). Physical activity 
was self-reported using age-appropriate questionnaires: the physical activity 
questionnaire for older children (PAQ-C) (age 8 – 14 years) 325 and the physical 
activity questionnaire for adolescents (PAQ-A) (age ≥14 years) 326. These PA 
questionnaires were used to facilitate comparisons with PA data previously 
collected in the control cohort.  
2.3.3 MRI & MRS Imaging 
2.3.3.1 Overview 
All MRI images were acquired using the same 3-Tesla MRI scanner (Prisma, 
Siemens, Erlangen, Germany) at the Glasgow Clinical Research Imaging Facility. 
Images were obtained using an 18-channel anterior array coil and 32-channel spine 
array. Participants attended a single MRI scanning session where all imaging was 
obtained over approximately 70 minutes. 
2.3.3.2 MRI assessment of trabecular microarchitecture  
2.3.3.2.1 Image acquisition 
Localiser scans were obtained to measure the length of the right femur – 
calculated as the distance between the superior aspect of the femoral head and 
the distal aspect of the medial femoral condyle. To aid mobilisation and minimise 
movement artefact, padding was placed around the right leg. Trabecular 
microarchitecture images were obtained from the distal metaphysis, measured as 
15% from the distal aspect of the femur. A series of twenty axial images with 
resolution of 0.2 x 0.2 x 0.4mm were obtained using a constructive interference 
in the steady state (CISS) pulse sequence (Table 2-1). 
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Table 2-1 MRI pulse sequence parameters for trabecular and cortical imaging 
 
Trabecular Microarchitecture Cortical Geometry 
 
Sequence Type CISS T1-weighted TSE 
Resolution (mm) 0.2 x 0.2 x 0.4 0.4 x 0.4 x 2 
TE (ms) 5.68 11 
TR (ms) 12.62 650 
Flip Angle (o) 50 150 
No. of Averages 4 1 
FoV (mm2) 100 x 100 140 x 140 
Matrix 448 x 448 320 x 240 
Number of Slices 20 20 
Bandwidth (Hz/pixel) 228 240 
Scan Time (mins:secs) 9:24 1:05 
CISS – constructive interference in the steady state; TSE – turbo spin echo; TE – echo time; ms – 
milliseconds; TR – repetition time; FoV – field of view; mm – millimetres; Hz – hertz; mins:secs – 
minutes:seconds 
2.3.3.2.2 Image pre-processing 
MRI images were analysed in MATLAB (MathWorks Inc., San Mateo, CA) software 
using code developed in-house by colleagues in NHS GGC medical physics. All MRI 
image analyses presented in this thesis were completed by the primary researcher 
(LS). Prior to analyses, trabecular images were pre-processed using a sharpening 
filter to improve the contrast between hyper- and hypo-intense tissue (i.e. 
marrow and bone). This involves subtracting a blurred version of each image from 
the original – known as ‘unsharp masking’. While this improves contrast, the filter 
does not compensate for blurring due to movement during the scan. Images were 
visually inspected for gross motion artefact and these were excluded from the 
analysis. The images were further processed through a low pass filter to correct 
for bone marrow inhomogeneity, which is a common occurrence particularly in 
paediatric bone and may erroneously lead to marrow being assigned as bone. 
2.3.3.2.3 Trabecular analysis 
The central slice within the image (slice 10) was used for analyses in all but one 
participant. A proximal slice (slice 19) was used for this participant due to artefact 
on other images. Images were analysed in triplicate and the mean value used for 
subsequent analyses. Trabecular images were of sufficient quality for analyses in 
41/42 participants (1 CD – excessive motion artefact). Inter-observer repeatability 
was assessed using a subset of 30 images, each also analysed in triplicate. Intra- 
and inter-observer repeatability were high with coefficient of variations (CVs) of 
<1% and <2% for all trabecular parameters, respectively. 
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A manually defined region of interest (ROI) was created by drawing a boundary at 
the endocortical surface (interface between trabecular and cortical bone). 
Another ROI equating to 50% of the total trabecular region was created by 
manually selecting the centre of the trabecular ROI. The central region was used 
for all subsequent trabecular analyses (Figure 2-1). 
 
Figure 2-1 Example image of trabecular microarchitecture analysis at the distal femur. 
The red line indicates the endocortical boundary between trabecular and cortical regions. Blue line 
represents the central 50% of the trabecular region used for subsequent analyses. 
Finally, prior to quantitative measurement of trabecular outcomes, images were 
segmented into bone and marrow phases. A fuzzy c-means algorithm was 
implemented to binarize the images before subsequent designation of individual 
pixels as ‘bone’ (value of 1) if they contained a membership grade within the bone 
cluster higher than the required threshold. All other pixels were designated as 
‘marrow’ (value of 0). Binarized images are displayed with bone in green and 
marrow in white and superimposed onto the original image for visual assessment 
of binarization quality (Figure 2-2) 
 
Figure 2-2 MRI image of trabecular microarchitecture binarized into bone and marrow phases. 
Images were binarized into bone and marrow phases in order to designate pixels to the bone or 
marrow grade. The binarized image contains only pixels within the designated ROI and illustrates 
bone as green and marrow as white. This image is then superimposed onto the original image for 
quality assessment purposes. 
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‘Apparent’ values were calculated for trabecular microarchitecture parameters as 
the voxel size of 0.2 x 0.2 0.4mm is insufficient for accurate measurement of 
smaller trabeculae. These ‘apparent’ values also account for potential partial 
volume effects, a currently known limitation of MRI in assessment of trabecular 
microarchitecture due to limited spatial resolution. 
2.3.3.2.4 Trabecular parameters 
Apparent bone volume to total volume ratio (appBV/TV) 
A measure of the volume of trabecular bone within the medullary cavity and 
primary outcome for trabecular microarchitecture. AppBV/TV is calculated as the 
ratio of bone pixels to the total number of pixels within the region of interest 
(ROI). The following equation is used: 
𝑎𝑝𝑝𝐵𝑉 ⁄ 𝑇𝑉 = 𝑛_𝑏𝑜𝑛𝑒/𝑛_𝑡𝑜𝑡𝑎𝑙  
Apparent trabecular thickness (appTbTh) 
The Mean Intercept Length (MIL) at a given angle θ was calculated by the number 
of trabeculae-marrow boundaries that intercept a set of parallel rays oriented at 
an angle θ to the image.  
The image was masked by a grid of parallel lines, each one pixel thick and 
separated by ten pixels, so only sections of the image contained within the lines 
were considered and the masked area is set to zero. Each grid line was examined 
pixel by pixel to ascertain the number of times the pixel designation changed from 
bone to marrow (1 to 0) or marrow to bone (0 to 1), defined as PL (θ). The number 
of bone pixels (PP) were also counted, and the MIL was calculated with the 
following equation: 




The MIL was calculated in steps of 10° through 0° to 360°, and apparent trabecular 
thickness (in mm) was computed by: 
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𝑎𝑝𝑝𝑇𝑏𝑇ℎ (𝑚𝑚) = 0 ∙ 5 × 𝑚𝑒𝑎𝑛(𝑀𝐼𝐿(𝜃)𝜗=0,360) × 𝑅 
Where R is pixel resolution in mm. 
Apparent trabecular number (appTbN) 





Apparent trabecular spacing (appTbSp) 





2.3.3.3 MRI assessment of cortical geometry 
2.3.3.3.1 Image acquisition 
Cortical geometry images were obtained from the same region (15% distal femur) 
as the trabecular microarchitecture parameters using a T1-weighted turbo spin 
echo sequence (parameters in Table 2-1). A series of twenty axial images were 
obtained. Due to differing image resolutions between trabecular and cortical 
images (slice thickness 0.4mm vs 2mm, respectively), scan series were conducted 
so that the 10th slice of each series were co-located. As such, the 10th slice of 
each series was used for subsequent analyses to provide estimates of 
microarchitecture and geometry at approximately the same region. Intra- and 
inter-observer repeatability were assessed using a subset of 30 images, each also 
analysed in triplicate. Mean CVs for intra- and inter-observer repeatability were 
<3% for all cortical parameters. 
2.3.3.3.2 Cortical analysis 
Analyses were performed using MATLAB. Manually determined boundaries were 
created for the endosteal and periosteal circumferences and processed through a 
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Savitzky-Golay filter for smoothing, before being superimposed on the original 
image to determine the cortical ROI (Figure 2-3). 
 
Figure 2-3 Example image of cortical geometry analysis at the distal femur. 
Boundaries were manually drawn round the endosteal (green) and periosteal (blue) circumferences 
and superimposed onto the original image. 
2.3.3.3.3 Cortical parameters 
Cortical area (mm2) 
The pixels contained between the endosteal and periosteal circumferences were 
designated as cortical bone, therefore the cortical area (Acortical [mm2]) was 
calculated using the number of cortical pixels (ncortical) and pixel resolution (R 
[mm]) in the following equation: 
𝐴𝑐𝑜𝑟𝑡𝑖𝑐𝑎𝑙 =  𝑛𝑐𝑜𝑟𝑡𝑖𝑐𝑎𝑙 × 𝑅
2 
Endosteal and periosteal circumference (mm) 
Endosteal and periosteal circumferences (C [mm]) were calculated from the 
manually derived boundaries. The sum of distances between adjacent points on 
the respective boundaries were calculated using the following equation: 
𝐶 = ((∑ √(𝑥𝑖+1 − 𝑥𝑖)2 + (𝑦𝑖+1 − 𝑦𝑖)2
𝑛−1
𝑖=1
) + √(𝑥1 − 𝑥𝑛)2 + (𝑦1 − 𝑦𝑛)2) × 𝑅 
Where n is the number of points manually defined and R is the pixel resolution. 
Mean cortical thickness (mm) 
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Mean cortical thickness (tcortical) was calculated using a circular model as 
previously described by Johnston 327. This method uses the endosteal and 






2.3.3.4 MRI assessment of muscle 
2.3.3.4.1 Image acquisition 
Muscle images were obtained at 33% distal femur to provide adequate coverage of 
the main muscle groups of the upper leg. For assessment of muscle cross-sectional 
area (M-CSA [mm2]) and fat fraction (FF [%], an indicator of fat infiltration) a 
series of twenty axial images were obtained using a six-point VIBE Dixon pulse 
sequence (Table 2-2). 
Table 2-2 MRI pulse sequence parameters for muscle and bone marrow adiposity imaging. 
 
Muscle Area & Fat Fraction Bone Marrow Adiposity 
 
Sequence Type 6-point VIBE DIXON PRESS 
Resolution (mm) 1.1 x 1.1 x 2 20 x 20 x 20 
TE (ms) 1.54, 2.97, 4.40, 5.83, 7.26, 8.69 30 
TR (ms) 10.7 2000 
Flip Angle (o) 4 90 
No. of Averages 6 80 
FoV (mm2) 204 x 204 - 
Matrix 192 x 192 - 
Number of Slices 20 - 
Bandwidth (Hz/pixel) 1090 1200 
Scan Time (mins:secs) 3:00 2:50 
PRESS – point resolved spectroscopy; TE – echo time; ms – milliseconds; TR – repetition time; 
FoV – field of view; mm – millimetres; Hz – hertz; mins:secs – minutes:seconds 
2.3.3.4.2 Muscle area and adiposity analysis 
For the assessment of cross-sectional area and fat infiltration, ROIs were manually 
determined around ten muscles of the thigh (Figure 2-4). M-CSA was defined as 
the sum of all individual muscle ROIs. Mean FF for each muscle was calculated as 
the proportion of fat to water signal within the respective ROI, and overall mean 
muscle FF (the sum of all mean FF values divided by number of muscle groups 
analysed) was used for subsequent analyses. To provide a surrogate measure of 
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functional muscle area, residual muscle area (RMA [mm2]) was calculated as the 
total M-CSA adjusted for FF using the following equation: 
𝑅𝑀𝐴 =  




Figure 2-4 Example image of muscle analysis and individual ROIs. 
Ten individual muscles were manually segmented, and total area and mean fat fraction calculated. 
1 – biceps femoris long head; 2 – semitendinosus; 3 – semimembranosus; 4 – biceps femoris short 
head; 5 – sartorius; 6 -vastus medialis; 7 – gracilis; 8 – vastus lateralis; 9 rectus femoris; 10 – vastus 
intermedius. 
2.3.3.5 MRS assessment of BMA 
2.3.3.5.1 Image acquisition 
Proton (1H-) MRS was performed at the lumbar spine (L3) for assessment of 
vertebral bone marrow adiposity (BMA) using a 32-channel spine array. Lumbar 
spine was selected as the ROI as this has been successfully implemented in 
previous research. A point resolved spectroscopy (PRESS) pulse sequence with no 
water suppression was used to obtain spectra from the vertebral body of L3 
(parameters in Table 2-2). Due to a sequencing error during initial scanning, 
comparable MRS data were only available in 23 CD and 27 control participants. 
2.3.3.5.2 BMA analysis 
MRS data were analysed within the Java-based magnetic resonance user interface 
software (jMRUI) 328 where spectra were fitted in the time domain using a least-
squares algorithm 329. BMA (FF %) was calculated with the following equation, 
where the lipid-to-water ratio was obtained from assessment of the area under 
the curve of the water (Awater) and lipid (Alipids) peaks, respectively 330: 







All CD participants were invited to a clinical DXA scan to assess aBMD. Fourteen 
CD participants underwent clinical DXA scans within four months following their 
study visit. These scans were included in this study to assess potential associations 
between MRI and DXA outcomes. All DXA scans were performed by the same 
densitometrist (SS) using a Lunar iDXA densitometer (GE Medical Systems, WI, USA) 
and analysed using encore software (Encore version 13.5, CA, USA). Participants’ 
height and weight were measured prior to being positioned supine on the scanner. 
Once positioned, the scintillator arm moved in a cranio-caudal direction. The total 
scan time was approximately 15 minutes per participant. Data were collected for 
total body less head bone mineral content (TBLH-BMC; g) and lumbar spine bone 
mineral apparent density (BMAD; g/cm3). Values were converted into age, sex, 
and ethnicity adjusted Z-scores based on UK reference data 170.   
2.3.5 Muscle function 
2.3.5.1 Mechanography 
Lower limb muscle function was measured using a Leonardo Mechanograph Ground 
Reaction Force Plate (Novotec Medical GmbH, Pforzheim, Germany). This device 
comprises a force plate with eight strain gauge force sensors, used to measure the 
vertical ground reaction forces applied during various physical tests. Force sensors 
sampled at a frequency of 800 Hz and data transferred to a connected laptop, 
where they were subsequently analysed in specialist software (Leonardo 
Mechanography GRFP Research Edition v4.4b01.50). Prior to assessment the tests 
were verbally explained and physically demonstrated to the participant. 
Participants’ bodyweight was measured during a two second stabilisation period 
after stepping onto the platform. All mechanography data were converted into 
separate sex-specific Z-scores adjusted for age and weight, respectively, using the 
LMS methods with previously published reference data 202. The two functional 
tests used were the single two-legged jump (S2LJ; hereafter ‘jumping test’) and 
multiple one-legged hops (M1LH; hereafter ‘hopping test’) tests. 
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2.3.5.1.1 Jumping test (S2LJ) 
The jumping test protocol consisted of a maximum effort vertical 
countermovement jump with freely moving arms, with the aim of achieving 
maximum height. Countermovement jumping is influenced by several factors 
including muscle power, technique, balance, and coordination. This test is 
designed to provide a more complex assessment of muscle function than is possible 
with isometric techniques. Each participant performed three maximum effort 
jump attempts and the result with the highest jump height was used in subsequent 
analyses. Outcomes of interest from jumping were maximum power (Pmax [kW]) 
and power relative to body mass (Rel. Pmax [W/kg]), recorded during the 
acceleration phase of the jump. Data were available in 20/21 CD participants (one 
participant – hardware error). 
2.3.5.1.2 Hopping test (M1LH) 
The hopping test protocol consisted of repeatedly hopping on the dominant foot, 
with the aim of achieving maximum ground reaction force. This test measures the 
maximal force to which the tibia is exposed and is applied as an assessment of the 
functional muscle-bone unit. Participants were instructed to hop as high as 
possible on the forefoot, while keeping their leg stiff and without allowing the 
heel to touch the ground between repetitions. All tests were performed using the 
dominant foot and each participant completed three attempts. The individual hop 
with the highest recorded ground reaction force was used for subsequent analyses. 
Outcomes of interest from hopping were maximum ground reaction force (Fmax 
[kN]) and force as multiples of bodyweight (Fmax*BW). Data were available in 17/21 
CD participants (two refused, two hardware error). 
2.3.5.2 Grip strength 
Upper limb muscle function was assessed by maximal isometric grip strength using 
a digital handheld dynamometer (Takei 5401 Digital Hand Grip Dynamometer, 
Takei, Japan). All tests were performed in a seated position using the dominant 
hand, with the elbow flexed at approximately 90 degrees and resting on an arm 
rest. The participants were instructed to squeeze the dynamometer as hard as 
they could for a period of two to three seconds, with verbal encouragement. Three 
attempts were made and the test with the highest value was used in subsequent 
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analyses. The control group did not undertake grip strength assessment; 
therefore, the CD group data were transformed into age- and sex-specific Z-scores 
using the LMS method with previously published UK reference data for comparison 
331. 
2.3.6 Biochemical analyses 
All CD participants were requested to provide a blood sample for assessment of 
clinical biochemistry and markers of bone turnover and inflammation. Non-fasted 
blood samples were drawn by a research nurse at the time of study visit or were 
collected during routine blood monitoring if this was conducted ±4 weeks of the 
study visit. Blood samples were available for 19/21 participants (1 refused, 1 
failed). Clinical samples were sent directly to the local NHS accredited laboratory 
for analyses of the following: 25-OHD, PTH, Alk. Phosphatase, calcium, albumin, 
ESR, and CRP. Research samples were centrifuged, aliquoted, and supernatant 
stored at -80°C. Research bloods were to be assessed for markers of bone 
turnover, GH/IGF-1, and inflammatory cytokines, however these analyses were 
not conducted as access to laboratory facilities were restricted due to Covid-19. 
Participants were also asked to submit a stool sample for assessment of faecal 
calprotectin. If a sample was not submitted, a clinical sample from ±12 weeks was 
used for analyses if available. Faecal calprotectin data were available in 14/21 CD 
participants. 
2.3.7 Control group 
Data from 21 age- and sex-matched controls were used for comparison of MRI & 
MRS parameters, anthropometrics, fracture history, and lifestyle factors (i.e. use 
of Vit D supplements and self-reported PA). These participants were part of a 
study within the research group using identical MRI & MRS methods to establish 
reference ranges for muscle, bone, and BMA in healthy children and young adults. 
Control participants were selected based on the closest match to participants in 
the current study by age and all were matched ±1 year and ±1 self-assessed Tanner 
stage of puberty. As part of that study, controls underwent physical measurements 
including height, weight, and BMI, and self-assessed pubertal status according to 
Tanner. Use of vitamin D or calcium supplements and history of fractures were 
self-reported and habitual PA was self-reported using the same age-appropriate 
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questionnaires 325,326. These participants did not provide blood samples or conduct 
assessments of muscle function. All MRI and MRS images of control participants 
were re-analysed by the primary researcher (LS) using the same methods as the 
CD group. 
2.3.8 Study power 
Study power was calculated based on data from a study of trabecular 
microarchitecture in healthy children within the research group (unpublished). 
Mean trabecular bone volume was 0.571 ± 0.028 in the first ten healthy controls. 
The minimum clinically meaningful difference in trabecular bone volume is 
currently unknown, so an arbitrary difference of 5% was selected. To detect a 5% 
lower trabecular bone volume in CD compared to controls, with a power of 0.8 
and α<0.05, a sample size of 15 per group was required. 
2.3.9 Statistical Analyses 
Continuous data are presented as median (range) and categorical data as 
frequency (%) unless otherwise stated. Data were visualised and assessed for 
normal distribution using Shapiro-Wilk tests. Between group comparisons for 
continuous variables were made using t-tests or Mann Whitney U tests for 
parametric and non-parametric continuous variables, respectively.  Categorical 
variables were compared using chi-squared tests. Cortical geometry parameters 
were also compared using multiple linear regression models adjusted for height. 
Age and sex-adjusted Z-scores for anthropometry, mechanography, and DXA 
outcomes were compared to respective reference data using single sample t-tests 
or Wilcoxon signed rank test for parametric and non-parametric data, 
respectively. Associations between MRI, DXA, and disease outcomes were analysed 
using Pearson or Spearman correlation analyses for parametric and non-
parametric data, respectively. Statistical analyses were performed using SPSS 
(Version 24; IBM Corp, Armonk, NY) and GraphPad Prism (Version 9; GraphPad 
Software, San Diego, CA). 
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2.4 Results 
2.4.1 Clinical characteristics 
Twenty-one children and adolescents with CD with median age 14.5 (10.6, 16.4) 
years and 21 age- and sex-matched controls were included in this study. There 
were no differences in height, weight or BMI Z-scores between CD and controls 
and both groups were not different from reference data (Table 2-3). Groups did 
not differ by self-assessed Tanner stage of puberty or age at menarche in females 
(Table 2-3). Six CD participants were currently taking vitamin D supplements 
compared to none of the control group (p = 0.01). Self-reported history of 
fractures was not different between groups. One CD participant with previous 
exposure to prolonged GC therapy reported multiple fractures, although the 
location of these could not be confirmed due to management in another health 
board. All other self-reported fractures were associated with trauma and there 
were no participants with history of vertebral fracture. No differences were 
observed between groups for self-reported PA. 
In CD, the median age at diagnosis was 8.9 (5.1, 14.2) years and median disease 
duration 3.6 (1.1, 8.0) years. Panenteric (42.9%) and ileocolonic (28.6%) disease 
were the most common disease locations at diagnosis, according to Paris disease 
classification. Anti-TNF-α biologics (76.2%) were the most common current 
medication followed by thiopurines (61.9%) and methotrexate (23.8%). One 
participant was currently on Ustekinumab monotherapy, and one was on a course 
of budesonide enemas. No other current GC use was self-reported. The median 
self-reported number of previous GC courses was 1 (0, 4) and three participants 
had received GC within the previous 12 months. At the time of study 15/21 had 
disease in remission and 6/21 had mildly active disease according to wPCDAI. For 
clinical biochemistry, median serum 25-OHD was 49 nmol/l (17, 106) and only 2/18 
samples were 25-OHD deficient (<25 nmol/l). Median serum PTH was 5.1 pmol/l 
(2.6, 12.36) and 6/18 samples were above the upper healthy reference range (>7.5 
pmol/l). Median faecal calprotectin (n = 14) was 152 ug/g (30, 1316), five of which 
were above the criteria for clinically relevant intestinal inflammation (>250 ug/g).  
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Table 2-3 Cohort characteristics of paediatric CD and controls 
 
Crohn’s Disease  
(n = 21) 
Controls  
(n = 21) 
p-value 
Cohort Characteristics  
Sex (f/m) 11/10 11/10  
Age (years) 14.5 (10.6, 16.4) 13.4 (10.5, 17.0) 0.58 
Height (cm) 158.5 (137.4, 180.3) 158.0 (137.0, 176.0) 0.92 
Height Z-score (SDS) -0.01 (-1.73, 1.91) 0.04 (-1.7, 2.36) 0.5 
Weight (kg) 48.8 (32.2, 79.4) 45.9 (29.9, 86.2) 0.99 
Weight Z-score (SDS) -0.01 (-1.33, 2.21) 0.42 (-1.33, 2.34) 0.79 
BMI (kg/m2) 19.5 (16.2, 28.2) 19.0 (12.9, 30.6) 0.84 
BMI Z-score (SDS) 0.22 (-1.45, 2.60) 0.16 (-2.83, 2.57) 0.68 
Tanner stage 3 (1, 5) 3 (1, 5) 0.58 
Pubertal Stage, n (%)    
Pre-pubertal (Tanner 1) 1 (4.8) 2 (9.5)  
Early pubertal (Tanner 2/3) 13 (61.9) 8 (38.1)  
Late/post-pubertal (Tanner 4/5) 7 (33.3) 11 (52.4)  
Clinical Characteristics    
Vitamin D / Calcium Supplements, 
n (%) 
6 (28.6) 0 (0) 0.01 
Reached menarche, n (%) 6 (54.5) 6 (54.5) 1.0 
Age at menarche (years) 12 (11, 15) 12 (10, 14) 0.51 
Previous Fracture, n (%) 7 (33.3) 5 (23.8) 0.49 
PA Score 2.3 (1.1, 3.7) 2.7 (1, 3.7) 0.46 
Age at diagnosis (years) 8 (5, 14)   
Disease duration (years) 3.6 (1.1, 8.0)   
Disease location, n (%) c    
L1: Ileal 0 (0)   
L2: Colonic 2 (9.5)   
L3: Ileocolonic 6 (28.6)   
L4a/L4b/L4ab: Upper GI disease 2 (9.5)   
L3L4: Panenteric 9 (42.9)   
Disease Activity    
wPCDAI Score 0 (0, 25)   
wPCDAI activity category, n (%)    
Remission 16 (76.2)   
Mildly active 5 (23.8)   
Moderate or severe 0 (0)   
Medications, n (%)    
Anti-TNF-α  16 (76.2)   
Thiopurines 13 (61.9)   
Methotrexate 5 (23.8)   
Glucocorticoids 1 (4.8)   
Ustekinumab 1 (4.8)   
Previous GC courses 1 (0, 4)   
GC ever, n (%) 13 (61.9)   
Recent GC (<12 months), n (%) 4 (19)   
Previous CD Surgery, n (%) 4 (19)   
f/m – female/male; cm – centimetres; kg – kilograms; m – metres; wPCDAI – weight paediatric 
Crohn’s disease activity index; TNF – tumour necrosis factor; anti-TNFα – infliximab/adalimumab; 
CD – Crohn’s disease. Continuous variables displayed as median (range). a t-test; b Mann Whitney 
U test. c Disease location and behaviour at diagnosis according to Paris classification of IBD. L4 or 
P disease location can be coexistent with L1/L2/L3. 
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2.4.2 MRI assessment of bone, muscle, and BMA 
2.4.2.1 Trabecular microarchitecture 
Trabecular bone volume was lower (0.55 [0.44, 0.62] vs 0.58 [0.53, 0.62], p = 
0.003) and trabecular separation higher (0.24 mm [0.21, 0.39] vs 0.22 mm [0.20, 
0.28], p = 0.002) in CD compared to controls (Figure 2-5 A & D). The difference in 
trabecular separation remained significant after removing the outlier (p = 0.01). 

















































































Figure 2-5 Trabecular microarchitecture parameters in paediatric CD and controls. 
Individual dot plots comparing trabecular microarchitecture parameters at 15% distal femur in CD 
and controls. Between group differences assessed by t-tests (A, B, C) or Mann Whitney test (D). 
Black circles – CD; red squares – controls. N = 40 (20 CD, 20 control). A – appBV/TV; B – appTbTh; 
C – appTbN; D – appTbSp. AppBV/TV – apparent bone volume fraction; appTbTh – apparent 
trabecular thickness; appTbN – apparent trabecular number; appTbSp – apparent trabecular 
separation. Horizontal line represents median.   
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2.4.2.2 Cortical geometry 
Median cortical area was 258.9 mm2 (199.3, 391.9) and 268.9 mm2 (215.4, 320.5) 
in CD and controls, respectively (p = 0.98) (Figure 2-6 A). Median cortical thickness 
was 2.39 mm (1.81, 2.94) and 2.5 mm (2.01, 2.82) in CD and controls, respectively 
(p = 0.34) (Figure 2-6 B). No differences were observed between CD and controls 
for endosteal or periosteal circumferences (Figure 2-6 C & D). In regression 
analyses adjusted for sex and height, there were no differences between CD and 
































































































Figure 2-6 Cortical geometry in paediatric CD and controls. 
Individual dot plots comparing cortical geometry parameters at 15% distal femur between paediatric 
CD and controls. Between group difference assessed by t-tests. Black circles – CD; red squares – 
controls. A – Cortical Area; B – Cortical Thickness; C – Endosteal Circumference; D – Periosteal 
Circumference. Horizontal line represents median.  
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Table 2-4 Multiple regression analyses of cortical geometry parameters at distal femur. 
 B (95% CI) Std. β Model R2 p-value 
Cortical Geometry   
 
 
Cortical Area (mm2) 0.98 (-13.4, 15.3) .138 0.64 0.89 
Cortical Thickness (mm) -0.08 (-0.23, 0.08) -.145 0.11 0.33 
Endosteal Circumference (mm) 3.34 (-2.31, 9.0) .146 0.43 0.24 
Periosteal Circumference (mm) 2.86 (-2.32, 8.04) .127 0.51 0.27 
B – Unstandardized Beta; Std β – Standardized Beta; mm – millimetres. Models are adjusted for 
height and sex. Controls used as reference group in each model. 
2.4.2.3 Muscle area & fat infiltration 
Median muscle CSA was 5170 mm2 (4350, 9473) and 5792 mm2 (4221, 9524) in CD 
and controls, respectively (p = 0.42) (Figure 2-7 A). Muscle fat fraction was not 
different between CD and controls (4.1 % [0.4, 8.2] vs 3.5 % [0.4, 9.2], p = 0.74) 
(Figure 2-7 B). After subtracting muscle fat fraction, median RMA was 4998 mm2 
(4082, 9439) and 5604 mm2 (4121, 8652) in CD and controls, respectively (p = 0.32) 
(Figure 2-7 C). In regression analyses adjusted for height, RMA was not different 































































Figure 2-7 Muscle area and adiposity in paediatric CD and controls. 
Individual dot plots comparing muscle area and adiposity at 33% distal femur between paediatric CD 
and controls. Between group differences assessed by Mann Whitney tests. Black circles – CD; red 
squares – controls. A – muscle cross sectional area; B – muscle fat fraction; C – residual muscle 
area. Horizontal line represents median. FF – fat fraction; RMA – residual muscle area; mm – 
millimetres. 
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2.4.2.4 Lumbar spine BMA 
Median BMA was 22.3 % (12.0, 51.1) and 21.1 % (10.0, 35.8) in CD and controls, 














Figure 2-8 Bone marrow adiposity in paediatric CD and controls. 
Individual dot plots comparing bone marrow adiposity of the lumbar spine between paediatric CD 
and controls. Between group difference assessed by Mann Whitney U test. Black circles – CD; red 
squares – controls. n = 36 (21 CD, 16 controls). Horizontal line represents median. BMA – bone 
marrow adiposity. 
2.4.3 Muscle function 
Assessment of the muscle-bone unit using jumping mechanography in CD produced 
Z-scores consistently lower than reference data (Figure 2-9). From the jumping 
test (n = 20), median Z-scores for absolute muscle power were -0.74 (-1.99, 1.17) 
(p = 0.02) and -1.13 (-2.78, 1.99) (p = 0.02) when adjusted for age and weight, 
respectively (Figure 2-9 A). Similarly, median Z-scores for muscle power relative 
to body mass were -1.08 (-4.20, 1.08) (p < 0.001) and -1.11 (-3.03, 0.99) (p = 
0.001) when adjusted for age and weight, respectively (Figure 2-9 A). From the 
hopping test (n = 17), median Z-scores for absolute maximum force generated 
were -0.55 (-2.68, 0.45) (p = 0.004) and -1.46 (-3.39, 0.64) (p < 0.001) when 
adjusted for age and weight, respectively (Figure 2-9 B). Median Z-scores for 
maximum force generated as a multiple of bodyweight were -2.08 (-4.03, 0.21) (p 
< 0.001) and -1.83 (-3.58. 0.19) (p < 0.001) when adjusted for age and weight, 
respectively (Figure 2-9 B). For upper limb muscle function, median grip strength 
was 20.1 kg (12.0, 37.1) (Figure 2-9 C). When converted into age and sex specific 
values, median grip strength Z-score was -0.42 (-2.62, 1.00), which was not 
different to the reference population (Figure 2-9 D) (p = 0.18). 
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Figure 2-9 Muscle-bone unit assessments of the upper and lower limbs in paediatric CD. 
Boxplots and individual dot plot displaying assessment of muscle function and the muscle-bone unit 
in paediatric CD. A – Muscle power and relative power Z-scores assessed by jumping 
(mechanography); B – maximum force and force as a multiple of bodyweight Z-scores assessed by 
hopping (mechanography); C – maximum isometric grip strength; D – maximum grip strength Z-
scores. Sex-specific age- and weight-adjusted Z-scores calculated using the LMS method with 
reference data for jumping mechanography (A & B) from Sumnik et al. 202. Age- and sex-specific Z-
scores calculated using LMS method with reference data for grip strength from Dodds et al. 331. Z-
scores were compared to zero using one sample Wilcoxon tests. A – n = 20; B – n = 17; C & D – n 
= 21. 
  88 
 
2.4.4 DXA 
In those with CD and available DXA (n = 14), LS BMAD was lower than reference 
data, but TBLH-BMC was not (Figure 2-10). Median LS BMAD was -0.6 (-2.1, 1.1) (p 
= 0.01). Median TBLH-BMC was -0.1 (-0.9, 2.2) (p = 0.49). One participant had LS 
BMAD Z-score < -2.0 SDS and 6/14 had LS BMAD Z-score < -1.0 SDS. No participants 
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Figure 2-10 Assessment of bone using DXA in paediatric CD. 
Individual dot plot displaying TBLH-BMC and BMAD at the total body and lumbar spine in paediatric 
CD. n = 14. Age-, sex-, and ethnicity-specific Z-scores were calculated using the LMS methods from 
UK reference data (Crabtree et al. 170). 
2.4.5 Associations between bone, muscle, and adiposity 
2.4.5.1 Trabecular bone 
Trabecular bone volume did not associate with absolute weight (r = 0.09, p = 0.7) 
or BMI (r = 0.17, p = 0.47) but was positively associated with weight Z-score (r = 
0.46, p = 0.04) in CD. No such associations were observed in controls. No 
associations were observed between trabecular microarchitecture parameters and 
RMA in CD or controls (Figure 2-11). Also, there was no evidence of any 
associations between trabecular microarchitecture parameters and DXA measures 
of LS BMAD or TBLH-BMC. Trabecular bone volume was, however, positively 
associated with self-reported PA in CD (r = 0.57, p = 0.01) but not controls (r = -
0.04, p = 0.88). 
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Figure 2-11 Associations between RMA and trabecular microarchitecture in paediatric CD and 
controls. 
Scatterplots displaying associations between RMA and trabecular microarchitecture in paediatric CD 
and controls. A – appBVTV; B – appTbTh; C – appTbN; D – appTbSp. Black circles – CD, red 
squares – controls. Associations assessed using Spearman rank correlation analyses for non-
parametric data. AppBV/TV = apparent trabecular bone volume; appTbTh – apparent trabecular 
thickness; appTbN – apparent trabecular number; appTbSp – apparent trabecular spacing. BMI – 
body mass index; mm – millimetre. 
2.4.5.2 Cortical bone 
Cortical area was strongly positively associated with height in both CD (r = 0.84, 
p < 0.001) and controls (r = 0.73, p < 0.001). Conversely, cortical thickness was 
positively associated with height in CD (r = 0.66, p = 0.001) but not controls (r = -
0.01, p = 0.97). Cortical area, but not cortical thickness, was positively associated 
with RMA in CD and controls (Figure 2-12). In multiple regression analyses adjusted 
for sex and height, cortical area was positively associated with RMA in CD only 
(Table 2-5). Cortical geometry was not associated with DXA measures of TBLH-
BMC or LS BMAD, nor was it associated with self-reported PA. 
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Figure 2-12 Associations between RMA and cortical geometry in paediatric CD and controls. 
Scatterplots displaying associations between RMA and cortical geometry. A – cortical area; B – 
cortical thickness. Black circles – CD, red squares – controls. Associations assessed using 
Spearman rank correlation analyses for non-parametric data. mm – millimetres. 
Table 2-5 Multiple regression analyses of residual muscle area and cortical geometry in 
paediatric CD and controls. 
 Crohn’s Disease (n = 21) 
Outcome B (95% CI) Std. β Model R2 p-value 
Cortical Area (mm2) 0.01 (0.004, 0.02) .437 0.82 0.01 
Cortical Thickness (mm) 6.0 x10-5 (0.00, 0.00) .296 0.42 0.25 
 Controls (n = 21) 
Outcome B (95% CI) Std. β Model R2 p-value 
Cortical Area (mm2) 0.01 (-0.00, 0.02) .341 0.59 0.16 
Cortical Thickness (mm) 1.1 x10-4 (0.00, 0.00) .610 0.17 0.09 
Multiple linear regression analyses of residual muscle area and cortical geometry in CD and controls, 
respectively. RMA is the predictor for each model. All models adjusted for sex and height. B – 
unstandardized beta coefficient; Std. β – standardized beta coefficient; mm – millimetre. 
2.4.5.3 Muscle area, adiposity, and function 
Muscle fat fraction also negatively associated with all measured muscle function 
Z-scores (Table 2-6). In CD, self-reported PA was positively associated with RMA 
in regression analyses adjusted for sex and height (Unstandardised β: 1022 mm2 
[95%CI: 450, 1594], p = 0.002). PA was also strongly negatively associated with 
muscle fat fraction in CD (r = -0.73, p < 0.001), and positively associated with Z-
scores for grip strength, muscle power and relative power, and relative force in 
CD (Table 2-6). 
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Spearman rank correlations for associations between muscle fat fraction and self-reported PA with 
muscle function Z-scores in paediatric CD. a n = 21; b n = 20; c n = 17. Parentheses represent p-
values. 
2.4.5.4 Bone marrow adiposity 
Lumbar spine BMA was negatively associated with trabecular bone volume in CD 
(r = -0.57, p = 0.01) but not controls (r = 0.22, p = 0.36). No other associations 
were observed between BMA and trabecular microarchitecture or cortical 
geometry parameters in CD or controls. BMA also did not associate with DXA-
derived measures of TBLH-BMC or BMAD in CD (n = 14). Additionally, BMA was 
negatively associated with self-reported PA in CD (r = -0.63, p = 0.002 [n = 20]) 
but not controls (r = 0.09, p = 0.76 [n = 16]).  
2.4.6 Associations between prior GC exposure and bone, muscle, 
and adiposity outcomes 
2.4.6.1 Trabecular and cortical bone 
Trabecular bone volume and trabecular thickness were higher in CD participants 
with no previous exposure to GC therapy (Figure 2-13 A & B). The number of 
previous courses of GC therapy was also negatively associated with MRI-derived 
trabecular bone volume (r = -0.47, p = 0.04) and trabecular thickness (r = -0.58, p 
= 0.01). Previous GC exposure was not associated with cortical geometry (Figure 
2-13 C & D).  






















































































Figure 2-13 Exposure to GC and trabecular and cortical bone in paediatric CD. 
Individual dot plots comparing trabecular bone volume (A), trabecular thickness (B), cortical area (C), 
and cortical thickness (D) in paediatric CD with and without previous exposure to GC therapy. Closed 
circles – previously exposed to GC; open circles – no previous GC exposure. Between group 
differences assessed using t-tests. 
2.4.6.2 Muscle area and adiposity 
RMA was not associated with prior GC exposure in regression analyses adjusted for 
height and sex (β = -105 mm2 [95% CI: -626, 414], p = 0.74). Muscle fat fraction 
also was not associated with previous GC courses (r = 0.36, p = 0.11) and did not 
differ between CD participants with and without prior GC exposure (p = 0.11). No 
associations were observed between prior GC exposure and any muscle function 
Z-scores. 
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2.5 Discussion 
This study used novel methods of combined MRI and MRS together with a battery 
of functional tests to assess the muscle-bone unit in paediatric CD compared to 
healthy controls. High-resolution MRI revealed deficits in trabecular 
microarchitecture in CD compared to controls, while no differences in cortical 
bone geometry or muscle area and adiposity were observed. Muscle mass and fat 
infiltration did not differ between CD and controls. Paediatric CD was, however, 
consistently associated with low Z-scores for muscle function parameters 
compared to previously published data. 
Despite paediatric CD being commonly associated with abnormalities in skeletal 
development, trabecular microarchitecture has not been well characterised in this 
population. In this study, paediatric CD was associated with lower trabecular bone 
volume and higher trabecular separation at the distal femur compared to healthy 
controls. Similarly, one study found low lumbar spine trabecular bone score in 
paediatric CD when compared to healthy controls and paediatric UC 332. That study 
corroborates the low trabecular bone volume and LS BMAD observed here. 
Conversely, newly diagnosed paediatric IBD was associated with normal trabecular 
bone volume at the iliac crest in another study using bone biopsy 
histomorphometry (n = 20; 17 CD) 209. In that study, the inclusion of some UC 
participants may have attenuated any association between CD and trabecular 
outcomes. However, in histomorphometric analysis, bone turnover appeared to be 
almost entirely suppressed, which may have explained the lack of trabecular 
deficit. Inflammation has been suggested as a primary regulator of bone loss in 
paediatric CD/IBD, yet trabecular deficits were observed in the current study 
despite currently quiescent disease activity. Systemic and local inflammation 
were not measured in the current study and the relative contribution of these to 
skeletal outcomes in paediatric CD requires assessment in prospective trials. 
Another potential contributor to bone abnormalities in paediatric CD is exposure 
to GC, which can have devastating effects on the growing skeleton. Previous GC 
exposure may have moderated the trabecular deficits observed in this cohort. 
Those with CD and no prior GC exposure were observed to have higher trabecular 
bone volume and trabecular thickness compared to previously GC-treated peers. 
Self-reported number of previous GC courses was also negatively associated with 
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trabecular bone volume (r = -0.47) and trabecular thickness (r = -0.58) in CD. 
These correlations may underestimate the true association between GC exposure 
and trabecular microarchitecture as, in several instances, one self-reported 
course of GC represented prolonged exposure of between several months up to 
approximately two years. Unfortunately, insufficient prescription data were 
available to calculate cumulative past GC exposure in this cohort. Nevertheless, 
these results indicate that any prior exposure to GC in paediatric CD may lead to 
systemic trabecular deficits. In paediatric patients with potential for skeletal 
growth, GC-induced bone deficits can be transient and reversible after cessation 
of therapy 36. However, few participants in the current study reported recent GC, 
suggesting any adverse effects of GC were incurred earlier in the disease course 
and have subsequently failed to improve. This is despite ongoing management 
with contemporary therapies, highlighting the role of other factors in skeletal 
recovery. However, CD is a model of a disease where the underlying insult is 
generally not removed and low-grade chronic inflammation is likely to be present 
on an ongoing basis. Alternatively, other factors that were not studied such as 
nutritional status may have regulated trabecular deficits in the current cohort. 
Further high-resolution imaging studies are required to characterise trabecular 
bone in paediatric CD and elucidate key clinical factors associated with trabecular 
deficits. 
The negative effects of GC exposure and inflammation are both moderated by the 
severity of underlying disease, which may serve as one of, if not the most 
important factor in the pathogenesis of musculoskeletal deficits in CD. Severe 
disease phenotypes are associated with greater inflammatory burden and 
increased risk of extraintestinal manifestations of disease. To compound these 
effects, severe disease is primarily treated with prolonged exposure to high dose 
GC, which, as discussed, have devastating effects in the growing skeleton 
243,247,248. In this cross-sectional study of children with established CD, current 
disease activity was low, and no longitudinal assessment of disease course was 
conducted. Nevertheless, it should be noted that the five CD participants with the 
poorest trabecular bone volume fraction scores were all noted to have severe 
disease at time of diagnosis that was treated with protracted courses of GC. 
Similar observations have been made in children with incident rheumatic diseases, 
where initial disease severity and subsequent cumulative GC exposure are 
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predictors of vertebral fracture, an extreme indicator of trabecular bone 
pathology 166. To assess the true associations between initial disease severity and 
clinical management with musculoskeletal outcomes in paediatric CD would 
require large scale, multi centre prospective studies with long term imaging follow 
up from onset of disease to several years post-diagnosis. 
Despite deficits in trabecular bone, no differences in cortical bone geometry at 
the distal femur were observed between CD and controls in the current study. This 
contrasts previous pQCT studies that have consistently observed low cortical area 
and thickness in paediatric CD, in both newly diagnosed 209,276 and previously 
treated patients 49,275,278. Cortical bone deficits in those studies may have been 
partly attributable to delayed growth, as height Z-scores were generally below 
zero, unlike the current study. Additionally, previous studies observed improved 
linear growth and cortical in children with CD treated with anti-TNF-α therapy 
47,49. The common use of anti-TNF-α in the current cohort may therefore have 
contributed to normal growth and cortical bone development. It cannot, however, 
be ruled out that cortical deficits may exist in paediatric CD that were not 
detected in this study. The heterogeneity of cortical parameters in growing 
children make it difficult to interpret these data in such a small cohort without 
access to suitable age, sex, and preferably height-adjusted reference values. This 
study represents the only evaluation of cortical geometry of the distal femur in 
paediatric CD to date and future trials are necessary to validate these results. 
Further analyses of the mechanical properties of the femoral cortex would provide 
further insight into cortical strength in this cohort. 
A sub-cohort of CD participants underwent total body and lumbar spine DXA scans 
(n = 14). LS BMAD, but not TBLH-BMC, Z-scores were lower than reference values, 
with 6/14 displaying low BMAD Z-score (< -1.0 SDS). This agrees with the MRI 
findings of deficits in trabecular but not in cortical bone, as the lumbar spine is a 
trabecular rich region, whereas TBLH-BMC is generally representative of cortical 
bone mass. These results add to the existing studies reporting low trabecular vBMD 
in paediatric CD 49,217,275-277,333,334. The present data highlight the persistence of 
skeletal concerns in children with CD, despite contemporary management. 
Although deficits in both trabecular microarchitecture and LS BMAD were 
observed, no associations between these or any other DXA or MRI parameters were 
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noted. Similarly, a lack of association between DXA and MRI outcomes have been 
reported in children 335 with type 1 diabetes mellitus, demonstrating that 
trabecular assessment by MRI provides additional information not available via 
densitometry. The lack of association may also be due to different anatomical 
locations and mechanical loading patterns between the femur and lumbar spine. 
MRI assessment of trabecular microarchitecture may offer an alternative outcome 
in the assessment of skeletal health in paediatric CD and its utility as a prognostic 
indicator of bone status should be investigated further. 
Risk factors for skeletal disorder in paediatric CD also negatively influence muscle 
mass and function. Prior imaging studies have reported low muscle mass in 
paediatric CD that persists after long-term follow up 276,280 or treatment with anti-
TNF-α therapy 49,217. In the current study, no differences were observed in muscle 
area of the mid-thigh between paediatric CD and controls. Improving underlying 
disease status may partially improve muscle mass deficits in CD and the quiescent 
disease activity of the current cohort may have facilitated regular muscle 
development under contemporary management. However, other non-clinical 
factors such as nutrition and PA are also integral to muscle growth. Self-reported 
PA was positively associated with RMA in CD, in regression analyses adjusted for 
height and sex (β: 1022 mm2 [95%CI: 450, 1594], p = 0.002). The inclusion of 
several highly active participants in the current study may have skewed the RMA 
findings towards a higher muscle mass than would be expected for the paediatric 
CD cohort in general. These data suggest higher levels of PA and exercise may be 
associated with greater muscle mass development in CD and muscle targeting 
interventions should be investigated.  
Independently of muscle mass, infiltration of skeletal muscle by adipocytes can 
lead to impaired muscle quality and function. This study quantified skeletal 
muscle fat in paediatric CD for the first time, finding no differences compared to 
healthy controls. Muscle fat fraction is strongly regulated by mechanical stimuli 
and PA, highlighted by high levels of fat infiltration in skeletal muscle in 
populations with impaired mobility 103. In accordance, a strong negative 
association between self-reported PA and muscle fat fraction (r = -0.73) was 
observed in the current CD cohort. Muscle adipocytes express pro-inflammatory 
adipokines that may contribute to systemic inflammation in CD, although this has 
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not been investigated. Further studies are required to elucidate any association 
between CD and muscle fat infiltration and its potential role in systemic 
inflammation. 
This comparison of paediatric CD and healthy controls found no differences in 
skeletal muscle area or fatty infiltration. In contrast, assessments of muscle 
function compared to previously published reference data produce some 
conflicting results. Firstly, grip strength Z-scores, adjusted for age and sex, were 
not different in CD compared to reference data from UK children 331. Conversely, 
sex specific Z-scores for jumping mechanography, adjusted separately for age and 
weight, respectively, were consistently low in CD compared to reference data 202. 
Low grip strength has been previously reported in paediatric CD in cohorts with 
concurrent muscle mass deficits 217,225. Mechanography Z-scores, on the other 
hand, were reported as normal in a prior cohort of paediatric IBD (n = 70; 53 CD), 
although muscle mass was not reported 278. The discordance between the current 
results and those of Maratova and colleagues 278 may be due to their adjustment 
of mechanography Z-scores for height rather than weight, owing to short stature 
in their CD cohort. Power and force Z-scores correlate very closely with weight in 
growing children and weight-adjusted Z-scores are thought to be preferable due 
to the wide variability in physical characteristics in children of the same age 202. 
Poor dynamic muscle function in paediatric CD after adjustment for weight, 
accounting for muscle mass, suggests a potential mechanism of dysfunction 
independent of muscle size. PA and muscle fat were positively and negatively 
associated with muscle function, respectively. Whether other disease specific 
factors contribute to muscle function requires further investigation. 
Muscle and bone development are closely paralleled during growth. One previous 
MRI study in typically developing children (age 6 - 12 years) reported strong 
associations between muscle volume at the mid-thigh with trabecular (r = 0.81) 
and cortical (r = 0.96) bone volume at distal femur 336. In the current study, RMA 
positively associated with cortical area but not trabecular bone volume in CD. The 
lack of association between muscle and trabecular bone may be due to small 
sample size in this study, or possibly represent the discordance between bone and 
muscle during the adolescent growth spurt. While muscle mass per se was not 
associated with trabecular bone, the potential importance of mechanical loading 
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for trabecular development was evidenced by the positive association between 
self-reported PA (r = 0.57) with trabecular bone volume. There is currently a lack 
of published data tracking the relationships between trabecular 
microarchitecture, muscle mass, and PA across the adolescent age in both health 
and disease and this warrants investigation in future prospective trials. 
BMA has emerged as a novel marker of bone health yet its association with skeletal 
health in inflammatory diseases is not well established. In this study, BMA did not 
differ between paediatric CD and controls. A negative association between BMA 
and trabecular bone volume was observed in CD but not in controls, as has been 
found in other diseases with associated skeletal morbidity 90,337,338. BMA is 
metabolically distinct to other adipose depots but was associated with muscle fat 
fraction in CD. Mechanical loading and exercise partly regulate BMA and a negative 
association between BMA and PA was found in CD (r = -0.63). It can be speculated 
that the negative associations between BMA and muscle fat fraction is most likely 
moderated by their respective associations with PA. Any disease associated 
mechanisms of BMA accrual in CD are not evident from the current study. 
Mechanistic studies are required to evaluate any contribution of BMA to bone loss 
in both CD and other inflammatory conditions. 
This study has some important limitations. Due to the cross-sectional nature of 
these analyses, no assessment of cause and effect is possible. For example, similar 
adverse associations were observed between low self-reported PA and previous 
GC exposure with trabecular bone volume. There is biological plausibility for the 
effects of both PA and GC in bone, but the available data does not permit an 
assessment of which, if any, contributed to skeletal deficits. Furthermore, other 
factors such as nutritional status or clinical biomarkers that were not measured 
may be involved. It can be speculated, however, that the combined effects of 
severe disease at baseline with subsequent high dose GC exposure, followed by a 
lack of habitual PA even when disease is brought into remission, may create a sub-
optimal environment for trabecular development that led to the observed deficits 
in some participants. As previously mentioned, heterogeneity in physical 
development between children of the same age limits assessment of skeletal 
muscle or cortical bone outcomes on a one-to-one matched basis and access to a 
much larger control group would be needed to assess these with adequate 
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statistical power. There may be underlying biochemical differences in bone 
turnover, GH/IGF-1, or inflammatory markers that were unable to be investigated 
due to restricted availability of laboratory facilities and these will be analysed in 
the future. The study had a small sample size but remained adequately powered 
to detect differences in trabecular bone volume which was the primary outcome. 
The reproducibility of MRI for assessing trabecular microarchitecture has been 
demonstrated in previous studies and mean inter-observer CVs of <2% were found 
for all current analyses. However, the use of MRI has some important limitations. 
Primarily, MRI scans are expensive and require specialist input for both pulse 
sequence design and scanning. The high-resolution and signal-to-noise ratio 
required to assess trabecular bone results in long scan times (approx. 9 minutes) 
that are highly susceptible to movement artefacts. No objective grading system 
exists for trabecular image quality, and this was subjectively assessed prior to 
analyses. Most scans were of sufficient quality for analysis, but it remains possible 
that some will have at least minor movement artefact which could have affected 
the results. Despite these points, MRI has many strengths including being the gold 
standard imaging modality for skeletal muscle assessment. Additionally, the 
combination of MRI and MRS enabled a comprehensive evaluation of the muscle-
bone unit that is not possible with other techniques, like HR pQCT. 
In conclusion, this study identified trabecular microarchitecture deficits at the 
distal femur in a cohort of paediatric CD with currently well-controlled disease. 
Trabecular bone in CD appeared moderated by prior exposure to GC therapy. 
Cortical geometry and muscle area were not different between groups, although 
muscle function in CD was low compared to reference data. Self-reported PA was 
associated with several musculoskeletal outcomes in CD, including trabecular 
bone volume, muscle mass and fat infiltration, and BMA. Future work should 
address the utility of targeted exercise interventions as an adjunct to improve the 
observed musculoskeletal deficits in paediatric CD. 
 
 
3 MRI assessment of the muscle-bone unit in 
young adults with childhood onset Crohn’s 
disease 
3.1 Abstract 
Background. Long term musculoskeletal outcomes in adults with childhood onset 
CD are currently unknown, especially in those managed with contemporary 
therapies. 
Aim. Investigate the muscle-bone unit in young adults with childhood onset CD in 
comparison with healthy age- and sex-matched controls. 
Methods. Cross-sectional, case-control study using 3 Tesla-MRI and MRS to assess 
trabecular microarchitecture and cortical geometry at 15% distal femur, muscle 
cross sectional area and adiposity at 33% distal femur and BMA at lumbar spine. 
Muscle function was assessed by grip strength dynamometry and jumping 
mechanography. Biochemical assessment of the muscle-bone unit, GH axis and 
inflammatory markers were measured in blood. 
Results. Twenty-seven adults (15 female) with CD with median age 23.2 (18.0, 
36.1) years were compared with 29 controls (15 females) with median age 22.7 
(18.2, 37.0). Median age at CD diagnosis was 12 (6, 17) years. Twenty of the 27 
CD participants were in clinical remission and seven had mildly active disease. 
Trabecular microarchitecture and cortical geometry parameters were not 
different between CD and controls. Median muscle cross sectional area was 6863 
mm2 (3404, 10667) and 8684 mm2 (5084, 13768) in CD and controls, respectively 
(p = 0.01). Median muscle FF% was 5.3% (0.6, 8.9) and 4.1% (0.5, 9.2) in CD and 
controls, respectively (p = 0.07). In multiple regression analyses, CD had 
significantly lower grip strength (-4.7 kg [95% CI: -7.2, -2.2], p < 0.001) and lower 
muscle power relative to body mass (-5.0 W/kg [95% CI: -8.8, -1.2], p = 0.01) 
compared with controls. Median BMA fat fraction was 31.0% (9.5, 58.8) and 29.5% 
(11.0, 47.1) in CD and controls, respectively (p = 0.644). Markers of bone and 
muscle metabolism were similar between groups, although serum OC was higher 
in CD (p = 0.002). Pro-inflammatory cytokines and IGFBP-2 were elevated in CD. 
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Disease activity was negatively associated with trabecular bone volume (r = -0.40, 
p = 0.04) and muscle cross sectional area (r = -0.41, p = 0.03). 
Conclusions. Young adults with well controlled CD do not display any deficits in 
trabecular microarchitecture or cortical geometry of the distal femur, as assessed 
by high-resolution MRI. Despite well controlled disease, however, childhood onset 
CD was associated with significantly lower muscle mass and function, and current 
disease activity was negatively associated with muscle-bone outcomes. Strategies 
to improve muscle mass and function warrant investigation to mitigate the future 
risk of musculoskeletal morbidity. 
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3.2 Background 
In Chapter 2, assessment of the muscle-bone unit in paediatric CD revealed 
deficits in trabecular microarchitecture and skeletal muscle function. This study, 
along with previously published research 217, highlights the persistence of 
musculoskeletal problems in children with CD, even in those managed with 
contemporary therapies. Few studies, however, have assessed long term 
musculoskeletal outcomes in young adults diagnosed with CD in childhood. It 
therefore remains unknown whether muscle-bone deficits persist into adulthood. 
Adolescents with IBD (n = 47; CD = 17) were observed to have deteriorating aBMD 
after five years of follow up into early adulthood in one historic study 323. Young 
adults with IBD (n = 102; CD =75) were found to have 10% reduced trabecular vBMD 
compared with healthy controls together with lower trabecular number and 
increased trabecular separation, although this cohort contained both childhood 
and adult-onset disease 283. Exposure to GC was higher in these cohorts relative to 
current treatment paradigms and few patients were treated with anti-TNFα 
therapy, which are being increasingly used in the long-term management of CD. 
Anti-TNFα therapy rapidly improves biomarkers of bone formation and IGF-1 in 
paediatric CD 49,339. However, persistent muscle-bone deficits in vBMD are 
observed after up to 12 months of treatment 49,217. Whether long term 
management with contemporary therapies may facilitate resolution of muscle-
bone deficits incurred early in the disease course is not clear. 
The aim of this study was, therefore, to perform high-resolution MRI imaging, 
biochemical, and functional assessment of the muscle-bone unit in young adults 
with childhood onset CD compared to healthy age- and sex-matched controls. 
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3.3 Methods 
3.3.1 Study Population and Design 
Between January 2017 and January 2019 adults with childhood onset CD were 
recruited from across NHS Greater Glasgow & Clyde. Eligible individuals were 
contacted by their gastroenterology consultant or signposted to the research team 
at outpatient clinic appointments. The operation of this study was taken over by 
the primary researcher (LS) in October 2017, at which point 31 participants had 
already been recruited by research nurses at the CRF. A total of 97 individuals 
with CD were invited and 27 volunteered and consented to participate in this 
study. Twenty-nine healthy age- and sex-matched controls were recruited from 
study advertisements at the local university hospital campus and through 
associates of CD participants. Eligibility criteria for the CD group were as follows: 
aged 18 – 40 years (inclusive), CD diagnosed in the paediatric age (≤17 years), 
diagnosed ≥12 months prior to study involvement, stable medication for >4 weeks 
prior to study involvement. Exclusion criteria were contraindication to MRI, 
significant comorbidity affecting muscle-bone, pregnancy, medications known to 
affect bone (excluding those used exclusively to treat CD [e.g. glucocorticoids]). 
Each CD participant was age- and sex-matched to at least one healthy control (± 
1 year). The study was approved by the North of Scotland NHS Research Ethics 
Committee (REC Ref: 16/NS/0060), and all participants provided written informed 
consent prior to participation. 
3.3.2 Data collection 
Health and lifestyle data were collected including self-reported physical activity 
(IPAQ long form 340), use of calcium/vitamin D supplements, fracture history, 
current medication use, comorbidities and age at menarche and oral 
contraceptive use (females only). Height was measured to the nearest mm and 
weight measured to the nearest 0.1 kg. Age at diagnosis, history of CD related 
surgery, disease location according to Paris classification 3 and self-reported 
number of glucocorticoid courses in the paediatric age were collected from the 
CD group and, where possible, verified in the medical history. Disease activity was 
assessed using the validated Crohn’s Disease Activity Index (CDAI) 22 with 
participants classed as severe disease (>451 CDAI score), moderate disease (221 – 
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450), mild disease (150 – 220) or clinical remission (0 – 149). All study participants 
were also requested to provide a stool sample for assessment of faecal 
calprotectin.  
3.3.3 MRI & MRS Imaging 
3.3.3.1 Overview 
MRI & MRS imaging methods were conducted as described in Chapter 2. These will 
be only briefly discussed here. The same 3-Tesla MRI scanner was used (Prisma, 
Siemens, Erlangen, Germany). Imaging lasted approximately 70 minutes per 
participant. 
3.3.3.2 MRI assessment of trabecular microarchitecture  
As previously described, a series of 20 axial images were acquired at 15% distal 
femur using a CISS pulse sequence. The central slice of the image (slice 10) was 
used for analyses in all but two participants, where this was not possible due to 
gross motion artefact. Trabecular images were of sufficient quality for analysis in 
54 participants for this study (n = 26 CD; n = 28 controls). The trabecular ROI was 
manually defined and the central region, equating to 50% of total trabecular ROI, 
was used for all subsequent analyses. Trabecular outcomes of interest were 
appBVTV, appTbTh (mm), appTbN (/mm), appTbSp (mm). 
3.3.3.3 MRI assessment of cortical geometry 
A series of 20 axial images were acquired also at 15% distal femur using a T1-
weighted turbo spin echo sequence. The central slice of the image (slice 10) was 
also used for cortical analyses as these were co-located with trabecular slice 10. 
Cortical images were of sufficient quality for analysis in all participants. Cortical 
geometry outcomes of interest were cortical area (mm2), cortical thickness (mm), 
endosteal circumference (mm), and periosteal circumference (mm). 
3.3.3.4 MRI assessment of muscle 
A series of 20 axial images were acquired at 33% distal femur using a six-point VIBE 
Dixon pulse sequence. The central slice of the image deck was used for all 
analyses. Muscle images were of sufficient quality for analysis in all participants. 
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Manual ROIs were drawn around ten muscle groups of the thigh, as described in 
Section 2.3.3.4. Muscle outcomes of interest were M-CSA (mm2), fat infiltration 
(FF%), and RMA (mm2). 
3.3.3.5 MRS assessment of BMA 
1H-MRS was performed at L3 for assessment of BMA using a PRESS pulse sequence 
with no water suppression. Due to an initial sequencing error, BMA data were 
available for 50 participants (CD, n=23; controls, n=27). BMA (%) was calculated 
using area under the curve of the respective lipid and water peaks on the spectra. 
3.3.4 Muscle function assessment 
3.3.4.1 Grip strength 
Maximal isometric grip strength (kg) of the dominant hand was measured using a 
digital handheld dynamometer (Takei 5401 Digital Hand Grip Dynamometer, 
Takei, Japan). Participants were instructed to stand with their elbow flexed at 
90°, holding the dynamometer with their hand in a neutral position and ensuring 
their elbow was not in contact with the trunk. After a countdown the participants 
were instructed to squeeze the dynamometer as hard as possible for 2-3 seconds, 
with verbal encouragement. This was repeated three times and the highest value 
was taken as maximal grip strength for subsequent analysis. 
3.3.4.2 Jumping mechanography 
Lower limb muscle function was assessed using jumping mechanography as 
previously described (Section 2.3.5.1). In this study, the jumping test (S2LJ) only 
was performed. Briefly, participants were asked to perform a maximum effort 
countermovement jump with freely moving arms. This was repeated three times 
and the jump with the highest height was used for subsequent analysis. Due to 
hardware issues, mechanography data were only available in 37 participants (19 
CD, 18 controls). Mechanography outcomes of interest from the jumping test were 
power (W) and power relative to body mass (W/kg). 
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Measured outcomes were absolute power (kilowatts [kW]), relative power 
(power/body mass [W/kg]), absolute force (kilonewton [kN]), relative force 
(force/bodyweight [*BW]) and jump height (cm). 
3.3.5 Biochemical analyses 
Participants arrived fasted from the previous evening and fasted blood samples 
were drawn between 0900 – 1000h by a research nurse. Research samples were 
centrifuged and aliquoted then stored at -80°C until subsequent analysis. Blood 
samples were available for all 27 CD participants and 28/29 controls (one refused). 
3.3.5.1 Markers of bone turnover 
Bone turnover activity was assessed through measurement of multiple biomarkers 
in bloods samples. Bone specific alkaline phosphatase (BSAP) and osteocalcin (OC) 
were measured as markers of bone formation and sclerostin and c-terminal 
telopeptide of type I collagen (CTX-1) were measured as markers of bone 
resorption in serum. BSAP was measured using immunoenzymatic assay (Ostase 
BAP, Immunodiagnostic Systems, Boldon, UK; intra-assay CV 10.8%). OC was 
measured by enzyme-linked immunosorbent assay (ELISA) (N-MID®, 
Immunodiagnostic Systems, Boldon, UK; intra-assay CV 7%). Sclerostin was 
measured by ELISA (TECO® Sclerostin, TECO Medical AG, Sissach, Switzerland; 
Intra-assay variance 5%). CTX-1 was measured by ELISA (Serum CrossLaps®, 
Immunodiagnostic Systems, Boldon, UK; intra-assay CV 2.3%). Serum 25-
hydroxyvitamin D (25-OHD) was measured in serum by liquid chromatography-
tandem mass spectrometry using an in-house method (Intra-assay CV <10%). 
3.3.5.2 Growth hormone / Insulin-like growth factor 1 axis 
Insulin-like growth factor 1 (IGF-1) and its binding proteins (IGFBP-) 2 and 3, and 
acid labile subunit (ALS) were measured in serum using ELISA (Mediagnost, 
Reutlingen, Germany; intra-assay CVs 6.9%, <1%, <1%, 3.2%, respectively). Serum 
myostatin was measured by ELISA (Cusabio, Hubei Province, China; intra-assay CV 
13.4%). 
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3.3.5.3 Markers of inflammation 
Measurement of serum pro-inflammatory cytokines was conducted on a Luminex 
based Bio-Plex multi array system using a Bio-Plex Pro Human Cytokine assay (Bio-
Rad, California, USA). This assay measured serum TNF-, IFN-, IL-6, and IL-8. 
Serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and 
faecal calprotectin (FC) were measured by the local NHS accredited laboratory. 
3.3.6 Sample size calculation 
Statistical power of this study was inferred post hoc using data from the first ten 
healthy controls. Mean trabecular bone volume in these ten control participants 
was 0.553 ± 0.018. Based on these data, the study was powered to detect a 3% 
difference in trabecular bone volume in CD vs controls (power of 0.8 and  < 0.05) 
with a sample size of 19 per group. 
3.3.7 Statistical Analyses 
Continuous data are presented as median (range) and categorical data as 
frequency (%) unless otherwise stated. Data were initially visualised then assessed 
for normality using Shapiro-Wilk tests. Between group comparisons of continuous 
variables were made using t-tests and Mann Whitney U tests for parametric and 
non-parametric data, respectively. Categorical variables were compared using 
chi-square tests. Due to the reliance of cortical geometry parameters on physical 
size, comparisons between groups were made using multiple regression analyses 
adjusted for sex and height. Comparisons of mechanography outcomes were also 
made using multiple regressions, adjusted for age and sex, as these data were 
available in unmatched participants. Associations between continuous variables 
were assessed using Pearson or Spearman rank correlation analyses for parametric 
and non-parametric data, respectively. Statistical analyses were performed using 
SPSS (Version 24; IBM Corp, Armonk, NY) and GraphPad Prism (Version 9; GraphPad 
Software, San Diego, CA).  
  108 
 
3.4 Results 
3.4.1 Clinical characteristics 
Twenty-seven adults (15 female) with CD with median age 23.2 (18.0, 36.1) years 
and 29 (15 female) healthy controls with median age 22.7 (18.2, 37.0) years 
participated in this study. Median BMI was 21.1 kg/m2 (16.1, 34.4) and 23.5 kg/m2 
(18.2, 28.6) in CD and controls, respectively (p = 0.03). Self-reported PA and use 
of vitamin D/calcium supplements were similar between groups (Table 3-1). Forty-
four percent and 31% of CD and control participants, respectively, reported a 
history of fracture (p = 0.3). All fractures were in long bones with associated 
history of trauma and no participants had history of vertebral fracture. None of 
the participants reported current or previous cigarette smoking. 
Median age at diagnosis of CD was 12 (6, 17) years and median disease duration 
was 9 (3, 22) years. The most common disease location at diagnosis was ileocolonic 
(59%) or isolated colonic (33%), according to the Paris classification. Twenty-nine 
percent had peri-anal involvement at diagnosis. At the time of study visit 74% 
(20/27) were in clinical remission and 26% (7/27) had mildly active disease 
according to CDAI. Current medications were most commonly thiopurines (63%) 
and anti-TNFα antibodies (48%) and only one participant was currently on GC 
therapy. Median self-reported courses of oral GC in the paediatric age were 1 (0, 
8) and 4/27 had received GC therapy within the previous 12 months.  Two-thirds 
of participants were currently, or had previously been, treated with anti-TNFα 
therapy.  
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Table 3-1 Clinical characteristics in CD and controls 
 
Crohn’s Disease  
(n = 27) 
Controls  
(n = 29) 
p-
value 
Demographics & Lifestyle  
Sex (f/m) 15/12 15/14 - 
Age (years) 23.2 (18.0, 36.1) 22.7 (18.2, 37.0) - 
Height (cm) 168.3 (154.0, 192.0) 172.0 (156.0, 193.0) 0.25 a 
Weight (kg) 61.5 (38.2, 104.1) 69.4 (49.8, 93.3) 0.06 a 
BMI (kg/m2) 21.1 (16.1, 34.4) 23.5 (18.2, 28.6) 0.03 b 
Physical Activity 
(MET-mins/week) 
2953 (585, 10392) 3373 (603, 12798) 0.77 b 
Calcium/Vitamin D Supplements, n 
(%) 
7 (25.9) 5 (17.2) 0.39 
Oral Contraceptives, n (%) 3 (20.0) 5 (33.3) 0.41 
Clinical Characteristics    
Age at menarche (years) 13 (11, 15) 12 (10, 15) 0.07 a 
Previous Fracture, n (%) 12 (44.4) 9 (31.0) 0.3 
Age at diagnosis (years) 12 (6, 17) -  
Disease duration (years) 9 (3, 22) -  
Disease Location, n (%) c    
L1: Distal Ileum 2 (7.4) -  
L2: Colonic 9 (33.3) -  
L3: Ileocolonic 16 (59.3) -  
L4a/L4b/L4ab: Upper disease 0/4/4 (29.6) -  
P: Peri-anal disease 8 (29.6) -  
Disease Activity    
CDAI Score 63 (0, 217) -  
Medications, n (%)    
Thiopurines 17 (63.0) -  
Anti-TNF 13 (48.1) -  
Methotrexate 2 (7.4) -  
Glucocorticoids 1 (3.7) -  
Vedolizumab 2 (7.4) -  
5-ASA 3 (11.1) -  
Number CD related surgeries, n (%)  -  
None 17 (63.0) -  
One 6 (22.2) -  
Two 1 (3.7) -  
Three 3 (11.1) -  
Recent GC (<12 months), n (%) 4 (14.8) -  
No. GC courses <18 years, n (%) 1 (0, 8) -  
Current/previous anti-TNF, n (%) 18 (66.7) -  
f/m – female/male; cm – centimetres; kg – kilograms; m – metres; MET – metabolic equivalent of 
task; CDAI – Crohn’s disease activity index; L4a – upper disease involvement proximal to the 
ligament of Treitz; L4b – upper disease involvement distal to the ligament of Treitz but proximal to 
the distal ileum; L4ab – combination of L4a and L4b; TNF – tumour necrosis factor; anti-TNFα – 
infliximab/adalimumab; CD – Crohn’s disease; biologic use – previous or current anti-TNFα therapy. 
Continuous variables displayed as median (range). a t-test; b Mann Whitney U test. c Disease location 
according to Paris classification of IBD. L4 or P disease location can be coexistent with L1/L2/L3. 
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3.4.2 MRI assessment of bone, muscle, and BMA 
3.4.2.1 Trabecular microarchitecture 
No between group differences were observed for any of the MRI-derived measures 




































































D p = 0.34
 
Figure 3-1 Comparison of trabecular microarchitecture at distal femur between CD and 
controls. 
Individual dot plots comparing trabecular microarchitecture parameters at 15% distal femur between 
CD and controls. Between group difference assessed by t-test (A, C, D) or Mann Whitney U test (B).  
Back circles – CD; red squares – controls. N = 54 (26 CD; 28 controls). A – appBV/TV; B – appTbTh; 
C – appTbN; D – appTbSp. AppBV/TV – apparent bone volume fraction; appTbTh – apparent 
trabecular thickness; appTbN – apparent trabecular number; appTbSp – apparent trabecular 
separation. Horizontal line represents median. 
3.4.2.2 Cortical geometry 
No differences were observed between groups for cortical area or cortical 
thickness (Figure 3-2 A & B). Endosteal and periosteal circumferences were both 
lower in the CD group compared with controls (p = 0.04 and p = 0.03, respectively) 
(Figure 3-2 C & D). However, in multiple regression analysis adjusted for sex and 
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height, there were no between group differences for any cortical geometry 
parameters (Table 3-2).  
 
Figure 3-2 Comparison of cortical geometry at distal femur between CD and controls. 
Individual dot plots comparing cortical geometry parameters at 15% distal femur between CD and 
controls. Between group difference assessed by t-tests (A, B) or Mann Whitney U test (C, D). Back 
circles – CD; red squares – controls. A – Cortical Area; B – Cortical Thickness; C – Endosteal 
Circumference; D – Periosteal Circumference. Horizontal line represents median. * denotes 
significant difference between groups. 
Table 3-2 Multiple regression analyses of cortical geometry parameters at distal femur. 
 




Cortical Geometry   
 
 
Cortical Area (mm2) -7.10 (-23.04, 8.84) -.082 0.58 0.38 
Cortical Thickness (mm) 0.05 (-0.13, 0.23) .068 0.14 0.61 
Endosteal Circumference (mm) -3.49 (-9.34, 2.36) -.127 0.43 0.24 
Periosteal Circumference (mm) -3.07 (-8.28, 2.14) -.117 0.51 0.24 
B – Unstandardized Beta; Std β – Standardized Beta; mm – millimetres. Models are adjusted for sex 
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3.4.2.3 Muscle adiposity and cross-sectional area 
Median muscle FF% was 5.3% (0.6, 8.9) and 4.1% (0.5, 9.2) in CD and controls, 
respectively (p = 0.07) (Figure 3-3 A). M-CSA was lower in CD compared with 
controls (p = 0.01) (Figure 3-3 B). After accounting for muscle FF%, median RMA 
was 6497 mm2 (3215, 10203) and 8367 mm2 (4874, 13102) in CD and controls, 
respectively (p = 0.004) (Figure 3-3 C). Adjusting for sex, height, and weight, 
multiple regression analyses demonstrated that CD was associated with 1096 mm2 
(95% CI: 483, 1709) lower RMA than controls (Model R2 = 0.75, p = 0.001). 
 
Figure 3-3 Comparison of muscle adiposity and cross-sectional area at the distal femur in CD 
and controls. 
Individual dot plots comparing muscle adiposity and area at 33% distal femur between CD and 
controls. Between group differences assessed by t-tests. Back circles – CD; red squares – controls. 
A – muscle fat fraction; B – muscle cross sectional area; C – residual muscle area. Horizontal line 
represents median. FF – fat fraction; M-CSA – muscle cross sectional area; RMA – residual muscle 



















































  p = 0.004
A
CB
  113 
 
3.4.2.4 Bone marrow adiposity 
No differences were observed in lumbar spine BMA between CD and controls (31.0% 
[9.5, 58.8] vs 29.5% [11.0, 47.1], respectively; p = 0.64) (Figure 3-4). 
  
Figure 3-4 Comparison of bone marrow adiposity at the lumber spine between CD and 
controls. 
Individual dot plots comparing bone marrow adiposity of the lumbar spine between CD and controls. 
Between group difference assessed by Mann Whitney U test. Back circles – CD; red squares – 
controls. n = 50 (23 CD, 27 controls). Horizontal line represents median. BMA – bone marrow 
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3.4.3 Muscle function 
3.4.3.1 Maximum isometric grip strength 
Grip strength was significantly lower in CD compared with controls (26.3 kg [17.0, 
41.8] vs 32.6 kg [22.1, 52.5], respectively; p = 0.02) (Figure 3-5). Multiple 
regression analyses adjusted for sex, height and weight indicated CD was 
associated with 4.7 kg (95% CI: 2.2, 7.2) lower grip strength than healthy controls 
(Model R2 = 0.73; p < 0.001). Further adjustment for RMA attenuated this 
association but CD remained associated with 2.4 kg (95% CI: 0.0, 4.8) lower grip 





















Figure 3-5 Comparison of maximal isometric grip strength between CD and controls. 
Individual dot plots comparing maximal isometric grip strength between CD and controls. Between 
group difference assessed by Mann Whitney U test. Black circles – CD; red squares – controls. 
Horizontal line represents median. kg – kilograms. * denotes significant difference between groups. 
3.4.3.2 Jumping mechanography 
Mechanography data were available in 37 participants (19 CD, 18 controls). Cohort 
characteristics of these participants are available in Table 3-3. There were no 
differences between the two groups for any characteristics other than grip 
strength, which was lower in CD. In unadjusted mechanography outcomes, no 
difference in power and force output were seen between control and CD (Figure 
3-6). In multiple regression analysis adjusted for age and sex, CD was associated 
with lower absolute and relative muscle power, and lower absolute force (Table 
3-4).  
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Table 3-3 Cohort characteristics of participants with available mechanography data 
comparing CD and controls. 
 
Crohn’s Disease 
(n = 19) 
Controls 
(n = 18) 
p-value 
Demographics & Lifestyle  
Sex (f/m) 11/8 9/9  
Age (years) 22.6 (18.0, 29.1) 23.1 (18.2, 37.0) 0.21 
Height (cm) 169.0 (154.0, 193.0) 174.1 (157.0, 193.0) 0.13 
Weight (kg) 61.8 (38.2, 104.1) 67.1 (55.2, 85.3) 0.23 
BMI (kg/m2) 21.8 (16.1, 34.4) 23.3 (18.8, 28.2) 0.34 
Physical Activity 
(MET-mins/week) 
5328 (585, 10392) 4351 (680, 9000) 0.51 
Residual muscle area (mm2) 7017 (3216, 10203) 7998 (4945, 12007) 0.08 
Grip strength (kg) 27.6 (17.0, 41.8) 32.7 (22.1, 52.5) 0.03* 
f/m – female/male; cm – centimetres; kg – kilograms; BMI – body mass index; m – metres; MET – 
metabolic equivalent of task; mins – minutes; mm – millimetres. * Denotes significant between 

















































































Figure 3-6 Comparison of lower leg muscle function parameters measured by jumping 
mechanography between CD and controls. 
Individual dot plots comparing lower leg muscle function parameters between CD and controls. 
Between group differences assessed by t-tests. Black circles – CD; red squares – controls. N = 37 
(19 CD, 18 controls). Horizontal line represents median. kW - kilowatts; W/kg – watts per kilogram 
body mass; kN – kilonewtons; *BW – force as multiples of bodyweight. * denotes significant 
difference between groups.  
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Table 3-4 Multiple regression analyses of jumping mechanography parameters between CD 
and controls. 
 B (95% CI) Std. β Model R2 p-value 
Mechanography outcome     
Power (kW) -0.45 (-0.80, -0.10) -.282 0.65 0.01 
Relative power (W/kg) -5.0 (-8.8, -1.2) -.302 0.6 0.01 
Force (kN) -0.21 (-0.41, 0.00) -.317 0.28 0.05 
Relative force (*BW) -0.22 (-0.48, 0.35) -.300 0.1 0.09 
N = 37 (19 CD, 18 Controls). kW - kilowatts; W/kg – watts per kilogram body mass; kN – kilonewton; 
*BW – force as multiples of bodyweight. Models adjusted for age and sex. Control group used as 
reference. 
3.4.4 Biomarkers of bone, muscle, and inflammation 
3.4.4.1 Markers of muscle-bone and GH axis 
There were no between group differences observed in BSAP, however median OC 
was higher in CD compared to controls (23.7 ng/ml [13.3, 57.2] vs 19.5 ng/ml [9.8, 
35.8]; p = 0.01) (Figure 3-7 B). Bone resorption marker CTX-1 and sclerostin were 
not different between CD and controls (Figure 3-7 C-D & Table 3-5). Median 25-
OHD was 51 nmol/l (14, 142) and 41 nmol/l (16, 101) in CD and controls, 
respectively (p = 0.76). No difference was observed in 25-OHD after adjustment 
for seasonal variation. Nineteen percent of CD participants and 11% of controls 
had a deficient serum 25-OHD level (<25 nmol/l). PTH was increased in CD 
compared to controls (p = 0.03) with 9/27 samples above the upper limit of normal 
(>7.5 pmol/l) (Table 3-5). Serum IGF-1 was not different between groups, nor 
were IGFBP3, ALS or myostatin (Table 3-5). 














































































Figure 3-7 Comparison of serum bone turnover markers between CD and controls. 
Individual dot plots comparing circulating bone turnover markers between CD and controls. Between 
group differences assessed by Mann Whitney U test (A, B, C) or t-test (D). Black circles – CD; red 
squares – controls. N = 54 (27 CD; 27 controls). Horizontal line represents median. BSAP – bone 
specific alkaline phosphatase; CTX-1 – C-terminal telopeptide of Type I collagen; µg – micrograms; 
ng – nanograms; ml - millilitre; L - litre.   
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Table 3-5 Biochemical markers of bone, muscle, and inflammation in CD and controls. 
 Crohn’s Disease Controls p-value 
Clinical biochemistry (n = 27) (n = 28)  
Albumin (g/l) 41 (32, 48) 42 (35, 47) 0.12 
Faecal Calprotectin (µg/g) a 81 (30, 1800) 30 (30, 217) 0.05 
ESR (mm/hour) 5 (1, 90) 2 (2, 8) 0.05 
CRP (mg/l) 1 (0, 63) 0 (0, 9) 0.002 
25-OHD (nmol/l) 51 (14, 142) 41 (16, 101) 0.76 
PTH (pmol/l) 6.5 (2.8, 13.6) 5.4 (1.8, 9.4) 0.03 
Alkaline Phosphatase (U/l) 70 (38, 124) 63 (23, 121) 0.11 
Markers of bone turnover    
BSAP (µg/l) 13.9 (8.4, 33.8) 13.0 (1.9, 30.1) 0.62 
Osteocalcin (ng/ml) 23.7 (13.3, 57.2) 19.5 (9.8, 35.8) 0.01 
CTX-1 (ng/ml) 0.38 (0.12, 1.43) 0.58 (0.15, 0.90) 0.94 
Sclerostin (ng/ml) 0.39 (0.18, 0.74) 0.44 (0.22, 0.87) 0.06 
Markers of GH/IGF-1 axis    
IGF-1 (ng/ml) 298 (142, 493) 334 (235, 539) 0.14 
IGFBP2 (ng/ml) 377 (107, 858) 334 (111, 634) 0.02 
IGFBP3 (ng/ml) 4337 (2718, 5971) 4421 (3092, 6244) 0.99 
ALS (ng/ml) 10802 (5484, 16348) 11770 (7566, 21974) 0.51 
Pro-inflammatory cytokines    
TNFα (pg/ml) 10.53 (3.51, 31.59) 5.67 (2.27, 18.42) 0.01 
IFN-γ (pg/ml) 2.48 (1.56, 6.56) 1.56 (0.36, 3.40) <0.001 
IL-6 (pg/ml) b 1.08 (0.36, 8.92) 1.38 (0.40, 5.72) 0.81 
IL-8 (pg/ml) c 11.40 (3.40, 122.72) 8.34 (3.40, 15.60) 0.02 
Myokines    
Myostatin (ng/ml) 2.77 (0.14, 21.95) 3.78 (0.09, 19.98) 0.27 
25-OHD – 25 hydroxyvitamin D; PTH – parathyroid hormone; ESR – erythrocyte sedimentation rate; 
CRP – C reactive protein; BSAP – bone specific alkaline phosphatase; CTX-1 – C terminal 
telopeptide of Type 1 collagen; IGF – insulin like growth factor; IGFBP – IGF binding protein; ALS – 
acid labile subunit; IL - interleukin. Continuous variables displayed as median (range). * denotes 
significant difference between groups. a n = 24 (13 CD, 11 controls), b n = 15 (9 CD, 6 controls), c n 
= 39 (27 CD, 12 controls). 
3.4.4.2 Markers of inflammation 
Serum ESR and CRP were significantly higher in CD compared with controls. Serum 
albumin was not different between groups (Table 3-5). IGFBP-2 was elevated in 
CD compared to controls (p = 0.02) as were pro-inflammatory cytokines TNF-α, 
IFN-γ and IL-8 (all p < 0.05). Serum IL-6 was not different between groups (Table 
3-5). Faecal calprotectin was higher in CD (n = 13) compared with controls (n = 
11) (p < 0.05). Only three CD participants had a clinically relevant faecal 
calprotectin of >250 µg/g. 
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3.4.5 Associations between bone, muscle, and adiposity 
3.4.5.1 Trabecular bone 
Trabecular bone volume and trabecular thickness were positively associated with 
BMI in CD (r = 0.53, p = 0.01 and r = 0.64, p = 0.004, respectively), but not controls 
(r = 0.16, p = 0.42 and r = 0.03, p = 0.89, respectively). In CD, RMA was positively 
associated with trabecular bone volume and thickness but not separation or 
number (Figure 3-8). No associations between RMA and trabecular 
microarchitecture were observed in controls (Figure 3-8). Additionally, no 
associations were observed between trabecular parameters and self-reported PA. 
RMA remained associated with trabecular bone volume and thickness in regression 
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Figure 3-8 Associations between RMA and trabecular parameters in CD and controls. 
Scatterplots displaying associations between RMA and trabecular microarchitecture in paediatric CD 
and controls. Associations assessed using Spearman rank (A, C, D) or Pearson (B) correlation 
analyses, respectively. Black circles – CD; red squares – controls. A – RMA vs appBV/TV; B – RMA 
vs appTbTh; C – RMA vs appTbN; D – RMA vs appTbSp. AppBV/TV = apparent trabecular bone 
volume; appTbTh – apparent trabecular thickness; appTbN – apparent trabecular number; appTbSp 
– apparent trabecular spacing. RMA – residual muscle cross-sectional area; mm – millimetre. 
  120 
 
Table 3-6 Multiple regression analyses of muscle area with trabecular parameters in CD and 
controls. 
  Crohn’s Disease 
Predictor Outcome β (95% CI) Std. β Model R2 p-value 
RMA (mm2) a 
appBV/TV 1.82 x10-5 (0.00, 0.00) .892 0.37 0.03 
appTbTh (mm) 1.17 x10-5 (0.00, 0.00) .647 0.56 0.06 
  Controls 
 β (95% CI) Std. β Model R2 p-value 
RMA (mm2) a 
appBV/TV 3.92 x10-6 (0.00, 0.00) .505 0.18 0.13 
appTbTh (mm) 2.17 x10-6 (0.00, 0.00) .256 0.14 0.45 
Multiple linear regression analyses of muscle function and selected trabecular parameters in CD and 
controls, respectively. Models adjusted for sex and grip strength. a – n = 54 (26 CD; 28 controls). 
appBV/TV – apparent trabecular volume; appTbTh – apparent trabecular thickness; appTbN – 
apparent trabecular number; appTbSp – apparent trabecular spacing; B – unstandardized beta 
coefficient; Std. β – standardized beta coefficient; kg – kilograms; kW – kilowatts; W/kg – watts per 
kilogram body mass. 
3.4.5.2 Cortical bone 
Cortical area was positively associated with RMA in both CD and controls, 
respectively (Figure 3-9). RMA positively associated with cortical thickness in the 
control but not CD group (Figure 3-9). In regression analyses adjusted for sex and 
height, RMA remained positively associated with cortical area in controls only 
(Table 3-7). 
 
Figure 3-9 Associations between RMA and cortical geometry in CD and controls. 
Spearman rank correlation analyses between residual muscle area and cortical geometry 
parameters in CD and controls. Black circles – CD; red squares – controls. Circ. – circumference; 
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Table 3-7 Multiple regression analyses of residual muscle area and cortical geometry in CD 
and controls. 
 Crohn’s Disease (n = 27) 
Outcome B (95% CI) Std. β Model R2 p-value 
Cortical Area (mm2) 0.008 (-0.002, 0.017) .285 0.64 0.1 
Cortical Thickness (mm) 3.92 x10-6 (0.00, 0.00) .017 0.05 0.34 
 Controls (n = 29) 
Outcome B (95% CI) Std. β Model R2 p-value 
Cortical Area (mm2) 0.007 (0.000, 0.013) .368 0.64 0.04 
Cortical Thickness (mm) 3.53 x10-5 (0.00, 0.00) .256 0.39 0.26 
Multiple linear regression analyses of residual muscle area and cortical geometry in CD and controls, 
respectively. RMA is the predictor for each model. All models adjusted for sex and height. B – 
unstandardized beta coefficient; Std. β – standardized beta coefficient; mm – millimetre; circ. – 
circumference. 
3.4.5.3 Bone marrow adiposity 
There was no evidence of any associations between BMA and MRI derived measures 
of trabecular microarchitecture, cortical geometry, or muscle area and adiposity. 
3.4.6 Associations between disease indices and bone, muscle & 
adiposity in CD 
3.4.6.1 Trabecular and cortical bone 
Current CDAI score was negatively associated with trabecular bone volume and 
thickness and positively associated with trabecular number (Table 3-8). Self-
reported number of GC courses was negatively associated with trabecular bone 
volume and cortical area (Table 3-8). Number of CD related surgeries was 
negatively associated with trabecular thickness and positively associated with 
trabecular number. 
Table 3-8 Associations between disease indices and trabecular microarchitecture and 
cortical geometry in CD. 
 CDAI score GC history No. of CD surgeries 
Trabecular Parameter a 
appBV/TV -0.4 (0.05) -0.42 (0.03) -0.17 (0.42) 
appTbTh -0.56 (0.003) -0.21 (0.31) -0.58 (0.002) 
appTbN 0.42 (0.04) -0.01 (0.97) 0.47 (0.02) 
appTbSp 0.0 (1.0) 0.34 (0.09) -0.12 (0.57) 
 CDAI score GC history No. of CD surgeries 
Cortical Parameter b 
Cortical area -0.05 (0.8) -0.47 (0.01) -0.37 (0.06) 
Cortical Thickness 0.02 (0.91) -0.37 (0.06) -0.19 (0.33) 
Spearman rank correlation analyses between markers of disease and trabecular microarchitecture 
and cortical geometry of the distal femur in CD only. Parentheses represent p-values. AppBV/TV – 
apparent bone volume fraction; appTbTh – apparent trabecular thickness; appTbN – apparent 
trabecular number; appTbSp – apparent trabecular spacing; CDAI – Crohn’s disease activity index; 
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GC history – self-reported courses of glucocorticoids in the paediatric age (<18 years). a n = 26; b n 
= 27. 
3.4.6.2 Muscle and adiposity 
Muscle FF and BMA were not associated with any disease indices. RMA was 
negatively associated with current CDAI score, self-reported GC courses, and 
number of CD related surgeries (Table 3-9). Grip strength was negatively 
associated with number of CD related surgeries. 
Table 3-9 Associations between disease indices and muscle and adiposity in CD. 
 CDAI score GC courses 
No. of CD 
surgeries 
Muscle Parameter    
RMA a -0.41 (0.03) -0.42 (0.03) -0.44 (0.02) 
Grip Strength a -0.33 (0.09) -0.3 (0.13) -0.48 (0.01) 
Mechanography Power b -0.25 (0.31) -0.37 (0.12) -0.23 (0.36) 
Mechanography Relative Power b 0.05 (0.84) -0.27 (0.27) -0.23 (0.35) 
 CDAI score GC courses 
No. of CD 
surgeries 
Adiposity Parameter    
Muscle FF a 0.03 (0.9) -0.16 (0.44) 0 (1.0) 
BMA c 0 (1.0) -0.07 (0.75) -0.27 (0.21) 
Spearman rank correlation analyses between markers of disease and muscle and adiposity in CD 
only. Parentheses represent p-values. RMA – residual muscle area; FF – fat fraction; BMA – bone 
marrow adiposity; CDAI – Crohn’s disease activity index; GC history – self-reported courses of 
glucocorticoids in the paediatric age (<18 years). a n = 27; b n = 19; c n = 23. 
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3.5 Discussion 
This study comprehensively assessed the muscle-bone unit in young adults with 
well controlled childhood onset CD using high-resolution MRI and MRS. Detailed 
evaluation of trabecular microarchitecture and cortical geometry at the distal 
femur revealed no deficits in CD compared to healthy age and sex matched 
controls. Conversely, CD was associated with lower muscle mass and function 
compared to controls. No differences in biochemical markers of the muscle-bone 
unit were observed, although CD was associated with elevated circulating 
inflammatory cytokines. Disease activity was also negatively associated with 
trabecular bone volume and muscle. 
In Chapter 2, paediatric CD was associated with deficits in trabecular bone volume 
compared to healthy controls. The current study, conversely, suggests young 
adults with well controlled childhood onset CD do not display deficits in trabecular 
microarchitecture. This study also contrasts with the few prior assessments of 
trabecular bone in adults with CD. In two studies using HR-pQCT, deficits in 
trabecular microarchitecture of the tibia and radius have been observed in cohorts 
of young (mean age 23.1 yrs; n = 102, 74% CD) 283 and middle aged (mean age 42.8 
yrs; n = 59) 282 adults with CD. Another bone biopsy histomorphometry study found 
markedly reduced trabecular bone volume in quiescent CD compared to healthy 
controls 341, although this cohort had previously established osteopenia. 
Discrepant results for trabecular bone between studies may be related to several 
disease and non-disease related factors. 
One likely explanation for the observed discrepancies may be prior GC exposure. 
The current cohort have been primarily managed in the era of contemporary 
management of paediatric CD, with EEN being preferred first line therapy. 
Resultantly, exposure to GC in the paediatric era was limited, with an average 
one course of GC reported. In contrast, around 20% of CD participants were 
currently being treated with GC in one study 283, and >50% of middle-aged CD 
participants had previous long-term exposure to high dose GC 282. The deleterious 
effects of GC on trabecular bone have been well described 244 and potentially 
contributed to trabecular loss in those cohorts. Additionally, those studies 
consisted primarily of individuals with adult-onset CD which may have limited the 
ability of bone to recover from any GC induced deficits post-treatment. Despite 
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the limited exposure to GC in the current study, prior GC courses were negatively 
associated with trabecular bone volume. It is, however, worth noting that 
information regarding the timing, duration and cumulative dose of GC was 
unavailable, and it was not possible to determine whether those treated with GC 
earlier in the disease course or at a younger age were able to recover any incurred 
trabecular deficits. The inclusion of participants with greater exposure to GC or 
calculable cumulative GC exposure would allow for assessment of its association 
with trabecular bone. Nevertheless, GC are used sparingly in modern CD 
management and the current cohort represent this contemporary approach.  
Aside from GC, the use of other therapies may also be associated with trabecular 
outcomes in CD. Long-term management with contemporary therapies, such as 
anti-TNF-α, has previously been found to improve markers of bone formation and 
IGF-1 49,217,339 and linear growth 47,49in paediatric CD. Markers of bone turnover 
were not different between CD and controls in the current study Two thirds of the 
current cohort had current or previous exposure to biologics which may have 
facilitated more normal trabecular development. Haschka et al. 282 also reported 
a high prevalence of current biologic therapy in their CD cohort (71%) despite 
observing deficits in trabecular microarchitecture. Indeed, the effects of anti-
TNF-α in adult bone are less clear, with inconsistent reports for effects on BMD. 
Improvements in lumbar spine aBMD have been reported after anti-TNF-α 
treatment in adults CD 342. However, anti-TNF-α has also been associated with 
increased rate of osteopenia and low trabecular bone score in other cohorts 343. 
Any association between anti-TNF-α and poor skeletal outcomes in adults with CD 
is likely confounded by disease phenotype. Anti-TNF-α biologics are generally 
reserved for adults with disease that is refractory to conventional therapy and 
therefore considered to be more severe, which may have independently 
contributed to bone loss in those studies. The use of thiopurines, which are 
commonly prescribed alongside anti-TNF-α and were the most common current 
therapy in this study, may also be associated with skeletal outcomes. A recent 
study in murine colitis demonstrated a negative effect of azathioprine on skeletal 
outcomes 344, although this has not been demonstrated in humans. Further 
investigation is required into the long-term effects of contemporary treatment 
strategies on skeletal development in paediatric and young adult CD. 
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Another potential explanation for the difference in trabecular results between 
studies is the method of assessment used. While 3T-MRI is a reliable method for 
assessing trabecular microarchitecture in other clinical populations 194,335,345,346, it 
may fail to detect subtle differences in microarchitectural parameters due to 
resolution limitations. Bone biopsy histomorphometry is the gold standard for 
trabecular assessment, while HR-pQCT employs increased spatial resolution 
compared to MRI (82µm vs 200µm, respectively). It remains possible that deficits 
in trabecular bone may exist in CD beyond the current resolution capacity of 3T-
MRI, although whether such minute differences would be clinically meaningful is 
unclear. Methods for assessing trabecular microarchitecture using high-resolution 
MRI are also in their relative infancy and as such there is no recognised standard 
between research groups, limiting comparisons between studies. Additional 
analyses of the current data using other methods such as topological analyses may 
have provided greater insight into the structural composition of trabecular bone 
in CD. Using those methods, high-resolution MRI at the proximal femur was 
reported as a sensitive tool for discriminating between individuals with and 
without fragility fracture that would not be identified by DXA 346. Indeed, MRI-
derived trabecular microarchitecture parameters do not associate with measures 
of bone density using DXA (Chapter 2) 335,345, highlighting the additional 
information attainable from MRI that cannot be achieved with DXA. Further work 
is required to determine if MRI assessment of trabecular microarchitecture at the 
distal femur may be a useful prognostic indicator of skeletal fragility. 
Deficits in cortical thickness and area have been observed in paediatric CD 
49,209,276,277,334 most likely due to inflammation induced relative increases in 
endocortical resorption. No differences were observed between CD and controls 
for any cortical parameters in the current study, after adjustment for sex and 
height, suggesting no cortical deficits in this cohort. Cortical geometry may 
improve after long term follow up in children with CD exposed to minimal GC 
doses and who achieve effective disease control 37. Cortical section modulus – a 
function of cortical geometry and an estimate of bone strength – was negatively 
associated with cumulative GC dose in adolescents and young adults with CD 347 
and decreased during follow up in newly diagnosed paediatric CD patients 
subsequently treated, primarily, with systemic GC 276. These findings corroborate 
the negative association between previous GC exposure and cortical area observed 
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in the current cohort, although this association was lost after adjusting for height, 
further highlighting the importance of linear growth for cortical development. 
Anti-TNF-α therapy may also facilitate improvements in cortical geometry via 
increased linear growth and muscle accrual 48, although persistent cortical deficits 
have been reported at follow up, despite some improvement 49. Long-term control 
of underlying disease mechanisms using contemporary therapies may facilitate 
improved skeletal development in children with CD, perhaps explaining the lack 
of cortical deficits in the current study.  
Skeletal muscle deficits are a common complication of paediatric CD. A systematic 
review of body composition in paediatric CD reported lean mass deficits in >90% 
of all included CD participants, when compared with healthy reference 
populations 348. Muscle mass deficits also persist in paediatric CD after long-term 
follow up 37,280 and up to 12 months of anti-TNF-α therapy 49,217, yet it was unknown 
whether such deficits remain into adulthood. In the current study, muscle area of 
the thigh was lower in CD compared to healthy controls. In regression analyses, 
RMA remained lower in CD compared to controls after adjusting for sex, height, 
and weight, indicating muscle mass relative to body size was also lower in CD. In 
young adults with childhood onset IBD, skeletal muscle index (SMI), assessed by 
DXA, was low in young men but not women with CD, compared to healthy controls 
292. Three retrospective studies of clinical CT and MRI scans at L3 level identified 
low skeletal muscle index (a proxy for sarcopenia) in 40 - 58% of adults with CD 
293,294,349. One study also reported higher likelihood of sarcopenia in those with 
active versus inactive disease (OR: 2.08 [95% CI: 1.03, 4,27]) 349. Likewise, despite 
generally low disease activity in the current cohort, a negative association 
between RMA and current CDAI score was observed, suggesting poorer disease 
control may contribute to muscle deficits.  
Chronic low-grade inflammation in CD may partly explain the muscle deficit 
observed, as circulating pro-inflammatory cytokines were elevated in comparison 
with controls. Chronically elevated cytokines induce increased muscle protein 
degradation and elevated TNF-α has been found to epigenetically alter skeletal 
muscle satellite cells which may inhibit their capacity for myogenesis 106. In 
contrast, a previous study found low muscle CSA in CD despite lower circulating 
TNF-α than the control cohort 269. Lower TNF-α may have been the product of 
  127 
 
effective disease control or elevated TNF-α in the control cohort and highlights 
the importance of factors other than inflammatory cytokines in the moderation of 
muscle mass in CD. Molecular analysis revealed no differences between CD and 
controls in atrophy related gene expression, but a significantly reduced capacity 
for muscle protein synthesis in CD, likely due to low circulating IGF-1 269,298. 
Abnormalities in GH/IGF-1 have been previously reported in CD and suggested as 
a potential mechanism of muscle-bone deficit 145 and improvements in IGF-1 were 
predictive of increases in muscle mass in children with CD undertaking anti-TNF-
α therapy 48. Despite this, IGF-1 was not lower in CD compared to controls in the 
current study. Lean mass deficits may be associated with poorer disease 
outcomes, including higher need for hospitalisation and surgery 294 and early 
treatment failure 300. It is therefore vital that the mechanism of muscle deficit in 
CD be further investigated and targeted in future interventions. 
Muscle function assessed by grip strength and jumping mechanography were also 
lower in CD compared to controls, as was also observed in the paediatric cohort 
of Chapter 2. After adjusting for sex, height, weight, and RMA, CD remained 
associated with reduced grip strength, suggesting a potential mechanism for 
muscle weakness that is independent of muscle size. Grip strength is a useful 
clinical indicator and the observed deficit in this study is equivalent to that 
associated with up to 20% higher risk of morbidity and mortality in prospective 
study of older adults 206. It can be speculated that muscle function deficits in 
young adulthood. Low handgrip strength has been previously reported in CD 296,297 
but was no different from healthy controls when expressed relative to FFM in 
another cohort 299. Improvements in muscle mass and function may therefore serve 
to improve clinical outcomes in CD but also reduce risk of morbidity and mortality 
from other diseases. The effects of CD on mechanisms underpinning muscle 
strength, independent of muscle mass, have not been elucidated and warrant 
further investigation in both pre-clinical and human studies. 
The current study is the first to report jumping mechanography outcomes in adults 
with CD. Paediatric studies have reported normal 278 or low values (Chapter 2, 277) 
compared to reference data. In one adult study, objectively measured muscle 
fatigue was worse in CD compared to controls, despite no differences in absolute 
muscle force 298. In that cohort, poor muscle function was associated with lower 
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vitamin D and IGF-1. However, these did not differ between CD and controls in 
the current study. There is, however, a possibility that malabsorption and loss of 
nutrients may have contributed to the observed muscle deficits, especially in 
those with a history of surgical resection, which was negatively associated with 
muscle mass and function. While the current cohort may not fit a predefined 
definition of sarcopenia, muscle mass and function deficits in early adulthood may 
predispose these individuals to increased likelihood of sarcopenia and frailty at a 
younger age than their healthy counterparts if muscle targeting strategies are not 
employed. 
Skeletal muscle fat infiltration progresses with age and may be accelerated by the 
primary or secondary effects of chronic disease. This study observed a non-
significantly increased level of muscle fat in CD compared to healthy controls 
(5.3% [0.6, 8.9] vs 4.1% [0.5, 9.2]; p = 0.07). The association between CD and 
muscle fat infiltration has not been extensively studied. However, CD shares 
previously reported risk factors for muscle fat accumulation such as GC exposure 
104, systemic inflammation 350, and low activity levels 351. The long-term clinical 
implications of increased muscle fat in CD are unclear. Muscle fat was, however, 
associated with increased length of hospital stay and short-term readmission in 
those with CD undergoing surgical resection 110. Older adults with rheumatoid 
arthritis were found to have comparable muscle fat to sex and BMI matched cohort 
aged 10 – 20 years older than themselves 352. This suggests inflammatory disease 
may accelerate the accumulation of muscle fat in a similar manner to regular 
aging, which could ultimately lead to impaired muscle function and increased risk 
of fracture, independently of muscle mass 353. Muscle adipocytes also express pro-
inflammatory adipokines that may contribute to systemic inflammation in CD. 
Bone marrow adiposity has emerged as a useful indicator of skeletal health, yet 
the role of BMA in bone health in CD remains unclear. In the current study there 
were no differences in BMA between CD and controls and BMA was not associated 
with any indices of disease. Furthermore, BMA was not associated with any 
trabecular microarchitecture parameters in CD. Only one previous study has 
assessed BMA in CD patients. Adults with CD in long-term, steroid-free remission 
had preserved BMA of the lumbar spine, despite low BMD in the lumbar spine and 
femoral neck in 19% and 47% of patients, respectively 354. Similarly, in a dextran 
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sodium sulfate (DSS) induced model of colitis, BMA was unaffected despite a 
reduction in cortical and trabecular thickness 355. Taken together, this and 
previous studies suggest no direct association between CD and BMA, although this 
still requires validation in future trials. 
This study has some important limitations that must be considered. Primarily, the 
cross-sectional nature of the data precludes any assessment of causality. There 
are several potential mechanisms involved in musculoskeletal deficit in CD which 
cannot be extricated from the current data and require further investigation to 
optimise improvement strategies. As mentioned, high-resolution MRI is unable to 
accurately delineate trabecular structures due to resolution limitations and may 
have failed to detect subtle differences between groups. Furthermore, there is a 
lack of available reference data using the current MRI parameters therefore we 
are unable to comment on a comparison between CD and the wider population. 
Finally, this study did not provide a concurrent assessment of BMD and it remains 
possible that these patients may exhibit deficits in bone mass, which remains the 
largest contributor to skeletal fragility. Despite these limitations, this study 
provides important insight into the current muscle-bone status of a cohort of 
young adults with CD and provides the basis upon which future interventions or 
monitoring studies may be founded.  
In summary, this study has comprehensively evaluated the muscle-bone unit of 
young adults specifically with childhood onset CD for the first time. In this cohort 
with generally well-controlled disease, young adults with CD displayed lower 
muscle mass and function but no abnormalities in trabecular or cortical bone of 
the distal femur. Biochemical markers of the muscle-bone unit did not reveal any 
evidence of abnormal bone or muscle metabolism and it is likely that the deficits 
observed in skeletal muscle are the product of multiple contributing disease and 
lifestyle associated factors. Deficits in muscle mass and function may augment the 
deleterious effects of CD on muscle-bone and interventions to improve these 




4 Associations between IBD and adverse 
musculoskeletal outcomes in middle-aged and 
older adults. 
4.1 Abstract 
Background. The chronic effects of inflammatory bowel disease and ageing may 
contribute to an increased risk of adverse muscle-bone outcomes. Furthermore, 
the association between IBD and falls has never been studied. 
Aim. To assess the likelihood of adverse musculoskeletal outcomes in middle aged 
and older adults with IBD and its subtypes CD and UC using data from a very large, 
population-based cohort study. 
Methods. Cross-sectional analysis of UK Biobank baseline data. Associations 
between IBD, CD, and UC with likelihood of self-reported falls and fractures, and 
muscle weakness assessed by grip strength dynamometry, were assessed by 
multivariable logistic regression analyses. Association between disease and 
estimated BMD, measured by QUS, was assessed using multivariable linear 
regression. Exploratory analyses also investigated risk factors associated with 
muscle-bone outcomes in CD.  
Results. A total of 401,850 participants were included in these analyses, of which 
4619 had a history of IBD. In the subtype analyses, 1386 had CD and 3007 had UC. 
IBD was associated with an increased likelihood of a self-reported fall in both 
women (OR: 1.13 [95%CI: 1.03, 1.25]) and men (OR: 1.16 [95%CI: 1.03, 1.29]). 
Women with CD were the only group to have higher likelihood of a self-reported 
fracture (OR: 1.35 [95%CI: 1.09, 1.66]) or fragility fracture (OR: 1.35 [95%CI: 1.06, 
1.73]) compared to controls. All disease subgroups were more likely to have 
muscle weakness compared to controls, with the strongest association observed 
in women with CD (OR: 1.55 [95%CI: 1.25, 1.92]). In CD, muscle weakness was 
associated with increased likelihood of a fall, and a previous fall was associated 
with increased likelihood of a fracture. 
Conclusions. This study revealed an association between mild IBD and adverse 
muscle-bone outcomes, with women with CD displaying the most severe 
131 
 
phenotype. Men and women with CD were at higher risk of falls which is one of 





Chronic inflammatory disease is associated with adverse musculoskeletal 
outcomes, even in individuals who achieve clinical remission. In this work, both 
children and young adults with currently quiescent CD have been observed to have 
a variety of bone and muscle deficits. Failure to resolve these deficits may lead 
to increased lifelong risk of adverse musculoskeletal outcomes, such as falls and 
fractures. 
Aging is associated with changes in the inflammasome that mimic some of the 
effects of inflammatory disease, such as chronic elevation of pro-inflammatory 
cytokines 218. As such, IBD has been compared to something like an accelerated 
aging process, whereby inflammatory mediated tissue destruction leads to early 
declines in bone and muscle. It is therefore possible that those with IBD may be 
at increased risk of typically age-related adverse musculoskeletal events due to 
the combined effects of disease and aging. Falls and fractures are major 
contributors to morbidity and mortality and one of the leading causes of disability 
adjusted life years 356. To date, no studies have assessed the risk of falls in older 
adults with IBD, while some have suggested an increased risk of hip fractures only 
in elderly IBD patients with prior GC exposure 324.  
The aim of this study was to characterise bone and muscle outcomes and 
associated factors in middle aged and older adults with IBD in a large population-
based cohort. The study investigated associations between a diagnosis of IBD and 






4.3.1 Study design 
UK Biobank is a prospective, population cohort study of middle-aged and older 
adults registered with the national health service (NHS) in England, Scotland, and 
Wales. Initially, approximately 9.2 million people were approached to participate 
in this study and 502,628 participants, aged 37 – 73 years, were recruited (5.5% 
response rate). Baseline assessments were conducted between April 2007 and 
December 2010 at one of 22 regional assessment centres. Baseline assessments 
involved a series of touch screen questionnaires, physical measurements, and 
biological sampling, followed by face-to-face interviews with trained research 
staff. Details of the protocol, including transcript for the touch screen 
questionnaires, can be found online (www.ukbiobank.ac.uk). UK Biobank is 
conducted under ethical approval from the North West Multi-Centre Research 
Ethics Committee (REC Ref: 11/NW/03820) and all participants provided written 
informed consent prior to enrolment in the study. This analysis of UK Biobank data 
was conducted under Application ID 7155. 
4.3.2 Data collection 
Detailed information was collected regarding sociodemographic factors (age, sex, 
ethnicity, postcode, associated area-based deprivation) lifestyle (smoking status, 
dietary intake, alcohol consumption, physical activity, sedentary behaviour), and 
medical history (prevalent comorbidities, current medications, surgical history, 
medical events [e.g., falls and fractures]). Age was calculated using date of birth 
and assessment date. Ethnicity was self-reported and categorised as: White, 
Black, South Asian, Chinese, mixed, or other. Area based socio-economic 
deprivation was derived from postcode using the Townsend deprivation index, 
with negative values indicating relative affluence and positive values representing 
greater deprivation 357. Dietary intake was collected using a validated 24 h recall 
questionnaire, the Oxford WebQ 358. PA was self-reported using the international 
physical activity questionnaire (IPAQ) 340 and expressed as the sum of walking, 
moderate, and vigorous PA over the previous seven days (MET-mins/week). 
Sedentary behaviour was derived from the sum of total self-reported time spent 
134 
 
watching televisions, using a computer, and driving in a typical day (hours). 
Smoking status was defined as ‘current’, ‘previous’, or ‘never’.  
Physical measurements were conducted by trained research nurses using standard 
procedures and calibrated equipment. Height was measured to the nearest 1 cm 
(Seca 202 height measure; Seca GmbH, Germany) and weight to the nearest 0.1 
kg (Tanita BC-418MA, Tanita, Japan). Corresponding BMI was calculated and 
categorised according to WHO criteria: underweight <18.5, normal weight 18.5 – 
24.9, overweight 25.0 – 29.9, and obese >30.0 kg/m2. Body composition (body fat 
percentage, fat mass, fat free mass) was measured using bio-impedance analyses 
(Tanita BC-418MA). Waist circumference was measured to the nearest 0.1 cm to 
assess abdominal obesity: ≥ 102 cm in males and ≥ 88 cm in females. Grip strength 
was measured using a Jamar J00105 hydraulic hand dynamometer and expressed 
in kilograms. The mean grip strength value of right and left hands was used in 
analyses. 
Bone mineral density (eBMD) was estimated using quantitative ultrasound, which 
has been validated as an acceptable tool for BMD measurement in large scale 
prospective studies and correlates highly with DXA derived measurements 187. 
Following correct calibration and positioning, a Sahara bone sonometer was used 
to measure eBMD in the left and right calcaneus using the following equation: 
𝐵𝑀𝐷 = 0.002592 × (𝐵𝑈𝐴 + 𝑆𝑂𝑆) − 3.687 𝑔/𝑐𝑚2 
where SOS is the speed of sound (m/s) and BUA is broadband ultrasound 
attenuation (dH/MHz). Each bone sonometer underwent daily quality control 
checks using quality control phantoms for at least one hour prior to use. Absolute 
BMD results were converted into T-scores, equalling the number of standard 
deviations the participant’s value differed from the mean value of a young adult 
of the same sex. eBMD was derived from the measurement of the left calcaneus 
(original protocol) or the mean value of measurements of both left and right 
calcaneus (updated protocol).  
Medical history and prevalent comorbidities were self-reported at baseline. 
Participants were asked to self-report any diagnoses that had been previously 
made by a physician. Any self-reported diagnoses were confirmed during interview 
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with research staff and mapped to associated three-character ICD-10 
(International classification of diseases, 10th edition) codes. Age at disease 
diagnosis was approximated using month and year of birth and the estimated date 
of disease diagnosis. Participants were asked to self-report history of previous 
surgeries and all procedures involving the lower GI tract were extracted and 
pooled into a single ‘lower GI surgery’ variable. Current medication use was also 
recorded during the interview by selecting the appropriate drug name from a pre-
defined list or adding as free text where the medication was not listed. To retrieve 
and code medications used in the treatment of IBD for inclusion in analyses, the 
names of all licensed therapies for the treatment of IBD (including brand names) 
according to the British national formulary (www.bnf.nice.org.uk) were manually 
searched within the database. This medication list was then reviewed by three 
consultant gastroenterologists from NHS GGC for relevant omissions. The use of 
bisphosphonate medications was also retrieved. Participants provided consent for 
UK Biobank to link to their NHS clinical data, including hospital in-patient and 
primary care records. In-patient data were available via Hospital Episode Statistics 
(HES) from 1997 onwards for England, Scottish Morbidity Records (SMR01) from 
1981 onwards for Scotland, and the Patient Episode Database for Wales (PEDW) 
from 1998 onwards for Wales. These data include all in-patient admissions and 
discharges and associated primary and secondary diagnostic ICD-10 codes. Primary 
care diagnosis data were available for approximately 45% (n = ~230,000) of the UK 
Biobank cohort at the time of analyses. Further information regarding the data 
linkage procedures can be found online (www.biobank.ac.uk). 
4.3.3 Exposure 
Exposures of interest in this study were a history of IBD or its subtypes (CD or UC) 
at time of baseline UK Biobank assessment. Disease history was considered present 
if participants had a relevant in-patient or primary care ICD-10 code in their 
medical records, or self-reported disease at baseline assessment. ICD-10 codes for 
CD and UC were K50 and K51, respectively. Where a participant had a recorded 
ICD-10 code for both CD and UC, this was cross-referenced with the self-reported 
diagnosis data. These participants were included in overall IBD analyses but 
excluded from subtype analyses unless they also self-reported either CD or UC at 
baseline assessment. Any participant who self-reported both CD and UC at 




In this cross-sectional analysis of UK Biobank baseline data, outcomes of interest 
were self-reported falls, fractures, and fragility fractures, estimated BMD, and 
muscle weakness. Self-reported falls and fractures were reported during touch-
screen questionnaires. Participants were asked ‘In the last year have you had any 
falls?’. The responses ‘only one fall’ and ‘more than one fall’ were grouped and 
recoded to create a binary answer of ‘yes’ or ‘no’ to this question. Participants 
were also asked ‘Have you fractured/broken any bones in the last 5 years?’, coded 
into a binary outcome ‘yes’ or ‘no’. Those who self-reported a fracture were then 
asked, ‘Did the fracture result from a simple fall (i.e. from standing height)?’, 
which was used as a measure of fragility fractures. Those who responded ‘yes’ 
were coded as having experienced a fragility fracture. For these three questions, 
participants who responded ‘do not know’ or ‘prefer not to answer’ were excluded 
from subsequent analyses. Muscle weakness was defined as low grip strength 
according to the European Working Group on Sarcopenia in Older People 
(EWGSOP2) criteria of <16 kg for females and <27 kg for males 359. Participants 
who were unable to perform grip strength measurements due to illness or 
disability were excluded from muscle weakness analyses. 
4.3.5 Statistical Analyses  
All baseline characteristics and subsequent analyses were stratified by sex. Cohort 
characteristics were summarised using descriptive statistics and expressed using 
median and interquartile range (IQR) for continuous variables and frequencies and 
percentages for categorical variables. Associations between IBD and its subtypes 
CD and UC with falls, fractures, muscle weakness and eBMD were explored using 
logistic and linear regression models. Regression models were designed with 
increasing adjustment for covariates as follows: model 0 was unadjusted; model 
1 was minimally adjusted for sociodemographic factors (age, ethnicity, and 
socioeconomic deprivation); and model 2 was adjusted for model 1 plus known 
risk factors for musculoskeletal health (BMI, smoking status, and self-reported 
PA). A sensitivity analyses was then performed using a more rigorously defined 
cohort for CD and UC. In sensitivity analyses, anyone with a history of both CD and 
UC was excluded. Exploratory analyses of factors associated with falls, fractures, 
muscle weakness, and BMD were conducted in CD only using multiple logistic and 
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linear regression analyses adjusted for age and deprivation (where these were not 
the exposure of interest). All statistical analyses were performed using Stata v16.0 
(Statacorp, TX, USA). Analyses were restricted to participants with available data 





4.4.1 Cohort characteristics 
A total of 401,850 participants were included in this study. The number of 
participants with data for each musculoskeletal outcomes of interest is available 
in Figure 4-1. A history of IBD was present in 4619 (1.2%) participants. After 
excluding those with a recorded episode of both CD and UC who did not also self-
report disease, 1386 (0.3%) participants were included in the final CD cohort and 
3007 (0.8%) in the final UC cohort (Figure 4-1). 
 
Figure 4-1 Consort diagram for participants included/excluded in the analyses. 
 
UK Biobank Participants 
N = 502,628 
Included in analyses 
N = 401,850 
Excluded. Missing covariate data:  
N = 100,778 
History of IBD 
N = 4619 
History of CD: n = 1619 
History of UC: n = 3266 
Included in IBD analyses 
Final CD cohort: n = 1386 
Final UC cohort: n = 3007 
Excluded from disease specific analyses 
due to history of both CD and UC: 
 
Excluded from CD cohort: n = 233 
Excluded from UC cohort: n = 259 
Included in separate CD and UC 
analyses 
Available outcomes data 
Falls: n = 401,066 
Fractures: n = 399,963 
Muscle weakness: n = 401,468 




Cohort characteristics stratified by disease category are available in Table 1 and 
Table 2 for women and men, respectively. Overall, those with CD were younger 
and those with UC older than the rest of the cohort. Both CD and UC had a higher 
proportion of white ethnicity than the rest of the cohort. In men, socioeconomic 
deprivation was higher in CD and lower in UC. Deprivation was similar in women 
with CD and UC compared to those without disease. Prevalence of current smoking 
was higher in CD and lower in UC compared to the rest of cohort. BMI was similar 
between groups in female participants but was lower in males with CD, as 
bodyweight was also lower. Prevalence of central obesity was also lower in men 
with CD. Grip strength was slightly lower in CD and UC, although differences were 
relatively small (difference in medians 0.5 – 2kg). Self-reported PA was lower in 
women with CD but no different in other disease groups compared to the cohort 
overall.  
Those with CD had a lower average age at diagnosis compared to UC and men with 
UC had a higher proportion of diagnoses at age >40 years. Immunosuppressant use 
was higher in CD and 5-ASA use higher in UC. There were no differences in self-
reported use of GC therapy between CD and UC, and only five participants with 
CD self-reported use of anti-TNF-α therapy. Over half of all CD (55.9%) and UC 
(51.2%) participants self-reported using no IBD-specific medications at all. Only a 
small proportion of CD (1.9%) and UC (2.1%) participants self-reported a history of 
lower GI surgery, which was similar to the rest of the cohort (2.2%). 
Adverse musculoskeletal outcomes were more common in women than in men for 
both CD and UC, as in the rest of the cohort. Across both sexes, the prevalence of 
falls and fractures was higher in CD than UC. History of at least one fall in the 
previous 12 months was self-reported by 307 (22.2%) and 613 (20.4%) of those with 
CD and UC, respectively, compared to 76,386 (19.1%) of the rest of the cohort. 
Any fracture within the five years prior to baseline assessment was self-reported 
by 160 (11.6%) and 292 (9.8%) of CD and UC participants, respectively, compared 
to 34,520 (9.5%) of non-IBD participants. Fragility fractures were reported by 94 
(6.8%) of CD, 186 (6.2%) of UC, and 21,639 (5.5%) of non-IBD participants. Fragility 
fractures, therefore, accounted for 58.8%, 63.7%, and 62.7% of all self-reported 




Table 4-1 Cohort characteristics of female participants with and without IBD, Crohn's disease, 
and ulcerative colitis. 
 
Non-IBD  
(n = 214,349) 
IBD  
(n = 2390) 
CD  
(n = 769) 
UC  
(n = 1503) 
Age (years) 57 (50, 63) 58 (51, 63) 58 (49, 63) 59 (51, 64) 










Height (cm) 163 (158, 167) 162 (158, 166) 162 (158, 166) 163 (158, 167) 
Weight (kg) 68.5 (61.3, 77.6) 67.7 (60.6, 76.6) 67.4 (59.3, 75.3) 67.9 (61.2, 77.0) 
BMI (kg/m2) 25.9 (23.3, 29.3) 25.7 (23.2, 29.1) 25.6 (23.0, 29.0) 25.7 (23.3, 29.1) 
BMI categories, n (%)     
Underweight 1683 (0.8) 22 (0.9) 12 (1.6) 10 (0.7) 
Normal 87 860 (41.0) 1004 (42.0) 324 (42.1) 630 (41.9) 
Overweight 79 214 (36.9)  889 (37.2) 283 (36.8) 566 (37.7) 
Obese 45 592 (21.3) 475 (19.9) 150 (19.5) 297 (19.8) 
Waist circumference (cm) 82 (75, 91) 82 (75, 91) 83 (75, 91) 82 (75, 91) 
Central obesity, n (%) 72 326 (33.8) 850 (35.6) 278 (36.2) 530 (35.3) 
Bodyfat (%) 36.4 (31.6, 40.9) 36.5 (31.8, 41) 36.4 (31.7, 40.8) 36.5 (31.9, 41.0) 
     
Physical activity (MET-
mins/week) 
1746 (792, 3480) 1640 (720, 3395) 1495 (693, 3393) 1680 (792, 3375) 
Grip strength (kg) 23.5 (19.5, 28) 23 (19, 27) 23 (18.5, 27) 22.5 (19, 27) 









Smoking status, n (%)     
Never 128 423 (59.9) 1255 (52.5) 365 (47.5) 818 (54.5) 
Previous 67 951 (31.7) 897 (37.5) 276 (35.9) 586 (39.0) 
Current 19 975 (8.4) 238 (10.0) 128 (16.6) 99 (6.6) 
Musculoskeletal outcomes     
Fall, n (%) 47 882 (22.4) 594 (24.9) 193 (25.1) 373 (24.8) 
Fracture, n (%) 21 812 (10.2) 281 (11.8) 104 (13.6) 160 (10.7) 
Fragility fracture, n (%)  14 890 (7.0) 206 (8.7) 72 (9.4) 123 (8.2) 
Muscle weakness, n (%) 20 292 (9.5) 299 (12.5) 103 (13.5) 180 (12.0) 









Disease & Medications     
Age at diagnosis (years) - - 36.2 (26.4, 48.8) 39.3 (29, 50.6) 
Disease duration (years) - - 17.7 (7.3, 29.0) 15.4 (7.6, 27.9) 
Diagnosis age category, n 
(%) 
    
<18 years - - 41 (5.3) 73 (4.9) 
18 – 40 years - - 403 (52.5) 705 (46.9) 
>40 years - - 324 (42.2) 724 (48.2) 





(n = 214,349) 
IBD  
(n = 2390) 
CD  
(n = 769) 
UC  
(n = 1503) 
Glucocorticoids 5465 (2.6) 184 (7.7) 64 (8.3) 112 (7.5) 
Immunosuppressants 1460 (0.7) 260 (10.9) 117 (15.2) 136 (9.1) 
5-Aminosalicylates 539 (0.3) 802 (33.6) 225 (29.3) 552 (36.7) 
Antibiotics 175 (0.1) 8 (0.3) 3 (0.4) 4 (0.3) 
Anti-TNF-α 63 (0.03) 4 (0.2) 4 (0.5) 0 (0) 
No IBD-related 
medication 
207 238 (96.7) 1346 (56.3) 439 (57.1) 825 (54.9) 
Vitamin D supplements 4635 (2.2) 103 (4.3) 36 (4.7) 61 (4.1) 
Bisphosphonates 5528 (2.6) 163 (6.8) 80 (10.4) 78 (5.2) 
History of lower GI surgery 4770 (2.2) 51 (2.1) 18 (2.3) 29 (1.9) 
All continuous variables are presented as median (IQR) and categorical variables as frequency 
(%).BMI – body mass index; cm – centimetres; kg – kilograms; MET – metabolic equivalent of task; 
mins – minutes; h – hours; immunosuppressants – azathioprine, mercaptopurine, cyclosporine, 
methotrexate; anti-TNF-α – anti-tumour necrosis factor alpha (adalimumab only); antibiotics – 
ciprofloxacin or metronidazole; GI – gastrointestinal; muscle weakness – grip strength <16kg for 




Table 4-2 Cohort characteristics of male participants with and without CD, Crohn’s disease, 
and ulcerative colitis. 
 
Non-IBD  
(n = 182,882) 
IBD  
(n = 2229) 
CD  
(n = 617) 
UC  
(n = 1504) 
Age (years) 58 (50, 64) 60 (51, 64) 57 (50, 63) 60 (52, 64) 










Height (cm) 176 (171, 180) 175 (170, 180) 175 (170, 179) 175 (171, 180) 
Weight (kg) 83.9 (76, 93.1) 82.4 (74.5, 91.2) 80.7 (73.5, 89.4) 83.0 (75, 91.8) 
BMI (kg/m2) 27.2 (24.9, 29.8) 26.9 (24.6, 29.4) 26.7 (24.2, 28.9) 27.0 (24.7, 29.6) 
BMI categories, n (%)     
Underweight 399 (0.2) 10 (0.5) 5 (0.8) 5 (0.3) 
Normal 47 242 (25.8) 626 (28.1) 190 (30.8) 411 (27.3) 
Overweight 91 864 (50.1) 1136 (51.0) 315 (51.1) 766 (50.9) 
Obese 43 557 (23.8) 457 (20.5) 107 (17.3) 322 (21.4) 
Waist circumference (cm) 95 (89, 103) 95 (89, 102) 94 (86, 101) 95 (89, 103) 
Central obesity, n (%) 52 102 (28.5) 602 (27.1) 145 (23.5) 424 (28.3) 
Bodyfat (%) 25.1 (21.3, 28.8) 25 (21.2, 28.8) 24.3 (20.3, 28) 25.2 (21.5, 29) 
     
Physical activity (MET-
mins/week) 
1960 (924, 4053) 1866 (840, 3954) 1839 (792, 4080) 1893 (855, 3884) 
Grip strength (kg) 40 (34, 45) 39 (33, 44.5) 38 (33, 44) 39 (33, 44.5) 









Smoking status, n (%)     
Never 90 547 (49.5) 945 (42.4) 246 (39.9) 640 (42.6) 
Previous 70 568 (38.6) 1092 (49.0) 292 (47.3) 7665 (50.9) 
Current 21 767 (11.9) 192 (8.6) 79 (12.8) 99 (6.6) 
Musculoskeletal outcomes     
Fall, n (%) 27 838 (15.3) 379 (17.0) 114 (18.5) 240 (16.0) 
Fracture, n (%) 15 708 (8.6) 200 (9.0) 56 (9.1) 132 (8.8) 
Fragility fracture, n (%)  6659 (3.7) 92 (4.2) 22 (3.6) 63 (4.2) 
Muscle weakness, n (%) 11 597 (6.4) 176 (7.9) 49 (8.0) 118 (7.9) 









Disease & Medications     
Age at diagnosis (years) - - 38.9 (27.1, 50.1) 43.1 (32.8, 53.5) 
Disease duration (years) - - 15.8 (7.4, 27.3) 12.0 (6.0, 23.9) 
Diagnosis age category, n 
(%) 
    
< 18 years - - 39 (6.3) 35 (2.3) 
18 – 40 years - - 283 (45.9) 595 (39.6) 
>40 years - - 295 (47.8) 873 (58.1) 





(n = 182,882) 
IBD  
(n = 2229) 
CD  
(n = 617) 
UC  
(n = 1504) 
Glucocorticoids 4501 (2.5) 227 (10.2) 67 (10.9) 148 (9.8) 
Immunosuppressants 890 (0.5) 293 (13.1) 99 (16.1) 184 (12.2) 
5-Aminosalicylates 380 (0.2) 867 (38.9) 196 (31.8) 644 (42.8) 
Antibiotics 180 (0.1) 15 (0.7) 3 (0.5) 10 (0.7) 
Anti-TNF-α 40 (0.02) 1 (0.04) 1 (0.2) 0 (0) 
No IBD-specific 
medication 
177 280 (96.9) 1118 (50.2) 336 (54.5) 713 (47.4) 
Vitamin D supplements 843 (0.5) 60 (2.7) 27 (4.4) 31 (2.1) 
Bisphosphonates 863 (0.5) 78 (3.5) 32 (5.2) 41 (2.7) 
History of lower GI surgery 3903 (2.1) 44 (2.0) 9 (1.5) 33 (2.2) 
All continuous variables are presented as median (IQR) and categorical variables as frequency 
(%).BMI – body mass index; cm – centimetres; kg – kilograms; MET – metabolic equivalent of task; 
mins – minutes; h – hours; Immunosuppressants – azathioprine, mercaptopurine, ciclosporin, 
methotrexate; anti-TNF-α – anti-tumour necrosis factor alpha (adalimumab only); anti-biotics – 
ciprofloxacin, metronidazole; GI – gastrointestinal; muscle weakness – grip strength <16kg for 




4.4.2 Associations of disease with falls 
A history of IBD was associated with higher likelihood of a self-reported fall within 
the previous 12 months in both men and women (Table 4-3). The magnitude of 
these associations remained consistent across different levels of covariate 
adjustment. In separate analyses of CD and UC, male CD but not UC was associated 
with a higher likelihood of a fall. In fully adjusted models, male CD was associated 
with a 29% (95% CI: 5 to 58%) higher likelihood of a fall compared to men without 
IBD (Table 4-3). Women with UC also displayed a higher likelihood of a fall than 
women without IBD, whereas the association appeared positive but was not 
significant in women with CD (Table 4-3). Sensitivity analyses strengthened the 
association between CD and falls in women (OR: 1.21 (1.02, 1.44), p = 0.03) but 
did not alter any other results (Table 4-7). 
Table 4-3 Association of disease status with history of self-reported falls by sex 
  Female Male 
  Odds Ratio (95%CI) p-value Odds Ratio (95%CI) p-value 
IBD 
Model 0  1.15 (1.05, 1.26) 0.004 1.14 (1.02, 1.27) 0.02 
Model 1 1.13 (1.03, 1.24) 0.01 1.12 (1.01, 1.26) 0.04 
Model 2 1.13 (1.03, 1.25) 0.01 1.16 (1.03, 1.29) 0.01 
CD 
Model 0 1.16 (0.99, 1.37) 0.07 1.26 (1.03, 1.55) 0.03 
Model 1 1.17 (0.99, 1.38) 0.07 1.25 (1.02, 1.53) 0.04 
Model 2 1.16 (0.99, 1.37) 0.07 1.29 (1.05, 1.58) 0.02 
UC 
Model 0 1.15 (1.02, 1.29) 0.02 1.06 (0.92, 1.21) 0.44 
Model 1 1.12 (0.99, 1.26) 0.07 1.04 (0.91, 1.2) 0.56 
Model 2 1.13 (1.01, 1.28) 0.04 1.07 (0.93, 1.23) 0.33 
Logistic regression assessing associations between IBD, CD, and UC with a history of self-reported 
falls within the previous 12 months. In all models, the reference group is participants without history 
of IBD. Model 0 – unadjusted; model 1 – adjusted for age, ethnicity, and socioeconomic deprivation; 
model 2 – adjusted for model 1 + BMI, smoking status, and PA.   
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4.4.3 Associations of disease with fractures 
IBD was associated with a higher likelihood of self-reported fracture and fragility 
fracture in women but not men. Indeed, in separate analyses of CD and UC, male 
sex was not associated with likelihood of fracture or fragility fracture across any 
model (Table 4-4). Women with CD displayed a higher likelihood of self-reported 
fracture and fragility fracture, whereas women with UC did not. In fully adjusted 
models, female CD was associated with a 35% (95% CI: 9 to 66%) and 35% (95% CI: 
6 to 73%) increased likelihood of fracture and fragility fracture, respectively 
(Table 4-4). When analyses of fragility fractures were restricted to those who self-
reported any fracture, those with IBD were not at increased risk of a fragility 
fractures. Associations were not altered in sensitivity analyses (Table 4-7). 
Table 4-4 Associations of disease status with self-reported history of fracture and fragility 
fracture by sex 
  Female Male 
  Odds Ratio (95%CI) p-value Odds Ratio (95%CI) p-value 
Any Fracture 
IBD 
Model 0  1.18 (1.04, 1.33) 0.01 1.05 (0.91, 1.21) 0.53 
Model 1 1.15 (1.01, 1.3) 0.03 1.06 (0.92, 1.23) 0.4 
Model 2 1.14 (1.01, 1.3) 0.04 1.08 (0.93, 1.25) 0.32 
CD 
Model 0 1.38 (1.12, 1.7) 0.002 1.06 (0.8, 1.39) 0.68 
Model 1 1.37 (1.11, 1.69) 0.003 1.02 (0.78, 1.35) 0.86 
Model 2 1.35 (1.09, 1.66) 0.01 1.03 (0.78, 1.36) 0.83 
UC 
Model 0 1.05 (0.89, 1.24) 0.55 1.02 (0.85, 1.22) 0.81 
Model 1 1.02 (0.86, 1.2) 0.83 1.07 (0.89, 1.28) 0.49 
Model 2 1.02 (0.87, 1.21) 0.8 1.08 (0.9, 1.3) 0.4 
Fragility Fracture 
IBD 
Model 0  1.26 (1.09, 1.45) 0.002 1.14 (0.92, 1.4) 0.23 
Model 1 1.21 (1.05, 1.4) 0.01 1.13 (0.92, 1.39) 0.25 
Model 2 1.21 (1.05, 1.4) 0.01 1.15 (0.93, 1.42) 0.2 
CD 
Model 0 1.38 (1.08, 1.76) 0.01 0.97 (0.64, 1.49) 0.9 
Model 1 1.37 (1.07, 1.75) 0.01 0.95 (0.62, 1.46) 0.82 
Model 2 1.35 (1.06, 1.73) 0.02 0.96 (0.63, 1.47) 0.85 
UC 
Model 0 1.18 (0.99, 1.43) 0.07 1.16 (0.9, 1.49) 0.26 
Model 1 1.13 (0.94, 1.37) 0.18 1.16 (0.9, 1.49) 0.25 
Model 2 1.14 (0.95, 1.38) 0.16 1.18 (0.92, 1.53) 0.19 
Logistic regression assessing associations between IBD, CD, and UC with a history of self-reported 
fractures within the previous five years. In all models, the reference group is participants without 
history of IBD. Model 0 – unadjusted; model 1 – adjusted for age, ethnicity, and socioeconomic 
deprivation; model 2 – adjusted for model 1 + BMI, smoking status, and PA.  
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4.4.4 Associations of disease status with eBMD 
A history of IBD was associated with lower eBMD T-score in both men and women 
(Table 4-5). The associations appeared stronger in males, with an estimated 
deficit of -0.15 (95% CI: -0.23, -0.08) T-score compared to those without IBD after 
adjustment for covariates. In women, CD was associated with lower eBMD, but UC 
was not. The magnitude of associations remained similar across different levels of 
covariate adjustment (Model 2: -0.16 [95% CI: -0.26, -0.06]). In males, both CD 
and UC displayed similar negative associations with eBMD T-score of -0.14 (95%CI: 
-0.28, 0.00) and -0.16 (95%CI: -0.24, -0.07), respectively, in fully adjusted models 
(Table 4-5). Sensitivity analyses did not alter the direction or magnitude of any of 
the observed associations (Table 4-7). 
Table 4-5 Associations of disease status with estimated BMD by sex 
  Female Male 
  β Coefficient (95%CI) p-value β Coefficient (95%CI) p-value 
eBMD T-score 
IBD a 
Model 0  -0.11 (-0.16, -0.05) <0.001 -0.2 (-0.27, -0.12) <0.001 
Model 1 -0.09 (-0.15, -0.03) 0.002 -0.19 (-0.26, -0.11) <0.001 
Model 2 -0.08 (-0.13, -0.02) 0.01 -0.15 (-0.23, -0.08) <0.001 
CD b 
Model 0 -0.18 (-0.29, -0.08) <0.001 -0.2 (-0.34, -0.06) 0.01 
Model 1 -0.18 (-0.28, -0.08) <0.001 -0.19 (-0.33, -0.05) 0.01 
Model 2 -0.16 (-0.26, -0.06) 0.002 -0.14 (-0.28, 0.00) 0.05 
UC c 
Model 0 -0.07 (-0.14, 0.01) 0.08 -0.2 (-0.29, -0.1) <0.001 
Model 1 -0.04 (-0.11, 0.03) 0.25 -0.18 (-0.27, -0.09) <0.001 
Model 2 -0.04 (-0.11, 0.04) 0.32 -0.16 (-0.25, -0.07) <0.001 
Linear regression analyses for associations between IBD, CD, and UC with estimated bone mineral 
density. In all models, the reference group is participants without history of IBD. Model 0 – 
unadjusted; model 1 – adjusted for age, ethnicity, and socioeconomic deprivation; model 2 – adjusted 
for model 1 + BMI, smoking status, and PA. a n = 2604 (1330 female, 1274 male); b n = 796 (437 
female, 359 male), c n = 1677 (819 female, 848 male).   
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4.4.5 Associations of disease with muscle weakness  
Men and women with IBD displayed a significantly higher odds of muscle weakness 
compared to the rest of the cohort (Table 4-6). In disease specific analyses, men 
and women with both CD and UC had increased likelihood of muscle weakness. 
After adjustment for covariates, the association was strongest in women with CD, 
who displayed an estimated 55% (95%CI: 25 to 92%) higher likelihood of muscle 
weakness (Table 4-6). Women with UC had an estimated 24% (95%CI: 5 to 45%) 
higher odds of muscle weakness than women without IBD. Men with UC and CD 
both had increased odds of muscle weakness, although these associations were no 
longer significant after adjustment for covariates (Table 4-6). In sensitivity 
analyses, the association between CD and muscle weakness was stronger in men 
and slightly weaker in women but remained consistent in UC (Table 4-7).  
Table 4-6 Associations of disease status with muscle weakness by sex 
  Female Male 
  Odds Ratio (95%CI) p-value Odds Ratio (95%CI) p-value 
IBD 
Model 0  1.37 (1.21, 1.55) <0.001 1.27 (1.08, 1.48) 0.003 
Model 1 1.33 (1.17, 1.5) <0.001 1.23 (1.06, 1.45) 0.01 
Model 2 1.33 (1.18, 1.51) <0.001 1.25 (1.07, 1.47) 0.01 
CD 
Model 0 1.48 (1.21, 1.83) <0.001 1.28 (0.95, 1.71) 0.1 
Model 1 1.55 (1.25, 1.91) <0.001 1.32 (0.98, 1.78) 0.07 
Model 2 1.55 (1.25, 1.92) <0.001 1.33 (0.99, 1.79) 0.06 
UC 
Model 0 1.3 (1.11, 1.52) 0.001 1.26 (1.04, 1.52) 0.02 
Model 1 1.22 (1.04, 1.43) 0.01 1.2 (0.99, 1.46) 0.06 
Model 2 1.24 (1.05, 1.45) 0.01 1.21 (1.00, 1.47) 0.05 
Binary logistic regression assessing associations between IBD, CD, and UC with muscle weakness. 
Muscle weakness is defined as low grip strength according to EWGSOP2 criteria: <16kg for women 
and <27kg for men. In all models, the reference group is participants without history of IBD. Model 0 
– unadjusted; model 1 – adjusted for age, ethnicity, and socioeconomic deprivation; model 2 – 




Table 4-7 Sensitivity analyses for associations between disease status and falls, fractures, 
BMD, and muscle weakness by sex 
  CD UC 
  Odds Ratio (95%CI) p-value Odds Ratio (95%CI) p-value 
Falls 
Females 1.21 (1.02, 1.44) 0.03 1.15 (1.02, 1.3) 0.03 
Males 1.25 (1.00, 1.56) 0.05 1.09 (0.95, 1.26) 0.24 
Fractures 
Females 1.33 (1.06, 1.65) 0.01 1.01 (0.85, 1.19) 0.94 
Males 1.01 (0.75, 1.35) 0.97 1.08 (0.9, 1.3) 0.43 
Fragility 
fractures 
Females 1.34 (1.03, 1.74) 0.03 1.14 (0.94, 1.37) 0.19 
Males 0.99 (0.63, 1.55) 0.97 1.2 (0.93, 1.55) 0.17 
Muscle 
weakness 
Females 1.39 (1.11, 1.76) 0.01 1.24 (1.06, 1.46) 0.01 
Males 1.42 (1.04, 1.93) 0.03 1.22 (1.00, 1.48) 0.05 
  β Coefficient (95%CI) p-value β Coefficient (95%CI) p-value 
eBMD  
T-score 
Females -0.14 (-0.25, -0.04) 0.01 -0.04 (-0.11, 0.04) 0.32 
Males -0.14 (-0.29, 0.01) 0.06 -0.15 (-0.24, -0.05) 0.002 
Sensitivity analyses excluding all participants with a recorded episode of both CD and UC from 
disease specific regression models. N = 190 were excluded from the CD group and N = 165 were 
excluded from the UC group. All models presented are adjusted as in model 2 (age, ethnicity, 
deprivation, BMI, smoking status, and PA).  
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4.4.6 Exploratory analyses of factors associated with 
musculoskeletal outcomes in CD 
4.4.6.1 Falls 
Overall, women with CD had increased odds of a previous fall compared to men 
(OR: 1.52 [95% CI: 1.17, 1.98], p <0.001). Muscle weakness was associated with an 
estimated 90% [95% CI: 21 to 199%] increased likelihood of a fall in women with 
CD (Figure 4-2). A similar association was observed in men but with wider 
confidence intervals, likely due to a reduced number of male participants with 
muscle weakness and fall events overall (Figure 4-3). In women, overweight and 
obesity were positively associated with likelihood of a fall (Figure 4-2). In men, 
being a current smoker or from an area with more socioeconomic deprivation were 
both positively associated with likelihood of a fall (Figure 4-3). No associations 
were observed between age or age at disease diagnosis and self-reported falls in 
men or women with CD. Women who self-reported current use of 5-ASA 
medications had 45% [95%CI: 2 to 107%] increased likelihood of reporting a fall, 
but no other associations between medications and falls were observed. 
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Figure 4-2 Factors associated with self-reported falls in women with CD 
Exploratory analyses of factors associated with self-reported falls in women with CD. OR (95%CI) 
represents the odds of a fracture compared to the reference groups in the respective analysis. BMI 
– body mass index; GC – glucocorticoids; immunosuppressants – azathioprine, mercaptopurine, 
methotrexate, cyclosporin; 5-ASA – 5-aminosalicylates. 
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Figure 4-3 Factors associated with self-reported falls in men with CD 
Exploratory analyses of factors associated with self-reported falls in men with CD. OR (95%CI) 
represents the odds of a fracture compared to the reference groups in the respective analysis. BMI 
– body mass index; GC – glucocorticoids; immunosuppressants – azathioprine, mercaptopurine, 





Female sex was also associated with increased odds of a previous fracture 
compared to males in CD (OR: 1.59 [95% CI: 1.13, 2.24], p = 0.01). The factor most 
strongly associated with a previous fracture in both male and female CD was a 
self-reported fall within the previous 12 months (Figure 4-4 & Figure 4-5). Females 
who experienced a fall were an estimated three times more likely to have a self-
reported fracture in the past five years (Figure 4-4). Males were almost four times 
as likely, although with much wider confidence intervals due to lower number of 
fractures overall (Figure 4-5). Women with low eBMD T-score were also an 
estimated 84% [95%CI: 3 to 231%] more likely to report a fracture than those with 
normal eBMD (Figure 4-4), whereas eBMD was not associated with fractures in 
male CD. Older age was positively associated with fractures in women but 
negatively with fractures in men with CD. 
In similar analyses exploring factors associated with fragility fractures, of the 
factors analysed only older age (>65 years OR: 2.31 [95% CI: 1.22, 4.39], p = 0.01) 
and history of a fall within the previous 12 months (OR: 2.96 [95% CI: 1.79, 4.87], 
p <0.001) were associated with a fragility fracture in the previous five years in 
women with CD. In men with CD, only a previous fall within 12 months was 
positively associated with likelihood of a fragility fracture over the previous five 
years (OR: 3.8 [95% CI: 1.58, 9.17], p = 0.003).  
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Figure 4-4 Factors associated with fractures in women with CD 
Exploratory analyses of factors associated with self-reported fractures in women with CD. OR 
(95%CI) represents the odds of a fracture compared to the reference groups in the respective 
analysis. BMI – body mass index; GC – glucocorticoids; immunosuppressants – azathioprine, 
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Figure 4-5 Factors associated with fractures in men with CD 
Exploratory analyses of factors associated with self-reported fractures in men with CD. OR (95%CI) 
represents the odds of a fracture compared to the reference groups in the respective analysis. BMI 
– body mass index; GC – glucocorticoids; immunosuppressants – azathioprine, mercaptopurine, 




4.4.6.3 Muscle weakness 
Women with CD were more likely to have muscle weakness compared to men (OR: 
1.93 [95%CI: 1.34, 2.78], p <0.001). Compared to younger women with CD, those 
in both the middle and older age group had significantly higher odds of muscle 
weakness (Figure 4-6). Older age was also positively associated with muscle 
weakness in men with CD (Figure 4-7). Higher socioeconomic deprivation was 
positively associated with muscle weakness in women with CD, an association that 
appeared similar in men but was not statistically significant. Women with CD who 
were physically active, according to their IPAQ data, were an estimated 64% 
[95%CI: 34 to 80%] less likely to have muscle weakness than women who were 
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Figure 4-6 Factors associated with muscle weakness in women with CD 
Exploratory analyses of factors associated with muscle weakness in women with CD. OR (95%CI) 
represents the odds of a fracture compared to the reference groups in the respective analysis. BMI 
– body mass index; GC – glucocorticoids; immunosuppressants – azathioprine, mercaptopurine, 
methotrexate, cyclosporin; 5-ASA – 5-aminosalicylates; low BMD – eBMD T-score < -1.0. 
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Figure 4-7 Factors associated with muscle weakness in men with CD 
Exploratory analyses of factors associated with muscle weakness in men with CD. OR (95%CI) 
represents the odds of a fracture compared to the reference groups in the respective analysis. BMI 
– body mass index; GC – glucocorticoids; immunosuppressants – azathioprine, mercaptopurine, 




4.4.6.4 eBMD T-score 
Older age and being a current smoker were associated with lower eBMD T-score 
in women but not men with CD (Figure 4-8). Underweight was associated with 
lower eBMD in both sexes, while overweight and obesity was associated with 
higher eBMD in men only, compared to normal weight reference groups (Figure 
4-9). Current use of any IBD medication, and particularly the use of 
immunosuppressants was associated with lower eBMD T-score in men only (Figure 
4-9). Current use of GC therapy and age at disease diagnosis were not associated 
with eBMD in either sex. 
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Figure 4-8 Factors associated with eBMD in women with CD 
Exploratory analyses of factors associated with eBMD in women with CD. β (95% CI) represents the 
difference in eBMD T-score compared to the reference group in multiple regression for the respective 
analyses. All analyses were adjusted for age and deprivation (when not the factor of interest). N = 
437. BMI – body mass index; GC – glucocorticoids; immunosuppressants – azathioprine, 
mercaptopurine, methotrexate, cyclosporin; 5-ASA – 5-aminosalicylates. 
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Figure 4-9 Factors associated with eBMD in men with CD 
Exploratory analyses of factors associated with eBMD in men with CD. β (95% CI) represents the 
difference in eBMD T-score compared to the reference group in multiple regression for the respective 
analyses. All analyses were adjusted for age and deprivation (when not the factor of interest). N = 
359. BMI – body mass index; GC – glucocorticoids; immunosuppressants – azathioprine, 





In this study, a history of IBD was associated with a range of adverse 
musculoskeletal outcomes in both men and women. The IBD cohort in this study 
most likely represent a group with mild disease, highlighted by low use of IBD 
medications and very low rates of GI surgery. This is the first study to investigate 
falls in IBD, reporting higher odds of a self-reported fall in both men and women 
with CD and women with UC. All disease groups were more likely to have muscle 
weakness, compared to non-IBD participants, and women with CD were the most 
likely to be affected. Deficits in eBMD T-scores were also observed in men and 
women with both CD and UC. Women with CD displayed an increased likelihood of 
a self-reported fracture or fragility fracture compared to those without a history 
of IBD. Despite the cohort of mild disease status, musculoskeletal deficits are 
observed in older men and women with IBD including clinically meaningful 
outcomes like falls and fragility fractures.  
The chronic elevation of pro-inflammatory cytokines is one of the key regulators 
of bone and muscle loss in IBD, as previously discussed. Chronic low-grade 
inflammation, however, also partly moderates tissue degradation and age-related 
disease pathogenesis in healthy ageing 360. Inflammatory-mediated ageing (termed 
‘inflammageing’) and IBD share some common mechanisms. These include chronic 
activation of the NFB pathway, elevated expression of pro-inflammatory 
cytokines, and excessive infiltration of M1 macrophages into adipocytes 360. 
Individuals with IBD may therefore experience something akin to an accelerated 
aging process. Subsequently, they may be at increased risk of adverse 
musculoskeletal events such as falls and fractures at an earlier age compared to 
typically aging counterparts. 
Falls are a major contributor to morbidity and mortality in aging adults and one 
of the leading causes of disability adjusted life years globally 356. A key risk factor 
for falls in older adults is muscle weakness. The economic costs of muscle 
weakness were recently estimated at £2.5 billion per year in the UK 361. Currently, 
no published studies have assessed muscle weakness and falls risk in older adults 
with IBD. Here, a history of IBD was associated with a higher likelihood of a recent 
fall and muscle weakness in both men and women, when compared to age 
matched, non-IBD peers. Only men with UC displayed no increased likelihood of a 
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fall, while all groups were at increased odds of having muscle weakness. Increased 
propensity for falls may be linked to the reduced functional capacity of the lower 
limbs that has been observed in CD cohorts in this thesis and previous research 
269,299. Small differences in grip strength, such as those observed in this study 
(median difference: 0.5 – 2kg), have also been found to mediate the risk of falls 
in older adults 362. The likelihood of a recent fall was approximately 3% lower (OR: 
0.97 [95%CI: 0.94, 0.99]) per 1kg increase in grip strength in a cohort of older 
adults (n = 808), adjusting for age and sex 362. Agreeably, low grip strength was 
strongly associated with falls in CD in the current study. Future prospective studies 
should investigate the risk of falls in CD and associated clinical risk factors, 
including muscle weakness. This may be particularly important for younger CD 
cohorts, as they consistently display poor muscle function that may increase the 
risk of falls and associated morbidity in future.  
Overall, women but not men with IBD displayed an increased likelihood of any 
fracture. This association was driven by a higher fracture risk in women with CD 
(OR: 1.35 [95% CI: 1.09, 1.66]) but not UC (OR: 1.03 [95% CI: 0.78, 1.36]). Women 
with CD also displayed an equally increased likelihood of fragility fracture. Recent 
studies have also reported significantly increased risk of fracture in older adults 
with IBD 324,363. Bartko et al found women with CD were more than twice as likely 
to have a hip fracture (OR: 2.91, [95% CI 2.17, 3.89]) compared to age and sex 
matched controls, after adjustment for confounders including prior GC exposure 
363. No associations between current GC and fractures were observed in the 
current study. Whether cumulative GC exposure may have been associated with 
fractures is unclear as these data were not available. In exploratory analyses, only 
a previous fall and low eBMD were significant predictors of fractures in women 
with CD. While further investigations are required into the risk of falls in CD, 
targeting bone and muscle may moderate falls and associated fracture risk in CD. 
Consistent with previous studies reporting low bone mass in IBD, eBMD T-scores 
were lower in men and women with CD, but also in men with UC, compared to 
controls. Disease severity and GC therapy are primary risk factors for low BMD in 
IBD. No association between GC and eBMD was observed, potentially due to the 
grouping of all GC therapies together, including systemic and topical treatments. 
In men with CD, immunosuppressant use was associated with lower eBMD. As 
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immunosuppressants are typically reserved for more active disease in older adults 
364, this association was likely an indicator of disease severity rather than an effect 
of therapy. However, a negative effect of azathioprine has been recently observed 
on trabecular bone volume of murine models of colitis 344 and has previously been 
associated with an increased risk of fracture across multiple conditions including 
CD 365. Further evaluation of medications and their association with 
musculoskeletal outcomes in older adults with IBD is needed.  
A strength of this study was the ability to assess musculoskeletal outcomes in IBD 
compared to a very large control population. The UK Biobank, however, had a low 
response rate (5.5%) and is affected by healthy volunteer bias, including lower 
rates of morbidity and mortality compared to population data 366. Nonetheless, 
the control population contained many participants with primary and secondary 
musculoskeletal disorders, therefore the observation of an adverse muscle-bone 
phenotype in IBD relative to age-matched peers is robust. The IBD cohort itself 
may not be immune to this healthy bias and, based on the clinical data available, 
appears to represent a group with uncomplicated disease. This is highlighted 
particularly low rates of GI surgery and non-use of IBD medications. The use of 
contemporary therapies such as anti-TNF were very low, partly due to the time 
of the study but also as these were primarily licensed for use in severe disease. 
The use of anti-TNF is now more commonplace among adults with IBD, although 
they are still used less often than in younger cohorts due to concerns of opportune 
infection 364. These drugs have been associated with recovery of some bone and 
muscle in young cohorts of CD. Nevertheless, recent studies are required to 
evaluate the risk of adverse musculoskeletal outcomes in older adults under 
modern treatment regimens. 
There are some important limitations to this study. The analyses relied on self-
reported falls and fractures which may be subject to recall bias. Prior studies have 
observed up to 14% false positives for fractures 367 but under reporting of falls by 
around 30% when recorded retrospectively 368. Linking analyses to clinically 
confirmed fractures via HES would be preferable. Heel eBMD was measured using 
QUS instead of DXA, which is the clinical gold standard for BMD. QUS does, 
however, correlate well with DXA and has been previously validated for use in 
epidemiological research 187. A QUS eBMD T-score of <-1.0 SDS was used to define 
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low eBMD; however, QUS and DXA BMD T-scores are not equivalent and the precise 
cut off for low bone mass by QUS is not known. The cross-sectional nature of the 
study precludes an assessment of causality, although the findings corroborate 
previous reports of adverse musculoskeletal health in IBD. Analyses were not 
adjusted for use of bisphosphonates as there was no information on timing of 
initiation of bisphosphonates. However, bisphosphonate use was ten times more 
common in men (5.2% vs 0.5%) and four times more common in women (10.4 % vs 
2.6%) with CD, compared to the non-IBD cohort.  
The methods of case ascertainment are another limitation to the study. History of 
IBD was based on primary care and in-patient ICD-10 codes together with self-
reported diagnoses data. As such, some individuals had a reported history of both 
CD and UC, potentially due to initial misclassification of disease or ‘working 
diagnoses’ in ICD codes. The accuracy of ICD codes has been previously improved 
by combination with other data such as prescriptions 369. Self-reported diagnoses 
were used to moderate history of CD/UC. Where someone had a history of both 
CD and UC, they were included in analyses based on their self-reported diagnosis. 
Individuals who self-reported both CD and UC were excluded from subtype 
analyses. Additionally, sensitivity analyses excluding all individuals with a history 
of both CD and UC (n = 386) were conducted. These analyses did not alter the 
direction or magnitude of any of the observed associations, suggesting the cross-
referencing of ICD codes with self-report may be a useful method of case 
ascertainment. Despite the known limitations, this study provides valuable 
information on adverse musculoskeletal outcomes in older adults with IBD and 
provides a precursor upon which more detailed research can be designed. 
In conclusion, this study has for the first time quantified an increased risk of falls 
in adults with IBD in what appears to be a cohort with generally uncomplicated 
disease. Fracture risk in IBD was only elevated in women with CD, however all IBD 
subgroups displayed in increased likelihood of muscle weakness and low eBMD 
compared to non-IBD peers. These data further suggest increased risk of adverse 
musculoskeletal outcomes in even mild IBD, consistent with the previous chapters. 
Future studies should aim to characterise musculoskeletal outcomes and 
associated clinical risk factors in older adults with IBD and assess the efficacy of 
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musculoskeletal interventions in this cohort, particularly as the elderly IBD 




5 Systematic review of exercise in inflammatory 
bowel disease 
5.1 Abstract 
Background. Exercise may be a suitable adjunctive therapy for alleviating many 
of the secondary complications of IBD, yet little is known about its utility in 
practice. 
Aim. Perform a systematic review to analyse the current evidence for the effects 
of exercise on disease symptoms and secondary complications of IBD in children 
and adults. 
Methods. A systematic search of four online databases (EMBASE, Medline, 
Cochrane, and CINAHL) was conducted from their inception through April 2021. 
Any studies including specific physical activity or exercise interventions in 
individuals with IBD were included. Studies were assessed for methodological 
quality using a modified Downs-Black checklist. 
Results. A total of 1362 articles were identified of which 17 were included in the 
final review. Thirteen studies were conducted in adults and four in paediatric 
populations. All studies included only participants with mild or inactive disease. A 
range of interventions and measured outcomes were implemented, making 
comparisons between studies difficult. One common theme was a small to 
moderate clinically meaningful improvement in HRQoL from exercise, as assessed 
by the IBDQ tool. Some evidence for improvements in physical function, BMD, and 
fatigue were also noted in individual studies. Very few exercise related adverse 
events and no exacerbations of disease symptoms due to exercise were reported 
across studies.  
Conclusions. The current evidence for the utility of exercise in IBD is limited by 
the small number of underpowered, heterogenous published studies. There is very 
little evidence on the potential role for exercise in alleviating the musculoskeletal 
or inflammatory burden in CD, and future, adequately designed studies are needed 




Exercise interventions are one of the most effective strategies for improving bone 
and muscle health, which are adversely affected across the lifespan in CD 
(Chapters 2, 3 & 4). Additionally, there is plausible rationale for the potential role 
of exercise for improving other secondary complications of CD, including fatigue, 
HRQoL, and chronic inflammation (Section 1.5.2). Currently, no disease specific 
exercise guidelines exist for individuals with CD and the general utility of exercise 
as a management tool for the complications of CD is unknown. Prior to designing 
future interventions assessing exercise utility in CD, it is important to synthesise 
the available evidence to establish what is currently known. 
The aim of this study, therefore, was to perform a systematic review of the 
literature to assess the effects of exercise on primary and secondary complications 





5.3.1 Search strategy 
A systematic search of the MEDLINE, EMBASE, CINAHL and Cochrane Central 
Library databases was conducted using records from their inception through April 
2021. Reference lists of potentially relevant articles and reviews were also 
searched manually. The original search strategy was devised within the MEDLINE 
database and subsequently adapted to each of the other databases, respectively 
(search strategy in Appendix 2). Due to the heterogeneity of exercise research in 
IBD, both randomised and non-randomised studies were included. Only eligible full 
texts that were available in English were considered for review.  
5.3.2 Eligibility criteria 
All randomised and non-randomised trials implementing a specific physical activity 
or exercise intervention in individuals with a diagnosis of inflammatory bowel 
disease (CD, UC, or IBDU) were included. Both paediatric and adult studies were 
eligible. Studies assessing both the acute and chronic effects of PA or exercise 
were eligible. A full description of the prescribed intervention was required and 
general information with regards to increasing PA were not included. Primary 
outcome measures included health related quality of life (HRQoL), immune and 
inflammatory response, disease activity, and body composition and 
musculoskeletal outcomes.  
5.3.3 Data extraction 
The titles and abstracts of retrieved articles were evaluated for eligibility. 
Abstracts that did not provide sufficient information for exclusion were retrieved 
for full-text analysis. After full text analysis, articles that were deemed eligible 
for inclusion had the following data extracted: title, first author, year of 
publication, study design, participant characteristics, sample size, intervention 
type, intervention length, measured outcomes, and main findings. A qualitative 
analysis was conducted to present the current body of evidence and identify 
future research needs. Results are presented by grouped outcomes associated with 
complications of CD. This systematic review was conducted in line with the 
169 
 
preferred reporting items for systematic reviews and meta-analyses (PRISMA) 
guidelines. 
5.3.4 Assessment of quality 
A modified version of the Downs-Black checklist was used to assess the 
methodological quality of studies included in this review 370. This tool is designed 
to assess the methodological quality of both randomised and non-randomised 
studies against a 27-item checklist. The tool assesses quality within five sub-
domains: reporting, external validity, internal validity (bias), internal validity 
(confounding) and study power. Study quality was assessed from a possible 28 
points as follows: excellent (26 – 28), good (20 - 25), fair (15 – 19), poor (≤14). 
Quality assessment was conducted independently by the researcher (LS) and a 
second reviewer (JW). The second reviewer’s assessment was conducted for 
purposes of quality control and was overall similar to the primary reviewer’s 
assessment. Minor discrepancies were resolved by consensus.  
5.4 Results: included studies 
5.4.1 Description of studies 
A total of 1362 potentially relevant articles were retrieved from electronic 
database searches and manual searches of relevant reference lists. A consort 
diagram of the number of retrieved articles and the selection process is available 
in Figure 5-1. After removing duplicates and scanning titles and abstracts, 52 
articles were selected for full-text analysis. Seventeen articles were selected for 




Figure 5-1 Consort diagram of search and study selection procedure. 
 
5.4.2 Study characteristics 
Of the seventeen articles included in the final review, 13 were conducted in adults 
371-383 and four in paediatric populations 384-387. A total of 623 participants with IBD 
(435 CD) were originally recruited across the 17 studies. Eight studies included 
individuals with both CD and UC, eight assessed only CD patients, and one assessed 
only UC patients.  
Three studies investigated the acute effects of a single bout of exercise, while 
thirteen studies investigated the effects of PA or exercise interventions ranging in 
duration from eight weeks to 12 months. A variety of interventions were 
implemented including walking 377,378, running 376, cycling 382, yoga 371,381,384, active 
videogame play 385,386, resistance training 374, aerobic and resistance training 
372,380,383, resistance and impact training 375, and core strengthening exercises 379. 
Study characteristics and results are displayed in Table 5-1.
Articles retrieved from 
database searches (n = 1362) 
Title & Abstracts Screened 
(n = 1121) 
Articles excluded: duplicates 
(n = 241) 
Full texts screened for 
eligibility (n = 52) 
Articles excluded: irrelevant 
title/abstract (n = 1069) 
Articles included 
(n = 17) 




Table 5-1 Data extraction table for studies exploring the effects of PA and exercise in populations with IBD 
Author 
(year) 






RCT UC [Clinical remission] 
N = 77 (IG: 29, CG 38). 
58/77 female. 
Age: 45  
 
12 weeks 
IG: 1 x 90 mins yoga per 
week + daily at home 
practice encouraged 






4 SAEs (unrelated) 
[3 IG, 1 CG] 
16 AEs [7 IG,9 CG] 
IBDQ ↑ in IG not CG: 
12 wk mean diff. 14.7 [95% CI: 2.4, 26.9], p = 0.02 
24 wk mean diff. 16.4 [95% CI: 2.5, 30.3], p = 0.02 
RI non-sig ↓ IG & ↑ CG: 





IBD [Clinical remission] 
N = 17 (IG: 15, CG: 8) 
5/17 female 
Age: IG 33 [IQR 31, 36],  
8 weeks  
IG: 3 per week progressive 
aerobic exercise & RT. 
CG: No intervention. 









Lean mass: IG +1.59kg [95%CI: 0.68, 2.69] vs CG -
1.38 [95%CI: -2.45, 0.26], p = 0.003. 
Bodyfat %: IG -2.1 [95%CI: -2.15, -0.45] vs CG +0.1 
[95%CI: -0.4, 1], p = 0.02. 
No change QoL, microbiome, cytokines. 
de Souza 





IBD [Clinical remission] 
N = 19 




2 x 20 mins progressive RT 









AE: Not reported 
Maximal isometric quadriceps strength ↑ ~40% 
(28.5 [± 5.6] to 39.0 [± 3.2] kg, p<0.001). 
No change thigh circumference. 






N = 6 (+ 6 HC) 
Age: CD 28.2 (±3.2)  
Acute study 











AE: Not reported 
No change symptoms, motility, or permeability.  
Similar immune response vs healthy controls. 
Klare et al 
(2015) 
RCT IBD [Remission/mild active] 
N = 36 [18 per group] 
19 CD, 11 UC 
26/36 female 
Age: IG 39.7 (± 14.7), CG 
42.5 (± 13.9) 
10 weeks 
IG: 3 x moderate intensity 
running per week 
CG: Maintain current 
activity <2 hrs per week 
IBDQ 




Mean 80% (24 [±4] 
of 30 sessions) 
 
1 AE 
IBDQ ↑ in IG (Mean change 28.3 [± 24.5], p = 0.001) 
and CG (mean change 14.5 [± 16.1], p = 0.004). 
No diff in IBDQ change between IG & CG 
No sig. change in RI/CDAI 












CD [Remission/mild active] 
N = 16 
10/12 female 
Mean age: 38.3 (± 7.5) 
12 weeks 
3 x group or individual 
walking sessions per week.  
Progressive: 20 - 35 mins 
IBDQ  
IBD stress index 
HBI 
CRF 
Mean 97.5% (35.1 
[± 3.6] sessions) 
 
AE: Not reported 
IBDQ ↑ 172 [± 27] to 189 [± 12], p = 0.01 
IBD stress index ↓ 29.2 [± 15.4] to 19.5 [± 10.8], 
p<0.001 
HBI ↓ 5.9 [± 5.0] to 3.6 [± 3.1], p = 0.02 
CRF ↑ 30.6 [± 4.7] to 32.4 [± 4.8], p = 0.001 
Ng et al 
(2007) 
RCT CD [Remission/mild active] 
N = 32 (16 per group) 
Sex unknown 
Mean age: IG 40.6 [± 11.7], 
CG 37 [± 12.7] 
12 weeks 
IG: 3 x 30 mins walking @ 
60% HRmax 







AE: Not reported 
IBDQ ↑ (p<0.05; data not clearly reported). 
IBD-SI ↓ (p<0.05; data not clearly reported). 




RCT CD [Remission/mild active] 
N = 117 (60 IG, 57 CG) 
69/117 female 
Mean age: IG 40.1 [± 12.6], 
CG 41.2 [± 14.1] 
12 months 
IG: ≥ 2 x dynamic core 
strengthening exercise 
sessions per week [10 per 
month min] 
CG: Not reported 
aBMD LS & Hip Adherence: 62% @ 
3 months, 52% @ 
12 months 
 
No AEs reported 
Non-sig. ↑ aBMD at all sites. 
Fully compliant cohort sig. ↑ aBMD at greater 
trochanter vs controls (Mean diff. 4.67 [95%CI: 
0.86, 8.48], p = 0.02). 
Sharma et 
al (2015) 
RCT IBD [Clinical remission] 
N = 100 
40 CD, 60 UC 
Sex & age not reported 
8 weeks 
IG: Daily 1-hour yoga for 1 
week, then unsupervised 1-
hour daily yoga at home for 
remaining time. 







CD mean 81%, 56 
(22, 100) 
mins/day 
UC mean 76%, 45 
(20, 77) mins/day 
AE: Not reported 
No. reporting arthralgia ↓ post-intervention in IG 
 
State (p = 0.01) and trait (p = 0.001) anxiety ↓ in 
UC but not CD (IG) 
 
No change in sIL-2R or ECP. 
Tew et al 
(2019) 
RCT CD [Remission/mild active] 
N = 36 
19 female 
Mean age: 36.9 [± 11.2] 
12 weeks 
HIIT: Cycling 10 x 1-min @ 
90% Wpeak, 3 x per week 
MICT: Cycling 30 min @ 35% 
Wpeak, 3 x per week 











HIIT mean 62% 





Good acceptability of HIIT & MICT 
No formal statistics performed for other outcomes. 
Descriptive data suggests no clear changes in CDAI, 
FC, body composition, QoL or fatigue in HIIT or 
MICT. 
CRF appeared to ↑ slightly in HIIT (+2.4 ml/kg/min) 





Study Design Cohort Methods Outcomes Adherence & 
Adverse Events 
Main Findings 
Jones et al 
(2020) 
RCT CD [Remission/mild active] 
N = 47  
32 female 
Mean age 49.3 [± 13] 
 
6 months 
IG: 3 x 60 mins RT & 
impact exercise per week.  
 
CG: No intervention 
aBMD LS & Hip 
Grip strength 












LS aBMD ↑ in IG vs CG (Mean diff. 3.8% [95% CI: 2.6, 
5.1], p<0.001). 
No diff. in hip aBMD. 
All muscle function ↑ in IG vs CG. 
IBDQ ↑ @ 3 months (Mean diff. 17 [95% CI: 7, 26], p 
= 0.001) but no diff. at follow up. 







CD [Quiescent/mild active] 
N = 45  
RT group: n = 15, 8 female, 
mean age 42 [± 13.1] years 
ET group: n = 17, 11 female, 
mean age 39.6 [± 12] years 
Control: n = 13, 9 female, 
mean age 43.7 [± 12] years 
 
12 weeks 
RT group: 3 x 30-40mins 
bodyweight RT  
ET group: 3 x 30 mins @ 60-
80% HRmax (gauged by RPE) 











AE: Not reported 
ET: 47% dropout; RT: 13% dropout. 
No change CDAI in any group. 
No change sIBDQ in ET or RT group. 
Quadriceps & grip strength ↑ in RT & ET (data not 
clearly reported) 




IBD [Quiescent + severe 
fatigue] 
N = 25 
21 CD, 2 UC, 1 IBDU 
10 female 
Mean age: 45 [± 2.6] years 
12 weeks 
3 x 60 mins per week 












AE: Not reported 
 
CIS ↓ (mean diff. -38 [95%CI: -48, -28], p<0.001). 
IBDQ ↑ (mean diff. 20 [95%CI: 11, 29], p<0.001). 
Bodyfat % ↓ (mean diff. -1.8 % [95%CI: -2.8, -0.8], 
p = 0.002). 
Non-sig. ↑ in CRF & sig. ↑ max power (mean diff. 







N = 9 
8 CD, 1 UC 
8 female 
Mean age: 14.1 years 
8 weeks 
Attend 1 x 60 mins yoga 
session in week 1, 3 & 8. 
Complete 3 x 30 mins yoga 






≥2/3 sessions. 8/9 
≥1 home video 
per week. 
AE: Not reported 











Case-control IBD [Remission/active] 
N = 22 
12 CD, 7 UC, 3 IBDU 
IBD-Remission: n = 14; 7 CD, 
4 UC, 3 IBDU; 6 female. 
IBD-Active: n = 7; 4 CD, 
3UC; 4 female. 
HC: n = 23. 15 female. 
8 weeks 
5 x 30 mins active 
















AE: Not reported 
No change QoL. 
Decreased sleep time in IBD-AD. Decreased REM 
sleep in IBD-RE & IBD-AD. No change subjective 
sleep. 
No change objective PA, self-reported PA reduced 









N = 21 
11 CD, 9 UC, 1 IBDU 
IBD-Remission: n = 14; 8 CD, 
5 UC, 1 IBDU; 8 female 
IBD-Active: n = 7; 3 CD, 4 
UC; 2 female 
HC: n = 23; 15 female 
8 weeks 
Intervention: 5 x 30 mins 
active videogame play per 
week 
 
Acute response: 6-minute 













AE: Not reported 
ESR and CRP ↓in IBD-AD & IBD-RE. 
Transient inflammatory response to acute exercise 
similar in all groups. Acute response to exercise did 






CD [Clinical remission] 
N = 15 
2 female 
Mean age: 14.5 [± 2.4] years 
 
HC: n = 15; 2 female; mean 
age 13.9 [± 2.2] years 
Acute response to HIIT & 
MICT. 
HIIT: 6 sets of 4 x 15s 
cycling @ 100% Wpeak  










15 CD & HC 
completed both 
HIIT and MICT 
 
AE: Not reported 
 
 
All immune cells ↑ during MICT but not HIIT in both 
groups. 
IL-6 ↑ during MICT in both groups, no cytokine 
change during HIIT. IL-6 return to baseline quicker 
in CD vs HC. (baseline higher in CD). 
IGF-1 ↓ at onset of HIIT and MICT in CD and return 
to baseline by mid-recovery. IGF-1 unchanged in 
HC. GH ↑ at onset of MICT in both groups and onset 
of HIIT in HC. 
Key characteristics of studies included in this systematic review (n = 15).  CD, Crohn’s disease; UC, ulcerative colitis; IBDU, inflammatory bowel disease unclassified; 
IBD, inflammatory bowel disease; IG, intervention group; CG, control group; HC, healthy controls;  RCT, randomised controlled trial; AE, adverse events;  IQR, inter-
quartile range; 95%CI, 95% confidence interval; diff., difference; sig., significant; ↑, increase;  ↓, decrease; CDAI, Crohn’s disease activity index; HBI, Harvey-Bradshaw 
index; PUCAI, paediatric ulcerative colitis activity index; RI, Rachmilewitz index; IBDQ, inflammatory bowel disease questionnaire; CIS, checklist individual strength; QoL, 
quality of life; FC, faecal calprotectin; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL-, interleukin; TNF-α, tumour necrosis factor alpha; ECP, 
eosinophilic cationic protein; sIL-2R, soluble interleukin 2 receptor; GH, growth hormone; IGF-1, insulin-like growth factor 1; PA, physical activity; 6MWT, 6-minute walk 
test; RT, resistance training; ET, endurance training; HIIT, high intensity interval training; MICT, moderate intensity continuous training; CRF, cardiorespiratory fitness; 
VO2max, maximal rate of oxygen consumption; EEG,  electroencephalogram; W, watts; ml, millilitres;  kg, kilograms;Wpeak, peak power output.
 
 
5.4.3 Results: Assessment of quality 
Table 5-2 presents the quality assessment score for each of the included articles 
according to the modified Downs Black checklist. The median score was 15 (range 
8, 23) from a possible 28 points. By this scoring system only two studies were rated 
as ‘good’ quality, nine were rated ‘fair’ and five studies were rated ‘poor’. One 
feasibility study performed no formal statistical analyses and as such some Downs 
Black checklist items were not applicable. This study scored 15 from an available 
21 points. All studies scored particularly poorly on external validity and the large 
number of pilot and feasibility trials meant that only 4/17 articles included an a 
priori power calculation. 
Table 5-2 Assessment of study quality using modified Downs Black checklist. 





















Arruda (2018) 5 0 5 3 0 15 Fair 
Cramer (2017) 11 0 6 5 1 23 Good 
Cronin (2018) 9 0 5 2 1 17 Fair 
De Souza 
Tajiri (2014) 
5 0 2 1 0 8 Poor 
D’Inca (1999) 9 0 5 2 0 16 Fair 
Jones (2020) 11 0 6 4 1 22 Good 
Klare (2015) 11 0 4 4 0 19 Fair 
Legeret (2019) 8 0 5 1 0 14 Poor 
Loudon (1999) 9 0 5 0 0 14 Poor 
Mahlmann 
(2017) 
8 0 5 1 0 14 Poor 
Ng (2007) 6 0 5 4 0 15 Fair 
Ploeger (2012) 8 0 5 2 0 15 Fair 
Robinson 
(1998) 
9 0 4 4 1 18 Fair 
Seeger (2020) 6 0 3 3 0 12 Poor 
Sharma (2015) 7 0 5 3 0 15 Fair 
Tew (2019) * 10/10 0/3 2/4 3/4 n/a 15/21 n/a 
Van Erp (2020) 10 0 5 3 0 18 Fair 
Assessment of study quality using modified Downs Black checklist. Maximum available score was 
28. Parentheses indicate score available per category. * No statistical analyses were performed in 
this study and some items from the checklist were not applicable. 
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5.4.4 Results: Adherence and safety of exercise in IBD 
Adherence to exercise varied quite widely across the different intervention 
studies. Adherence tended to be lower in longer duration interventions that 
contained a large proportion of unsupervised exercise 371,375,379,382. A mean 
adherence of 62% was reported in cycling 382, resistance training 375, and core 
strengthening 379 exercise, although adherence dropped to 52% by 12 months in 
the latter. Adherence to other interventions was good, with walking being the 
highest (97.5% 377 and 100% 378). Three intervention studies failed to report on 
adherence 374,380,385. Reporting of exercise safety was poor, with 11/17 studies not 
providing any data on adverse events. In studies that reported on safety, very few 
AEs occurred, highlighting the overall safety of various modes of exercise IBD. No 
intervention-related SAEs occurred in any study. All studies included exclusively 
individuals with disease in remission or mildly active, therefore the safety of 
exercise in moderate or severely active disease remains unknown. 
5.4.5 Results: Effects of exercise on IBD complications 
5.4.5.1 Disease activity and symptoms 
The effects of PA and exercise on disease activity and symptoms were assessed in 
ten studies 371-373,376-378,380-382,384. Disease activity was assessed using different 
validated clinical indexes including the CDAI 372,376-378,380,382, Harvey Bradshaw 
index (HBI), PCDAI 385, paediatric ulcerative colitis activity index (PUCAI) 384, 
Rachmilewitz index (RI) 371,376, and the simple colitis index (SCI) 372. Two studies 
qualitatively assessed disease symptoms post-intervention 373,381. Twelve weeks of 
thrice weekly low-intensity walking resulted in statistically significant reductions 
in mean HBI score in two separate studies of adults with CD 377,378. Mean difference 
in HBI scores post-intervention were -2.3 (p = 0.02) 377 and -3.0 (p < 0.05) 378, 
respectively, reducing the overall mean HBI scores from ‘mildly active’ to 
‘remission’ in both studies. Three studies of yoga in adolescents 384 and adults 
with IBD 371,381 reported no significant benefits to disease activity or bowel 
symptoms. Cramer et al did report a significant mean difference in RI score after 
long term follow up in favour of the yoga cohort, but only by -1.2 (95% CI: -2.5, -
0.1; p = 0.03) points. Similarly, a single bout of moderate cycling exercise did not 
have any effects on intestinal symptoms in a small cohort of male CD (n = 6) 373. 
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Ten weeks of moderate intensity running 376 or eight weeks of progressive 
moderate intensity aerobic and resistance training 372 did not significantly alter 
disease activity scores in two cohorts of adults with quiescent IBD. Bodyweight 
resistance or endurance training also did not alter CDAI score in adults with CD 
380. While no formal statistical testing was completed, results from a pilot RCT of 
moderate or high intensity cycling in CD suggest no clear effects of either disease 
modality on CDAI 382. It should be noted that all these cohorts included only 
participants in clinical remission or with mildly active disease and the low clinical 
disease activity scores reported at baseline reflected this. In one study that 
included participants with active disease, Legeret et al observed reductions in the 
PCDAI or PUCAI scores of all adolescent participants with active disease who 
undertook an eight-week active videogame play intervention (n = 7). Despite this, 
the pooled effect of intervention on disease status of the active and remission 
groups were not significant, as many in the remission group reported a baseline 
activity score of zero 385.  
5.4.5.2 Immune & inflammatory markers 
The acute inflammatory response to exercise was assessed in three studies 
373,385,387 and the long-term effects of exercise on inflammatory markers were 
evaluated in six studies 372,376,381,382,384,385. In adolescents with CD, Ploeger et al 
reported a single 60-minute bout of moderate intensity exercise (MICT), but not a 
shorter bout of high intensity exercise, significantly increased circulating immune 
cells in a manner similar to the healthy control group 387. Exercise did not increase 
circulating TNF-α in CD, but IL-6 increased during MICT, peaking at 30-minutes 
post-exercise, before returning to baseline. The magnitude of increased IL-6 was 
greater in controls, but absolute peak levels were higher in CD as mean baseline 
levels were six times higher (approx. 6 pg/ml vs 1 pg/ml) 387. A similar bout of 
cycling exercise did not alter immune function in young men with CD 373. An acute 
sub-maximal walking test did not alter CRP or ESR in adolescents with IBD 385, 
suggesting no exercise induced increase in IL-6. After eight weeks of combined 
aerobic and resistance training in adults with quiescent IBD (n = 13), circulating 
pro-inflammatory cytokines IL-6, TNF-α and IL-8 were unchanged from baseline 
levels 372. Faecal calprotectin (FC), a validated clinical marker of intestinal 
inflammation, was measured in only three studies 376,382,384. Yoga did not alter FC 
in paediatric IBD, although baseline levels were not reported 384. Twelve weeks of 
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moderate or high intensity cycling had no apparent effect on FC (baseline vs follow 
up: 45 ± 40 ug/g vs 63 ± 113 ug/g and 89 ± 72 vs 100 ± 113 ug/g, respectively), 
although no formal statistical testing was conducted 382. Moderate intensity 
running resulted in a mean within group change of +186 ± 324 ug/g in the 
intervention group, yet this did not reach statistical significance (p = 0.06) 376. 
Median (range) FC at follow up in this group was 141 (<30 – 1069) ug/g and the 
number of participants with potentially pathological FC (>250 ug/g) was not 
reported. 
5.4.5.3 Quality of life & psychological wellbeing  
HRQoL was assessed in ten studies of adult participants, eight of which applied 
the IBDQ tool 371,374-378,382,383. In two paediatric studies, no benefits to HRQoL or 
psychological wellbeing were reported after a yoga 384 or active videogame play 
386 intervention, respectively. Conversely, a yoga intervention improved mean 
IBDQ scores in adults with UC (143.5 ± 22.3 to 159.8 ± 32.2) resulting in a 
significant between group difference compared to controls, whose scores did not 
change from baseline (mean difference: 14.7 [95% CI: 2.4, 26.9], p = 0.02) 371. A 
separate yoga intervention was found to reduce anxiety levels, but only in UC, not 
CD participants 381. Klare et al observed improvements in IBDQ after 10 weeks of 
moderate intensity running (156.5 ± 35.0 to 184.9 ± 20.9, p = 0.001) with 
improvements in all sub-dimensions 376. Surprisingly, the non-exercising control 
group also experienced improved IBDQ in this study (167.7 ± 31.1 to 182.2 ± 26.6, 
p = 0.004) and in all sub-dimensions excluding social function, meaning the change 
in IBDQ over time did not differ between groups 376. Twelve weeks of walking was 
associated with a statistically significant improvement in IBDQ scores in adults 
with CD (172 ± 27 to 189 ±12, p = 0.01) 377. A similar walking intervention also 
observed improvements in IBDQ although the absolute values were not reported 
378. Both walking studies also reported improvements in IBD stress index (IBD-SI) 
scores despite scores being relatively low at baseline (mean: 29.2 ± 15.4 to 19.5 
± 10.8 377 and 31.4 to 18.7 378, respectively. Scores range from 0 – 102). IBDQ scores 
improved after eight weeks of quadriceps focused resistance training in women 
with IBD (10 CD) and quadriceps weakness at baseline 374. The age and disease 
status of these women was unknown, but IBDQ increased from 156.3 ± 29.0 to 
180.5 ± 24.2 (p < 0.001) with significant improvements in all sub-dimensions. A 
combination of resistance training and aerobic exercise also improved IBDQ in a 
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cohort of middle-aged adults (n = 25; 21 CD) with mild IBD and severe fatigue at 
baseline 383. Improvements in all sub-dimensions except bowel functioning were 
reported in this group, with overall mean increase in IBDQ of 20 (95% CI: 11, 29; p 
< 0.001). Conversely, combined resistance and impact training had no effect on 
IBDQ, although mean score was high at baseline (183  23) 375.  
5.4.5.4 Muscle-bone, body composition, and physical fitness 
Few studies assessed the effects of PA or exercise intervention on physical 
outcomes in IBD. Combined aerobic and resistance training in sedentary adults 
with IBD resulted in a gain in DXA-derived lean mass (median 1.59 kg [IQR: 0.68, 
2.69]) and reduction of fat mass (-1.52 kg [IQR: -2.32, -0.04]) and bodyfat 
percentage (-2.1 % [IQR: -2.15, -0.45]) 372. Progressive resistance training was 
effective for improving quadriceps strength in women with IBD and quadriceps 
weakness (28.5 kg ± 5.6 to 39.0 kg ± 3.2, p < 0.001), despite no concurrent increase 
in thigh circumference 374. Resistance and impact training also had large positive 
effects on several muscle function parameters including grip strength and upper 
and lower limb isokinetic strength, with improvements of up to 50% 375. Both 
resistance and endurance training were associated with increased grip strength in 
CD although the absolute changes were not reported 380. Estimated 
cardiorespiratory fitness was improved by a 12-week walking programme (VO2max 
30.6 [± 4.7] ml/kg/min to 32.4 [± 4.8] ml/kg/min, p = 0.001) 377 and appeared to 
be improved by high intensity, but not moderate intensity, cycling (mean increase 
2.4 ml/kg/min) 382 in separate cohorts of CD. Adolescents with active (n = 7) and 
remissive (n = 14) IBD increased their submaximal 6MWT distance at follow up 
compared to control, which was reported as an improvement in exercise capacity 
386. 
Two studies investigated the effects of exercise on skeletal outcomes. Low impact 
core exercises improved aBMD at the hip in CD but only in participants who 
achieved full intervention adherence 379. The aBMD improvement in exercise group 
was significantly greater than that observed in non-exercising controls (7.77 % ± 
8.2 vs 3.1 % ± 5.83, p = 0.02). Another CD cohort had significantly greater LS aBMD 
compared to controls after six months of resistance and impact exercise (Mean 
diff. 3.8% [95% CI: 2.6, 5.1], p<0.001) 375. In both studies, aBMD improvements 




Two directly addressed the effects of exercise on fatigue in IBD 375,383. Twenty-
five adults with clinically quiescent IBD (21 CD) who had severe fatigue at baseline 
(CIS Fatigue sub-scale score ≥35) were enrolled to participate in three supervised 
sessions of combined aerobic and resistance training per week for 12 weeks. In 
the 22 who completed the intervention, mean CIS-F sub-score reduced from 49 ± 
4.7 to 29 ± 8.9 (p < 0.001)383. IBD-F score was significantly different between 
exercise and control group after resistance and impact training, although this was 
due to deteriorating score in controls rather than improvement in the exercise 
group (Mean diff. -2 [95% CI: -4, -1], p = 0.004) 375. Objective and subjective sleep 
quality, potential contributors to fatigue in adolescent IBD, were assessed in one 
study but were not improved by an active videogame play intervention 386. 
5.5 Discussion 
The potential mechanisms by which PA and exercise could benefit individuals with 
IBD are multifactorial. Despite this, the currently available evidence for the role 
of exercise in the management of IBD has several limitations. In this review, 
assessment of study quality indicated only two studies to be of good quality and 
none were rated as excellent. The wide heterogeneity in terms of methodological 
approaches and measured outcomes makes between study comparisons difficult. 
Subsequently, a pooled review of the evidence is not possible for many of the 
outcomes. The multiple use of single arm cohort studies inhibits assessment of 
interventions versus control conditions and limits the statistical power of any 
reported associations. Exercise of various formats do, however, appear to be a 
safe and feasible intervention for individuals with IBD. Larger, more rigorously 
designed studies are required to further explore the potential benefits of exercise 
in the management of IBD and its associated complications. 
A consistent finding across studies was mild improvements in HRQoL from exercise, 
as assessed by IBDQ 371,374,376-378,383. The IBDQ has been validated as a reliable and 
responsive measure of HRQoL in IBD 388. The mechanisms that mediate the effects 
of exercise on HRQoL in IBD are unclear but may be linked to improved physical 
function. Some improvement was reported in all sub-dimensions of the IBDQ in 
most studies 374,376,377,383, suggesting a multifactorial benefit. Debate regarding the 
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change in IBDQ required to reflect a clinically meaningful benefit exists, with 
different studies suggesting an improvement of 16 to 27 points 389,390. Most studies 
therefore reported a change in IBDQ that likely reflected a small clinically 
meaningful improvement in HRQoL. The inclusion of only remissive or mildly active 
disease was reflected in baseline IBDQ scores, which were slightly lower than the 
accepted cut-off for remission 391. Whether exercise may elicit a stronger benefit 
to HRQoL in those with active disease or with low baseline HRQoL should be 
investigated in future. 
There were no clear effects for exercise on disease activity or symptoms. 
Exploration of the beneficial effects of exercise on disease activity was 
confounded by the inclusion of only mild or inactive disease, meaning baseline 
disease activity scores were low. The evidence does, however, indicate that 
exercise has no detrimental effect on disease activity in this population as no 
worsening of symptoms or markers of inflammation were observed in any study. 
The acute inflammatory response to exercise was not different between IBD and 
controls 373,385,387. Critically, the upregulated expression of IL-6 induced by 
exercise was not associated with a concurrent increase in TNF-α, suggesting a 
similar inflammatory response to exercise in CD as is observed in healthy 
populations 94. As the only study to date to assess the acute effects of exercise on 
cytokine response, further research using different modes and intensities of 
exercise are required to validate these findings. Also, whether exercise can help 
alleviate systemic inflammation in more active IBD remains unclear.  
Exercise has vast potential for improving the musculoskeletal burden associated 
with IBD, yet few studies directly addressed this. Resistance and impact training 
induced large improvements in muscle function 375, while another much shorter 
quadriceps training programme also elicited 40% increases in strength with no 
concurrent increases in muscle mass 374. These studies highlight the potential 
utility of exercise for overcoming functional deficits in IBD as muscle in quiescent 
IBD is clearly responsive to resistance exercise. The high prevalence of low bone 
mass in IBD, particularly CD, represents a clinical problem that could also 
potentially be alleviated by exercise. Resistance training with or without impact 
exercise improved aBMD in adults with CD in those with high levels of adherence. 
Strategies to promote adherence to exercise interventions are needed to augment 
182 
 
the potential physiological effects of exercise for improving muscle and bone in 
IBD. Exercise including impact-based activities have been shown to promote the 
greatest effects on bone mass and geometry 120,317 but are relatively unexplored 
in IBD, particularly in younger populations. Successfully improving bone and 
muscle mass in young populations is likely to confer long term benefits 121,392. 
There is currently a paucity of exercise research in paediatric IBD, and 
interventions designed to alleviate the substantial musculoskeletal burden in this 
population should be conducted. 
In conclusion, exercise appears to be safe and feasible for people with IBD. Despite 
being limited by small, heterogenous studies, there is evidence of small clinical 
improvements in HRQoL from exercise in adults with mild or inactive IBD. Many 
aspects regarding the potential role for exercise in the management of IBD and its 
secondary complications remain unanswered. The effects of exercise on systemic 
inflammation in IBD and the potential role of exercise for augmenting muscle-
bone development in IBD are two key avenues of research that warrant 
investigation, as these have the potential to improve other aspects of disease. 
 
 
6 Feasibility of jumping based exercise as 
complementary therapy in adolescents and 
adults with Crohn’s disease: a questionnaire 
study 
6.1 Abstract 
Background. Exercise may be a useful and cost-effective adjunctive therapy for 
alleviating the secondary complications of CD, particularly muscle-bone deficits. 
There is currently limited evidence for the utility of exercise in young CD 
population and the acceptability of different exercise methods are unknown. 
Aim. To assess the feasibility and acceptability of introducing high impact exercise 
as a therapeutic option for improving bone and muscle health in adolescents and 
adults with CD. 
Methods. An online questionnaire was designed to survey the attitudes of 
adolescents and adults with CD towards the exploration of jumping based exercise 
as an adjunctive therapy in CD. 
Results. Forty-eight (22 adolescents, 26 adults) CD patients with median (range) 
age 19 years (13, 40) responded. Overall disease control was good, and wellbeing 
was primarily ‘very well’ (51%), or ‘slightly below average’ (40%). Fifty-six percent 
said CD makes exercising difficult, primarily due to fatigue (78%), joint pain (56%) 
and abdominal pain (52%). Perceived benefits of exercise included improved mood 
(77%), improved strength and fitness (56%) and improved energy (31%). Exercise 
was reported to exacerbate fatigue and joint pain in 44% and 31% of respondents, 
respectively. Exercise had no negative effects in 38% of respondents. Sixty-five 
percent of respondents were willing to exercise three or more times per week, 
and 98% believed the opportunity to improve bone health was worth participating, 
three times per week, in high impact exercise. Attitudes towards exercise 
research participation were positive, with 83% stating they would be interested in 
taking part in future exercise studies. 
Conclusions. Adolescents and young adults with CD displayed generally positive 
attitudes towards the exploration of jumping based exercise as a therapeutic 
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option. Most respondents stated a willingness to exercise several times per week 
for potential benefits to health and intentions to participate in future research 
studies, highlighting the acceptability of jumping based exercise. These data were 





The previous chapters have clearly demonstrated bone and muscle deficits among 
children and young adults with CD, even with well controlled disease and 
contemporary disease management. Other studies have shown that, despite 
improving underlying disease, contemporary therapies such as EEN 225 and anti-
TNF-α 49,217 are associated with persistent muscle-bone deficits in paediatric CD 
at 12-months follow up. These data suggest that current therapies may be 
ineffective for resolving musculoskeletal deficits in CD. Muscle-bone deficits in 
young CD patients, if unresolved, predisposes these individuals to increased risk 
of adverse musculoskeletal events in adulthood. Despite this, little attention has 
been given to developing novel strategies to target muscle-bone deficits in CD in 
conjunction with pharmacological disease management. 
Exercise has great potential as a treatment modality for targeting secondary 
complications of CD. However, at present, no evidence-based guidelines regarding 
PA and exercise exist for individuals with CD. The published exercise studies in CD 
are generally small and underpowered, with heterogeneous outcomes (Chapter 5). 
However, a mild positive benefit to HRQoL 374,376,377,383 and improvements in 
musculoskeletal outcomes 375,379,382 have been observed from different 
interventions. Additionally, no safety concerns or exacerbation of disease 
symptoms linked to exercise have been reported in any study to date. Importantly, 
the inflammatory response to even high intensity exercise does not appear to 
differ from healthy controls 387. Despite this, observational data suggests habitual 
PA is low in CD 272 and that exercise participation and subjective feelings of 
physical fitness are reduced compared to pre-diagnosis 271,393. These observations 
are likely mediated by multiple disease specific barriers to exercise participation 
that have been reported by individuals with CD 271,272,309. There is, therefore, a 
need to evaluate easily accessible interventions that can be implemented with 
consideration to disease specific barriers. 
Jumping based exercise offers a potentially cost-effective and accessible 
intervention that provides combined anabolic stimulus to counteract the muscle 
and bone deficits observed in CD. The acceptability of such high impact exercise 
is unknown among those with CD and requires evaluation prior to consideration 
therapeutically. This preliminary study, therefore, employed an electronic 
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questionnaire to evaluate the feasibility and acceptability of exploring high 
impact, jumping based exercise as a potential complementary therapy in 
adolescents and adults with CD. 
6.3 Methods 
6.3.1 Population 
Patients attending routine gastroenterology outpatient clinic appointments across 
three hospitals within NHS Greater Glasgow & Clyde were approached to complete 
an electronic questionnaire. Potential respondents were identified by their 
clinical gastroenterology team and signposted to the researcher (LS) after 
outpatient appointments. Any individual with CD aged from 13 – 40 years was 
eligible to participate in this questionnaire. According to research governance, 
this anonymous questionnaire gathering opinions on the exploration of exercise as 
a potential complementary therapy in CD did not require ethical approval 394. All 
questionnaires were completed voluntarily, and consent was implied by 
questionnaire completion, or by verbal confirmation of a parent/guardian prior to 
completion by adolescents. 
6.3.2 Questionnaire 
This questionnaire was designed to assess the feasibility and acceptability of 
exploring jumping based exercise as a complementary therapy in adolescents and 
adults with CD. Two versions of the questionnaire were developed for use in 
adolescents (aged 13 – 17 years) and adults (18 – 40 years), respectively. These 
questionnaires followed an identical format with only minor wording differences. 
The questionnaires were checked for content validity among adult and paediatric 
gastroenterologists and for readability among laypeople. The questionnaires were 
hosted on the online platform SurveyMonkey. 
The questionnaire collected information regarding participants’ age, disease 
status, and current exercise habits. They were asked if participating in exercise 
positively or negatively affected any of their disease symptoms and about their 
attitude and perceptions towards exercise participation. The perceived difficulty 
of exercise participation and intentions towards participation in future exercise 
research studies were assessed, based on a short video demonstrating a series of 
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jumping based exercises (https://www.youtube.com/watch?v=_uvyOJITB_Q). 
Most questions were multiple choice; two questions employed a visual analogue 
scale (coded from 0 to 100) when asking about recent disease control and 
perceived difficulty of exercise; and general wellbeing was assessed using a five-
point Likert scale (from 0 ‘very well’ to 4 ‘terrible’) as used in the validated and 
routinely applied Crohn’s disease activity index. Participants were also asked to 
provide free-text comments regarding potential barriers during participation in 
jumping based exercise. The questionnaires can be accessed in full in Appendix 3. 
6.3.3 Statistical Analysis 
The primary aim of this survey was to gather data on the feasibility and 
acceptability of jumping based exercise in individuals with CD. Data were 
collected for descriptive purposes and no formal statistical testing was conducted. 
Data are presented as median (range) for continuous variables and frequency 
(percentage) for categorical variables. Data for the adolescent and adult survey 
are presented together unless otherwise stated. 
6.4 Results 
6.4.1 Cohort Characteristics 
Forty-eight of 56 approached individuals completed the questionnaire (86% 
response rate). There were 22 adolescent (68% male) and 26 adult (50% male) 
respondents with an overall median age of 19 years (13, 40) and median age at 
diagnosis of 11 years (2, 34). Current medications were most commonly anti-TNFα 
therapy (69%, 33/48) and immunomodulators (67%, 32/48). One respondent was 
currently on GC therapy. Approximately one third (35%, 17/48) had a history of 
CD related surgery (  
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Table 6-1). Median recent disease control was rated as good (visual analogue 
scale: 79 [8, 100]) (Figure 6-1). General wellbeing was rated as ‘very well in 50% 
(24/48) or ‘slightly below average’ in 40% (19/48). Nearly half of respondents 
stated they were not concerned about their bone health (44%, 21/48), with 46% 





Table 6-1 Cohort characteristics stratified by age group. 
 Adolescents (n = 22) Adults (n = 26) 
Male, n (%) 15 (68) 13 (50) 
Age (years) 15 (13, 17) 24 (18, 40) 
Age at diagnosis (years) 11 (5, 17) 12 (2, 34) 
Disease duration (years) 4 (0, 9) 9.5 (1, 30) 
Medications, n (%)   
Anti-TNFα 16 (73) 17 (65) 
Immunomodulators 18 (82) 14 (54) 
5-ASA 0 (0) 2 (8) 
GC 1 (5) 0 (0) 
Nutritional Supps. 2 (9) 3 (12) 
Other 7 (32) 6 (23) 
Wellbeing, n (%) a   
Very well 13 (59) 11 (44) 
Slightly below average 8 (36) 11 (44) 
Poor 0 (0) 3 (12) 
Very poor 1 (5) 0 (0) 
Terrible 0 (0) 0 (0) 
Previous CD surgery, n(%)   
None 13 (59) 18 (69) 
One 6 (27) 3 (12) 
Two or more 3 (14) 5 (19) 
Cohort characteristics of adolescents and adults with CD. Continuous data are displayed as median 
(range). a n = 47 (22 adolescents, 25 adults). Anti-TNFα – infliximab, adalimumab; 5-ASA – 5-
aminosalicylates; immunomodulators – azathioprine, mercaptopurine, methotrexate; other – proton 
pump inhibitors (n = 7), antispasmodics (n = 2), thalidomide (n = 1), cholecalciferol (n = 1), 










Figure 6-1 Assessment of recent disease control among adolescents and adults with CD. 
Box plot with individual data points illustrating answers to the question ‘How would you rate the 
overall control of your Crohn’s disease over the last 3 months?’. Answers were recorded using a 
visual analogue scale rated 0 (Worst possible) to 100 (Best possible). a n = 25. 
6.4.2 PA & Exercise Habits 
Seventy-five percent (36/48) of respondents reported regularly participating in at 
least one form of exercise and 40% participated in two or more. Team sports were 
most common among adolescents (41%, 9/22), whereas walking (42%, 11/26) and 
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resistance training (39%, 10/26) were most common in adults. Twelve respondents 
(25%, 12/48) stated they did not take part in any exercise at all (Figure 6-2). 
Fifteen percent reported walking as their only form of PA and if this was excluded 








































Figure 6-2 Current exercise habits of adolescents and adults with CD. 
Bar chart displaying percentage responses to the question ‘In a typical week, which of the following 
exercises do you do?’. In the adolescent survey, this question included the phrase ‘excluding during 
school time’ to ensure only leisure time activity was included. Black bars – adolescents; grey bars – 
adults. RT – resistance training; Other - yoga (n = 1). 
6.4.3 Barriers to exercise 
Fifty-six percent of respondents (27/48) stated that having CD made exercise 
participation more difficult (10/22 [46%] adolescents; 17/26 [65%] adults). The 
most common barriers to exercise participation in these individuals were fatigue 


































































Figure 6-3 Barriers to exercise participation among adolescents and adults with CD. 
Bar chart displaying percentage responses to the question ‘In what way does your Crohn’s disease 
make exercising more difficult?’. N = 27 (a n = 10, b = 17). Grey bars – adolescents, black bars – 
adults. 
6.4.4 Effects of exercise on CD symptoms 
Perceived benefits of exercise participation were improved mood (77%, 37/48), 
improved strength and fitness (56%, 27/48) and improved energy/fatigue levels 
(31%, 15/48) (Figure 6-4). Two adolescent respondents stated that exercise had 


































































Figure 6-4 Perceived benefits of exercise in adolescents and adults with CD. 
Bar chart displaying percentage responses to the question ‘When you take part in exercise, does it 
make you feel better in any of the following ways?’. Grey bars – adolescents, black bars – adults. 
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Perceived negative effects of exercise were exacerbation of fatigue (44%, 21/48), 
increased joint pain (31%, 15/48) and feelings of weakness (15%, 7/48). Thirty-
eight percent (18/48) stated that exercise had no negative effects on their health 













































































Figure 6-5 Perceived negative effects of exercise in adolescents and adults with CD. 
Bar chart displaying percentage responses to the question ‘When you take part in exercise, does it 
make you feel worse in any of the following ways?’. Grey bars – adolescents, black bars – adults. 
6.4.5 Acceptability of exercise participation for improving skeletal 
health 
Sixty-five percent (31/48) of participants stated they would be able to exercise 
for 30 minutes on three or more occasions per week (Figure 6-6). After viewing 
the video, 98% (47/48) believed that, for potential improvements in bone health, 
participating in similar types of exercise three times per week would be 
worthwhile. Perceived difficulty of jumping exercise was generally rated as low 
(median VAS: 2.5 [0, 87]) (Figure 6-7). Thirteen participants provided free text 
responses about potential barriers to participation in jumping exercise. These 
responses contained themes regarding concerns of fatigue (n = 5), joint pain (n = 
5), abdominal pain (n = 3), physical inability (n = 2), and inability due to disease 
flares (n = 1). Five free text responses were given to a question asking for general 
comments regarding exercise, all of which contained positive responses (Table 
6-2). Intentions towards participation in future research studies exploring the 
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utility of jumping exercise in CD were generally positive, with 83% saying they 
would take part in such research. Intentions to participate in exercise research 
































Figure 6-6 How often adolescents and adults with CD are willing to exercise per week. 
Bar chart displaying percentage responses of adolescents and adults with CD to the question ‘How 
many times per week do you think you would be able to set aside 30 minutes for exercise?’ Grey 









Figure 6-7 Perceived difficulty of participation in jumping based exercise. 
Boxplot with individual data points illustrating answers to the question ‘How easy do you think it would 
be to participate in exercise like this, three times per week?’. Answers were recorded using a visual 




Table 6-2 Qualitative responses to question regarding general comments about jumping exercise and research. 
Question Responses (n = 5) 
Q20. Do you have any additional comments that you 
would like to make regarding exercise, or the 
research studies we are going to conduct? 
“I am very interested in this research and would like further info on this” 
“Think it would be beneficial” 
“The real struggle I have is sometimes getting the energy to get up and go to the gym to exercise. 
Once I’m over that hurdle, I enjoy being there and feel it helps me both mentally and physically” 
“After long periods of time (weeks with continued exercise) it seems to help” 
“I would be keen to participate” 
Free text responses (n = 5) to the question ‘Do you have any additional comments that you would like to make regarding exercise, or the research studies we are going 




This preliminary study investigated the feasibility and acceptability of jumping 
based exercise in adolescents and adults with CD. The primary results indicate a 
good level of acceptability of jumping based exercise. Attitudes were positive 
towards participation in jumping exercise and future research studies exploring 
its utility as a complementary therapy in CD. Perceived difficulty of exercise 
participation was low, although some potential barriers to jumping exercise were 
also identified.  
Epidemiological data suggests high levels of habitual PA may be protective against 
the onset of developing CD 395. However, whether the implementation of PA or 
exercise in those with established CD may improve disease status remains unclear 
from the limited published data (Chapter 5). Seventy five percent of respondents 
regularly participated in one or more forms of exercise, suggesting this to be an 
active cohort. Team sports (41%) and walking (42%) were most common among 
adolescents and adults, respectively. Nearly all participants reported some 
benefits of exercise participation, with perceived improvements in psychological 
wellbeing (77%), physical strength and fitness (56%), and fatigue (31%) being most 
common. This agrees with prior exercise research in CD that reported improved 
HRQoL from exercise interventions, including walking 377,378, running 376, and 
resistance training 375,383. 
Musculoskeletal deficits remain a commonly reported complication in studies of 
CD, despite contemporary therapies (Chapters 2 & 3). In this survey, around half 
of the respondents stated they were not concerned about their bone health. This 
may be linked to a lack of routine bone monitoring, which is generally reserved 
for those exposed to chronic GC 44. Despite this, most respondents reported a 
willingness to investigate the role of jumping based exercise for improving bone 
health through research. Even among those who reported no current exercise, 80% 
stated a willingness to participate in exercise research. Almost all respondents 
(47/48) also believed participation in jumping based exercise would be worthwhile 
for potential improvements to bone health. Finally, the generally low perceived 
difficulty of jumping exercise among respondents highlights the potential 
feasibility of the intervention, even for those who were currently undertaking no 
exercise at all. This demonstrates good preliminary acceptability of jumping 
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exercise among adolescents and adults with CD, regardless of current activity 
levels. Intentions to participate in hypothetical research may not translate into 
consent for a clinical trial. For this reason, pilot studies of jumping exercise are 
warranted prior to designing larger controlled trials, to test its feasibility in 
practice.  
As mentioned previously, research assessing the effects of high impact exercise 
on musculoskeletal health in CD is currently lacking. One study of combined 
resistance and impact exercise in middle-aged CD reported improvements in bone 
and muscle parameters compared to non-exercising controls 375. Jumping exercise 
provides high mechanical strains that may induce skeletal adaptation more 
effectively than previous low-impact interventions in CD 320,379. Jumping protocols 
have been observed to improve bone health in several paediatric populations 317. 
Additionally, plyometric exercise has been reported to induce comparable lower 
limb muscle hypertrophy to resistance training in previously untrained adults 162. 
These data suggest jumping exercise to be an effective strategy for improving 
bone and muscle that warrants investigation in young CD populations. 
Individuals with CD experience multiple barriers to exercise participation. 
Interventions that can be easily implemented at home should therefore be given 
increased consideration. Over half of the current cohort stated that their CD 
diagnosis makes exercising more difficult. These figures are comparable with a 
previous survey of children with IBD (45%) 393 but lower than previously reported 
in adults with CD (81%) 272. Primary barriers to exercise among these participants 
were fatigue and abdominal or joint pain, again like other reports 272,309,393. 
Fatigue is among the most common clinical problems in CD 308 and has been 
previously associated with reduced PA 274. Only one study, however, has assessed 
the effects of exercise in CD patients with fatigue at baseline, reporting marked 
improvements 383. In addition to fatigue, fear of incontinence and subsequent 
social avoidance are highly prevalent among those with IBD 396. This concern 
adversely affects QoL 396 and has also been cited as a barrier to exercise 
participation 272. Implementing accessible, home-based exercise, such as a simple 
jumping protocol, may provide a suitable intervention for those who are unable 
or do not wish to seek out specialist exercise facilities due to these concerns. 
197 
 
Importantly, some potential barriers to participation in jumping exercise were 
identified in the current study. Exercise was reported to negatively influence 
fatigue and joint pain in some participants These were highlighted as potential 
concerns in free text responses. As mentioned, chronic exercise training may be 
an effective strategy for improving fatigue in chronic disease, including CD 383. 
Joint pain, which is a common complaint in people with CD 397, is adversely 
affected by physical inactivity in inflammatory disease and can potentially be 
alleviated by regular exercise 398. Even carefully implemented high-impact 
exercise has been reported as safe in cohorts with established joint degeneration, 
without any exacerbation of pain 399. In the only study including assessment of 
impact exercise in CD, there were no adverse events reported relating to 
increased joint pain 375. While these barriers to exercise cannot be discounted, 
strategies to educate individuals with CD on the potential alleviation of fatigue 
and joint pain via exercise may address their concerns. Nonetheless, careful 
consideration and detailed reporting of these should be a feature of any future 
exercise trials. 
The results of this study are limited to respondents from a single geographical 
area and may not be representative of the wider CD population. The aim of the 
study, however, was to assess the acceptability of exploring jumping exercise as 
a potential complementary therapy for CD patients in this region. For this purpose, 
the survey has provided important positive feedback. Three quarters of 
participants currently undertook at least one form of exercise per week and the 
results could be confounded by non-response bias, whereby those interested in 
exercise were more likely to participate and thus provide a more positive outlook 
than may be expected from the whole CD population. Most participants also 
reported good recent disease control and jumping exercise could be viewed less 
favourably by those with ongoing active disease.  
In conclusion, adolescents and adults with CD displayed positive attitudes towards 
the exploration of jumping based exercise as a complementary therapy for 
potentially improving bone health in CD. The results of this questionnaire suggest 
that jumping based exercise is an acceptable intervention for people with CD and 




7 Feasibility of jumping based exercise in children 
and adolescents with Crohn’s disease 
7.1 Abstract 
Background. Jumping based exercise is an accessible intervention that may 
reduce the musculoskeletal burden associated with paediatric CD. Prior studies 
have not investigated jumping exercise in paediatric CD, although survey results 
suggest this to be an acceptable mode of exercise in young people with CD. 
Aim. Assess the feasibility and safety of a short-term, jumping based exercise 
intervention in children with CD. 
Methods. A pilot study of four-weeks, primarily home-based, jumping exercise. 
The intervention consisted of three sessions per week, with approximately 50 – 
100 loading cycles per session. Primary outcome was feasibility and acceptability, 
measured through recruitment rate and adherence to protocol. Secondary 
outcomes were HRQoL, fatigue, and muscle function assessed by mechanography. 
Results. Six children with CD and median age 13.1 (10.2, 14.9) years participated 
in this study. Median baseline wPCDAI was 8.75 (0, 15) and 5/6 were in clinical 
remission. Median adherence to the exercise intervention was 95.8% (66.7, 100), 
equating to 11/12 sessions. Recruitment rate was lower than expected at 20.7%. 
No clear effect was observed for exercise on HRQoL, fatigue, or muscle function. 
A total of 23 AEs were reported, although these were all minor in nature. 
Conclusions. Adherence to short-term exercise appears feasible in quiescent 
paediatric CD. Acceptability may be lower than expected as a recruitment rate of 
only 20% was observed. Expansion of the study will provide further insight into the 





Musculoskeletal deficits remain a prominent issue in paediatric and adult CD 
despite modern therapies, yet few interventions have addressed this issue. A 
twelve-month intervention of daily vibration therapy was ineffective for improving 
bone mass compared to sham therapy in paediatric CD patients with low 
trabecular vBMD at baseline 320. This level of mechanical stimuli may have been 
insufficient to upregulate accelerated bone formation in an ambulatory cohort, 
and greater mechanical loads may be necessary, potentially through targeted 
exercise interventions. In middle-aged adults with CD, low impact core 
strengthening 379 and resistance plus impact exercise 375 were associated with 
small improvements in aBMD 375,379 and large gains in muscle function of up to 50% 
375. These data highlight how exercise may successfully improve muscle-bone 
outcomes in adults with CD, but no studies have been conducted assessing its 
utility for augmenting muscle-bone in paediatric cohorts. 
Despite the known beneficial effects of PA and exercise in muscle-bone 
development, no studies have assessed the utility of exercise for improving 
musculoskeletal outcomes in paediatric CD. One observational study reported a 
positive association between accelerometer measured MVPA and BMD in paediatric 
IBD 273, while self-reported PA was positively associated with trabecular bone 
volume and muscle CSA in the prior MRI study of paediatric CD reported in Chapter 
2. The current paucity of exercise research in paediatric CD means the feasibility 
and utility of different modes of exercise are currently unknown. Jumping exercise 
has been demonstrated as an accessible and effective strategy for improving bone 
mass in other paediatric populations 117-119,317,392 and has been reported to be as 
effective as resistance at inducing muscle hypertrophy in untrained individuals 162. 
Feedback from patient survey in Chapter 6 suggests this to be an acceptable 
method of exercise among young people with CD, with >80% of respondents stating 
they would be interested in participating in jumping based exercise research. 
This study therefore aimed to assess the feasibility and safety of participation in 
jumping based exercise as a potential method for improving musculoskeletal 




7.3.1 Study population 
This was a pilot feasibility study of jumping based exercise in children and 
adolescents with IBD. For this work, only children with CD were targeted for 
recruitment in line with the other studies of this thesis. Recruitment activity 
commenced in October 2019 and participants recruited up to October 2020 were 
included in this write up. Eligible CD participants were identified and approached 
by a member of their clinical IBD team and asked if they were happy to be 
contacted by the research team. Eligibility criteria for this study were a confirmed 
diagnosis of IBD at least 6 months prior to intervention, age 10 to 17 years 
(inclusive), stable medication >4 weeks prior to recruitment, ability to mobilise 
and perform the exercises independently, and mild, inactive, or moderately active 
disease at time of recruitment (according to HBI). Exclusion criteria were recent 
(<12 weeks) or planned surgery, contraindication to jumping exercise, any 
significant comorbidity, medications known to affect bone turnover (excluding 
GC), BMI > +3.5 SDS or a bodyweight >120kg, and pregnancy. All participants 
provided written informed consent or assent based on competency, and a parent 
or legal guardian of all participants also provided written informed consent. The 
study was approved by the South East Scotland Research Ethics Committee 01 (REC 
Ref: 19/SS/0084). Participants were provided with £40 of gift vouchers to 
compensate for their time and effort during the study. They were advised that 
gift vouchers were not linked to their adherence to the protocol to explicitly 
remove this as incentive for improved participation. 
7.3.2 Study design & intervention 
This was a single-arm pilot study. Children and adolescents with CD were recruited 
and were enrolled into a four-week, home-based intervention of jumping exercise. 
This four-week intervention consisted of exercises designed to dynamically load 
the muscle-bone unit, as high mechanical loading and plyometric movements are 
known to promote improvements in bone mass and muscle function. All 
participants were enrolled on the same four-week exercise intervention of three 
jumping based sessions per week (12 total sessions) (Appendix 4). The intervention 
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required no equipment other than an adjustable step, which was provided at the 
baseline assessment. Exercise intensity was progressed over the intervention 
period to increase mechanical loading and introduce plyometric movements. Basic 
movements such as vertical jumps, jumping jacks, and drop landings were 
progressed to movements including one-legged hopping, drop jumps, and 
plyometric jumps. Each session included between 50 – 110 loading cycles and took 
approximately 15 to 20 minutes to complete. Participants were instructed to 
complete a five-minute warm up prior to each exercise session. Participants were 
asked to attend the first exercise session of each week in-person at the clinical 
research facility, QEUH. These sessions were used to introduce the new exercises 
for the respective week and ensure participants were able to perform these safely 
and with the correct technique. Any concerns or required modifications to the 
protocol could also be discussed at these sessions. The remaining two exercise 
sessions were to be completed at home and participants were asked to leave at 
least 24 hours between sessions. Baseline and follow up visits were arranged 
within 14 days of the start and end of the intervention, respectively.  
7.3.3 Data collection 
7.3.3.1 Baseline characteristics 
Disease specific data including age at diagnosis, current medications, history of GI 
surgery, and history of GC exposure were self-reported. Participants’ height was 
measured to the nearest 1mm using a wall mounted stadiometer, weight was 
measured to the nearest 0.1kg, and BMI (kg/m2) was calculated. Height, weight, 
and BMI were converted into age- and sex-specific Z-scores 400. Anthropometrics 
were measured again at follow up. Pubertal status was self-reported according to 
Tanner. Fracture history and menarche (females) were also self-reported. 
Participants were provided a wrist worn accelerometer (ActiGraph wGT3X-BT, 
ActiGraph Corp, FL, USA) to wear for seven days after their baseline assessment 
to measure habitual PA. Accelerometers were worn on the non-dominant wrist 
and sampled at a frequency of 30Hz. Previously published activity cut-offs for 
children were used to define time spent in light, moderate, and vigorous PA 401. 
PA outcomes of interest were how much time was spent in each domain of PA and 
sedentary behaviour, and whether the participants were meeting the current 
guidelines of 60 mins of MVPA per day. 
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7.3.3.2 Primary outcomes 
This was a pilot feasibility study and the primary outcomes assessed were rate of 
recruitment and adherence to the protocol. Recruitment rate was reported as a 
percentage of the total individuals approached who consented to take part in the 
study. Adherence to the protocol was self-reported by the participants. Each 
participant was provided an exercise diary to be completed after each session. 
This diary contained specific guidance on how to complete the prescribed 
exercises, in case participants were unable to attend any of the in-person study 
visits. The specific sets and repetitions prescribed for each session were also 
listed. Participants recorded the number of sets and repetitions they completed 
of each of the prescribed exercises during the session. If the session was missed 
for any reason, they were requested to provide a reason for this. Exercise safety 
was also recorded with participants asked to record if they experienced any pain 
either during or after exercise, and any trips or falls during the exercise. 
Participants were also asked to self-report any exacerbations of disease 
symptoms. 
7.3.3.3 Secondary outcomes 
7.3.3.3.1 Disease activity, HRQoL, and fatigue 
To assess any potential effects of short-term jumping-based exercise several 
secondary outcomes were measured at baseline and follow up. Disease activity 
was assessed using the wPCDAI (CD). HRQoL was assessed using the paediatric IBD 
specific IMPACT III questionnaire 402. IMPACT III is a 35-item, self-administered 
questionnaire regarding aspects of HRQoL including general wellbeing, emotional 
and social functioning, and disease symptoms over the previous two-week period. 
Questions are answered on a five-point Likert scale with total scores ranging from 
35 (poor) to 175 (best). A cut off value of 143 points has been suggested for 
remission, and an improvement of 11 points reflects a clinically meaningful 
change 402.  
Generic HRQoL was assessed using the PedsQL Generic Core Scale v4.0 403 and 
fatigue was assessed using the PedsQL Multidimensional Fatigue scale 404. These 
tools assess child and parent perspectives via self-administered and parent proxy 
questionnaires. The acute versions of these tools were used, which assess HRQoL 
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and fatigue over the previous seven-day period. Results are transformed onto a 
linear scale of 0 (worst) to 100 (best). Both tools have been previously validated 
in healthy children and paediatric IBD and found to negatively associate with 
disease activity 405,406. 
7.3.3.3.2 Muscle function assessment 
Assessment of the muscle unit was conducted using jumping mechanography at 
baseline and follow up, as described in Chapter 2. Briefly, the S2LJ and M1LH tests 
were used, providing data for dynamic muscle function (power [kW], power 
relative to bodyweight [W/kg]) and maximum applicable force to the muscle-bone 
unit (force [kN] and force as a multiple of bodyweight), respectively. Results were 
converted into and weight-adjusted, sex-specific Z-scores using previously 
published data 202.  
7.3.3.3.3 Biochemical analyses 
At baseline and follow up, non-fasted blood samples were drawn to evaluate 
potential effects of exercise on biomarkers of bone, muscle, and inflammation. 
Serum levels of 25-OHD, PTH, ESR, CRP were measured at the local NHS accredited 
clinical laboratory, following standard procedures.  
7.3.3.4 Statistical Analyses 
The primary outcomes of this feasibility study were descriptive statistics regarding 
recruitment rate and protocol adherence, which are reported as such. Due to the 
very small sample size and lack of follow up data available for two participants, 
no formal statistical testing was performed. All data are presented descriptively, 
and secondary outcome data reported at the individual participant level.  
7.3.4 Impact of COVID-19 on this study 
All non-essential clinical research activity in NHS GGC was suspended in March 
2020 for a period of approximately six months because of the COVID-19 pandemic. 
This had a profound negative impact on recruitment and data collection for this 
study. Prior to the suspension of recruitment, three individuals who expressed an 
interest in participating in the study were in contact with the research team (LS). 
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These individuals were re-contacted when recruitment activity resumed but were 
no longer interested in participating. When study activity was suspended, two 
participants were currently on study. At this point, one participant was entering 
the final week of the intervention and the other was approximately halfway 
through the intervention. These two participants were unable to attend a follow 
up visit and therefore did not have follow up data available for secondary 
outcomes. They did, however, have data available for the primary outcome via 
self-completed exercise diaries. These diaries were collected in October 2020, 
after study activity was approved to resume. Recruitment activity resumed in late 
September 2020 and three further participants were recruited. Recruitment 
activity post-lockdown was impacted by much reduced clinical activity at RHC, 
including no regular IBD outpatient clinic, which moved to online. Those who were 
recruited post-lockdown attended only baseline and follow up visits and 
completed the four-week intervention at home, with weekly telephone or email 
contact. As the original ethical approval allowed for participants to complete the 
four-week intervention exclusively at home, this did not require an amendment 
to the protocol.  
7.4 Results 
7.4.1 Recruitment 
Recruitment for this study occurred across approximately seven months within the 
period of October 2019 – October 2020. A targeted recruitment approach was 
taken involving pre-screening of potential participants with the paediatric IBD 
research nurse. A total of 41 children with CD were referred for potential inclusion 
in this study, of which 29 were approached to participate. Potential recruits were 
sent study information by post and followed up at outpatient clinic appointments 
where possible or contacted directly by the research nurse. Of the 29 children and 
adolescents who were approached, 17 refused and 12 expressed an initial interest 
in participating in the study. Reasons cited for refusal included general non-
interest in research (n = 4), no interest in the proposed exercise (n = 2), concerns 
exercise exacerbates fatigue (n = 1), a recent injury (n = 1), and being too busy 
with school (n = 3). The other six refusals did not provide a specific reason. From 
the 12 interested in participating, a further six dropped out after initial interest 
due to concerns regarding the ongoing COVID-19 situation (n = 3), fatigue (n = 1), 
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a current disease flare (n = 1), and failure to reply (n = 1). Finally, six participants 
were recruited to the study, resulting in a successful recruitment rate of 20.7% of 
the patients approached.  
7.4.2 Baseline cohort characteristics 
Six children (4 male, 2 female) with CD consented to participate in this study. 
Median age at baseline was 13.1 (10.2, 14.9) years and median age at diagnosis 
was 8 (7, 11) years. Median wPCDAI score was 8.75 (0, 15) and 5/6 were in clinical 
remission, with one having mildly active disease. All six participants were 
currently treated with anti-TNF-α biologic therapy (5 infliximab, 1 adalimumab) 
and concurrent immunosuppression (4 azathioprine, 1 methotrexate, 1 6-
mercaptopurine). Only one participant had a history of GI surgery and two had 
previously been treated with GC. Median self-reported Tanner stage of puberty 
was 2.5 (1, 5) and both girls had achieved menarche. None of the participants 
reported a history of fracture. Median self-efficacy for exercise at baseline was 
68.5 (52, 80). All participants were meeting current PA guidelines with a median 
of 126 (73, 81) minutes of MVPA on average per day. Percentage of time spent in 
sedentary behaviour was 51.2% (47.3, 54.2), in light PA was 38.4% (35.1, 41.8), 
and in moderate PA was 11.5% (5.5, 14.5). Participation in vigorous PA was zero 
percent for all participants. 
7.4.3 Exercise adherence 
No participants formally withdrew from the study, although two did were unable 
to attend a follow up visit due to COVID-19 lockdowns. All six participants 
completed and returned the self-reported exercise diaries. Median self-reported 
adherence to the exercise intervention was 95.8% (66.7, 100), which equated to a 
median 11/12 sessions completed. Overall, 65 out of 72 total sessions were 
completed. In 64/65 completed sessions, participants self-reported completing 
100% of the prescribed sets and repetitions of jumping-based exercises. Reasons 
provided for not completing exercise sessions included forgetting (n = 4), not 
feeling ‘up for it’ (n = 1), abdominal pain (n = 1), and a non-related injury (n = 1). 
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7.4.4 Exercise safety 
There were no self-reported exacerbations of disease symptoms during the 
intervention period and clinical activity scores remained low at follow up in the 
four participants with available data (median wPCDAI 3.75 [0, 12.5]). A total of 
23 AEs were reported during the intervention. Median self-reported AEs per 
participant was 2.5 (1, 10). Twenty-two of 23 AEs were related to the exercise 
intervention (sore knee from unrelated fall [n = 1]). All reported AEs were minor, 
and no SAEs were reported. Exercise related AEs were pain in the forefoot during 
hopping or plyometric type exercises (n = 10), non-specific knee pain (n = 4), ankle 
pain during hopping or plyometric exercises (n = 3), trip or fall during exercise (n 
= 2), back pain (n = 1), stitch (n = 1), knee ‘gave way’ the day after exercise (n = 
1). One participant, who completed the intervention exclusively at home, 
reported 9/10 AEs relating to sore feet during hopping or plyometric exercises. 
This was not raised as a concern during weekly contact by the participant or their 
parent, so no adjustments to the protocol were made. None of the reported AEs 
were cited as a reason for subsequent non-participation in exercise. 
7.4.5 HRQoL and fatigue 
Individual participant data for HRQoL and fatigue are presented in Figure 7-1. 
Median IMPACT III score was 155 (136, 166) and 159 (140, 164) at baseline and 
follow up, respectively (Figure 7-1 A). Median change of IMPACT III score was -1.5 
(-4, 9) (n = 4). Self-reported HRQoL scores were 77.2 (66.4, 96.7) and 83.9 (80, 
94.2) at baseline and follow up, respectively (Figure 7-1 B). Parent proxy HRQoL 
scores were 80.2 (67.2, 94.2) and 74.3 (65.3, 97.5) at baseline and follow up, 
respectively (Figure 7-1 C). Median changes in the self-reported and parent proxy 
HRQoL scores were 3.7 (-4.8, 13.6) and -0.7 (-5.8, 4.1), respectively (n = 4). 
Median self-reported fatigue scores were 68.8 (59.7, 83.3) and 66.0 (45.8, 94.4) 
at baseline and follow up, respectively (Figure 7-1 D). Median parent proxy fatigue 
scores were 59.7 (51.4, 95.8) and 51.4 (38.9, 98.6) at baseline and follow up, 




Figure 7-1 HRQoL and fatigue in paediatric CD. 
Individual data for HRQoL and fatigue before and after four weeks of jumping based exercise. Each 
participant is represented by an individual colour. Participant 1 – black, 2 – purple, 3 – orange, 4 – 
red, 5 – blue, 6 – green. No follow up data were available for participants 2 & 3. Data presented are 
for disease specific HRQoL (IMPACT III) (A); self-reported and parent proxy generic HRQoL 
(PedsQL generic core scale) (B & C); self-reported and parent proxy generic fatigue (PedsQL 
Multidimensional fatigue scale) (D & E). For all assessment tools, higher scores are better. 
7.4.6 Muscle-bone unit 
Weight-adjusted Z-scores for dynamic muscle power and maximum force 
applicable are presented in Figure 7-2. Median weight-adjusted Z-scores for 
absolute muscle power were -0.4 (-1.73, 0.5) and -0.57 (-1.47, 0.68) at baseline 
and follow up, respectively (Figure 7-2 A). Weight-adjusted Z-scores for relative 
muscle power were -0.31 (-1.68, -0.1) and -0.36 (-1.56, -0.01) at baseline and 




























































































absolute force were -1.87 (-2.86, 0.39) and -0.77 (-2.62, 0.33) at baseline and 
follow up, respectively. (Figure 7-2 C). Median weight-adjusted Z-scores for force 
relative to bodyweight during hopping were -2.15 (-2.51, -0.42) and -1.06 (-2.03, 
-0.45) at baseline and follow up, respectively (Figure 7-2 D).  
 
Figure 7-2 Weight-adjusted Z-scores for jumping mechanography in paediatric CD. 
Individual data for weight-adjusted, sex-specific Z-scores for jumping mechanography before and 
after four weeks of jumping based exercise. Participant 1 – black, 2 – purple, 3 – orange, 4 – red, 5 
– blue, 6 – green. No follow up data were available for participants 2 & 3. Data presented are for 
absolute (A) and relative (B) muscle power during countermovement jumping, and absolute (C) and 














































































This study provides preliminary data on the feasibility and safety of jumping based 
exercise in children and adolescents with CD. Despite the very small sample size, 
high adherence to the intervention suggests that jumping based exercise is a 
feasible mode of exercise, at least in children with well controlled CD. 
Recruitment activity was disrupted by the COVID-19 pandemic and it is unclear 
how much this contributed to the low recruitment rate of 20%. Jumping based 
exercise was safe, as no exacerbations of disease symptoms were reported, 
although several minor AEs were reported; suggesting greater supervision or a 
slower progression of exercise intensity may be required.  
Exercise may be an effective strategy for improving bone and muscle mass in 
children with CD. Particularly, jumping based exercise interventions have been 
shown to increase bone mass and strength in various paediatric populations 117-
119,317. Despite this, the feasibility of impact exercise in paediatric CD had not 
been explored to date. In this study, six children with CD completed a jumping 
based exercise intervention with high levels of adherence. Median adherence was 
>95% and only one participant reported an adherence below 80%. This participant 
was on study at the time of COVID-19 national lockdown, which may have 
contributed to their non-adherence, as they had completed 5/6 of sessions until 
that point but only completed three of the remaining six. Adherence to short term 
exercise therefore appears feasible, albeit in a very small sample. This agrees 
with the data from Chapter 6 stating that most children with CD would find 
jumping based exercise easy to participate in. However, whether short-term 
adherence translates into long-term participation in jumping based exercise 
requires future investigation. One study reported good adherence in the first four 
weeks (median 72.5%) of a six-month exercise intervention aimed at improving 
muscle-bone outcomes, including jumping exercise, in juvenile arthritis 407. 
Adherence rapidly dropped off after this period and six-month median adherence 
was only 47%. At follow up, no improvements in DXA, HR-pQCT or mechanography 
assessed Z-scores for muscle-bone outcomes were reported 407.  
Jumping exercise was not associated with any worsening of subjective disease 
symptoms or disease activity scores, suggesting it to be safe for children with mild 
CD. This concurs with all previous exercise research in CD, in which no exercise 
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related exacerbations of disease have been reported (Chapter 5), although 
primarily in adults. Despite this, several minor AEs were reported that were 
specific to the type of exercise being employed. Particularly, several AEs occurred 
during plyometric type movements, such as pain of the forefeet and joints. 
However, although several AEs were reported, these did not negatively impact 
exercise adherence. Additionally, none of the participants reported AEs during 
weekly contact and no adjustments to the protocol were required, suggesting 
these were likely transient and mild in nature. Nevertheless, a slower progression 
to plyometric movements and increased supervision and teaching of exercise 
techniques may be warranted. 
This cohort, despite meeting the criteria of no more than two hours of leisure time 
weight bearing exercise per week, contained participants who did routinely 
exercise. According to baseline accelerometer data, all participants were meeting 
the guidelines of >60 minutes of MVPA per day. This suggests potential selection 
bias within the cohort of children who have interests in exercise being more likely 
to take part. Two participants indicated they did not participate in any leisure 
time activity which was reflected in their lower habitual MVPA compared to the 
others. Despite this, these participants still met the recommended guidelines of 
>60 minutes of MVPA on average per day. The recruitment of children not 
currently meeting PA guidelines would provide more information on whether 
jumping exercise is feasible in an inactive paediatric CD cohort, although being 
able to successfully screen inactive children based on self-reported PA is difficult. 
Exercise has been shown to have a moderate positive influence on HRQoL in adults 
with CD 376-378,383, but no effects were observed in two paediatric studies to date 
384,386. The influence of exercise on HRQoL in CD may be mediated by its effects 
on fatigue, physical function, or body composition. Here, descriptive data suggests 
short-term jumping exercise did not have any effect on disease specific HRQoL 
scores. Self-report of disease specific and generic HRQoL scores were generally 
high at baseline and remained so at follow up, suggesting a potential ceiling 
effect. Discrepant results were found between participants for fatigue, although 
these data are hindered by the very small sample size. 
Baseline jumping mechanography produced weight-adjusted Z-scores that were 
generally below reference values, particularly for muscle assessment during one 
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legged hopping, suggesting abnormal function of the muscle-bone unit. At follow 
up, improvements in Z-scores for absolute and relative force were observed in two 
participants, which could be linked to neuromuscular adaptations associated with 
short-term jump training 408,409. A descriptive upward trend in all mechanography 
Z-scores was observed for 3/4 participants although the relevance of these 
changes is unclear. One participant had lower muscle power Z-scores at follow up 
compared to baseline, despite reporting full adherence to exercise. This may have 
been linked to underlying iron deficiency that was subsequently identified shortly 
after study cessation and treated clinically. While this study was not powered to 
detect changes in mechanography outcomes, these initial data suggest short-term 
improvements are possible. Jumping mechanography may, therefore, be a 
sensitive marker for evaluating adaptations in muscle function after short-term 
exercise even in children who currently meet PA guidelines.  
This study was primarily limited by its very small sample size. The 20% recruitment 
rate is in stark contrast to the data collected in Chapter 6, which suggested >80% 
of CD patients would be interested in participating in jumping based exercise. 
Even among the survey respondents who did not currently participate in any 
exercise, 80% expressed an interest in research participation. This perhaps 
suggests that assessing feasibility of exercise interventions in this group of 
patients via a survey may provide quite inaccurate information on possible 
recruitment rate. However, the negative influence of COVID-19 on study 
recruitment cannot be disregarded and COVID-19 concerns were understandably 
cited by several potential recruits as a reason for non-participation. The study 
would have benefited from subjective feedback regarding the acceptability of 
jumping based exercise to guide the development of a more definitive trial in this 
population of patients. Despite these limitations, some useful preliminary data 
has been generated and the expansion of the study in future will provide a deeper 
understanding of the feasibility of jumping exercise in paediatric CD. 
In conclusion, this study provides preliminary data on the feasibility of jumping 
based exercise in children with well controlled CD. Adherence to short-term 
exercise appears feasible in this population. However, the acceptability of 
exercise participation may be lower than previously stated as reflected by a low 
recruitment rate. Improving the sample size will provide further data regarding 
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exercise feasibility and the potential influence on markers of the muscle-bone 




8 General discussion and future directions 
8.1 General discussion 
Crohn’s disease is associated with multifactorial insult to the muscle-bone unit. 
Paediatric CD is associated with reduced bone and muscle mass and strength that, 
if unresolved, may predispose to increased risk of adverse musculoskeletal 
outcomes as adults. Despite this, few studies have performed a comprehensive 
evaluation of the muscle-bone unit in children and adults with CD using high-
resolution imaging. As such, there is a dearth of information regarding skeletal 
microstructure in young populations of CD, particularly in contemporary cohorts. 
Such detailed evaluations of bone and muscle health in young CD cohorts may 
identify specific deficits that can be targeted in future interventions. 
Exercise is an effective strategy for improving bone and muscle health across the 
lifespan, yet its utility in CD has not been well established. This thesis aimed to 
characterise the muscle-bone unit in children and young adults with childhood 
onset CD. Furthermore, the associations between IBD and adverse musculoskeletal 
outcomes in middle aged and older adults were investigated in a large population-
based cohort study. Finally, the potential role for jumping based exercise in CD 
was explored via an online survey and short-term feasibility intervention of 
8.1.1 The muscle-bone unit in children & adults with CD 
(Chapters 2, 3, & 4) 
The first half of this thesis was dedicated to investigating the muscle-bone unit 
and adverse musculoskeletal outcomes in paediatric (Chapter 2), young adults 
(Chapter 3), and middle-aged and older adults with CD (Chapter 4). In each of 
these studies, CD was associated with musculoskeletal deficits, although with 
some discrepancy. High-resolution MRI revealed deficits in trabecular 
microarchitecture in paediatric CD but not young adults with paediatric onset CD, 
when compared to respective healthy age and sex matched control cohorts. 
Estimated BMD of the calcaneus, a trabecular rich region, was also low in the older 
CD cohort compared to controls, indicative of trabecular bone deficits. Discordant 
trabecular results between paediatric and young adult cohorts opens questions 
regarding the natural history of trabecular development in paediatric CD. Early 
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trabecular loss, or impaired development, in paediatric CD may be alleviated by 
effective long-term disease control with contemporary therapies, which have 
been found to improve biochemical markers of bone and muscle development 
49,217,339. Short term prospective studies (12 - 24 months follow up) have reported 
only modest improvements in muscle-bone deficits 49,217,225; however, longer term 
contemporary disease management may facilitate continued normalisation of 
previously incurred skeletal deficits into young adulthood. Disease severity and 
prior GC exposure were both negatively associated with trabecular bone volume 
in these studies, while a proxy of disease severity (i.e. current immunosuppressant 
use) also negatively associated with eBMD in the older cohort. These factors are 
therefore again highlighted as primary precipitators of poor bone health in CD 
across different age groups, even in those with generally mild disease at time of 
study. The implications of skeletal deficits were highlighted in the middle-aged 
CD cohort as low eBMD was associated with likelihood of any fracture in this group. 
Disparity in trabecular bone between paediatric and young adult cohorts could 
also be moderated by the influence of PA and mechanical loading on recovering 
disease or GC mediated bone loss. The importance of PA for trabecular bone 
development has been demonstrated in children with impaired mobility, who 
display marked trabecular deficits 115. In paediatric CD, PA was positively 
associated with trabecular bone volume. Those with combined low PA and 
trabecular bone volume also tended to have a history of severe disease. This may 
have reduced tolerance or motivation for PA, subsequently inhibiting the 
trabecular bone development. In young adults, no association between PA and 
trabecular bone was discovered, but all PA scores reported were indicative of 
being physically active. Of course, the two studies presented here are 
independent, cross-sectional CD cohorts, and longitudinal assessment of 
trabecular bone in a large cohort of paediatric CD into young adulthood would be 
required to test these hypotheses. 
Deficits in skeletal muscle were consistent across all the CD cohorts. Paediatric 
and young adults with CD had low muscle function compared to controls and 
reference data, respectively. Muscle mass was also low in the young adult cohort 
but not in the paediatric cohort, likely due to the large heterogeneity of muscle 
mass in children matched by age only. Jumping mechanography identified muscle 
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function deficits in paediatric CD that were not evident using grip strength 
dynamometry. Therefore, mechanography may be a more sensitive and useful tool 
for muscle function assessment in younger populations. The ability to dynamically 
assess several components of the muscle-bone unit using typical paediatric 
movement patterns makes mechanography easy to implement and preferable over 
the limited data available via isometric grip dynamometry. In both cohorts, after 
size adjustment, muscle function remained low. This suggests some intrinsic cause 
of reduced muscle function in CD that requires future investigation. Accurately 
defining muscle function deficits and their associated mechanisms in young CD 
cohorts may facilitate the development of targeted interventions, ultimately 
reducing risk of future adverse musculoskeletal events. Such events, including 
muscle weakness indicative of sarcopenia and falls, were significantly more likely 
in middle aged and older adults with CD compared to non-IBD peers. These issues 
were present despite representing a mild disease cohort, again highlighting the 
musculoskeletal burden of CD even in those with mild disease. The increased risk 
of adverse musculoskeletal outcomes in the older CD cohort has extended 
implications for younger CD populations. Childhood onset CD is generally accepted 
as a more severe disease phenotype than adult-onset disease. Childhood onset CD 
may therefore be associated with higher risk of poor long term musculoskeletal 
outcomes compared to adult-onset disease, as has been demonstrated for risk of 
fractures 324. Together, these data emphasise the importance of addressing 
muscle-bone deficits early in the disease course in young people with CD. 
The studies highlight the sensitivity of high-resolution MRI for identifying 
trabecular differences between cases and controls. Conversely, cortical geometry 
results were somewhat surprising. No deficits in cortical geometry between CD 
and control groups were observed, which is feasible considering no evidence of 
growth disturbance in either CD cohort. However, previous data consistently 
indicate cortical deficits in paediatric 49,217,276,277 and adult CD 282,283 using pQCT 
or HR-pQCT. This discrepancy could indicate the limitations of MRI for cortical 
assessment in CD.  The hypointense signal of cortical bone and surrounding 
connective tissue, and corticalisation of peripheral trabeculae at the endocortical 
boundary of the metaphysis, make clear definition of the periosteal and endosteal 
circumferences difficult. Resultantly, subtle differences in cortical geometry may 
not have been identified, making these analyses less useful in mild disease 
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cohorts. The calculation of cortical thickness was also based on assumption of 
concentric cortical bone, which did not represent the asymmetrical geometry 
observed in most participants. Similarly, lumbar spine BMA was heterogeneous 
among paediatric and young adult CD and does not appear to be a useful outcome 
in these groups, although its association with patients with greater degree of 
inflammation deserves future investigation. 
8.1.2 The potential role for exercise in improving muscle-bone in 
CD (Chapters 5, 6, & 7) 
The second half of this thesis investigated the evidence and potential utility for 
exercise as an intervention to improve bone and muscle in children and adults 
with CD. Systematic review revealed sparse evidence for exercise in IBD, with only 
one prior study designed to address this issue (Chapter 5). In paediatric IBD, the 
evidence base for utility of exercise was almost non-existent, despite its potential 
to improve muscle-bone development. Themes among the limited evidence base 
included a mild positive effect of exercise on HRQoL and improvements in markers 
of physical function. Importantly, few adverse events and no exacerbations of 
disease related to exercise had been reported, although generally the reporting 
of these was poor. One method of exercise not studied in children or adults with 
CD was jumping based exercise, which may be an effective and accessible 
intervention for improving muscle mass and function and bone health. 
The feasibility of jumping based exercise was surveyed in local adolescents and 
adults with CD, with positive feedback (Chapter 6). Attitudes towards exercise 
were positive and almost all respondents agreed that participation in jumping 
exercise would be worthwhile for potential musculoskeletal improvements. In 
survey, intentions to participate in jumping based exercise research were high, 
with >80% saying they would participate. However, in practice, the recruitment 
rate in paediatric CD patients for a short-term jumping-based exercise 
intervention was much lower at 20% (Chapter 7). This suggests a selection bias 
among survey respondents, although 80% of those who reported current 
participation in no exercise also stated an interest in research participation. The 
discrepancy between signalled interest and actual uptake may represent 
difference in attitudes between respondents versus those approached for the 
intervention study. Nonetheless, this brings into question the relative usefulness 
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of small patient surveys for assessing feasibility of future interventions. The direct 
implementation of feasibility interventions with close monitoring of recruitment 
uptake and reasons for non-enrolment may be more useful for gathering 
information about the relative feasibility and acceptability data. Recruitment 
activity for the intervention is likely to have been negatively impacted by the 
Covid-19 pandemic and the lower-than-expected recruitment rate was reflective 
of this. Several prospective participants cited the pandemic as a reason for not 
enrolling and recruitment would likely have been more successful under different 
circumstances. In the small cohort who did participate, jumping based exercise 
was a feasible intervention, highlighted by the high overall adherence. Minor AEs 
were common and linked to more high-impact exercises, suggesting more 
supervision or slower progression of exercise intensity may be preferable. This 
provides useful preliminary data on jumping exercise in paediatric CD which 
should be expanded on in future as a potential intervention for improving the 
functional muscle-bone unit. 
8.2 Conclusion 
In conclusion, the data presented in this thesis has provided novel insights into 
the macro- and microarchitecture of the muscle-bone unit in contemporary 
cohorts of children and young adults with CD, using high-resolution MRI. Despite 
advances in therapies, mild CD remains associated with adverse musculoskeletal 
outcomes, including low trabecular bone volume in paediatrics and low muscle 
mass in young adults. Poor muscle function was characteristic in these populations 
and present at increased rates and linked to an increased risk of falls in early old 
adults with CD. In all, these data further highlight associations between CD and 
poor muscle-bone outcomes and underline the need for effective strategies to 
combat this. This research will help inform the development of future prospective 
and interventional studies aiming to characterise the natural development of 
muscle and bone in young CD populations, risk of adverse musculoskeletal 
outcomes in older adults with CD, and investigation the role of exercise in 




8.3 Future directions 
The data presented can provide a framework upon which several future avenues 
of research can be based. The primary areas of research that can be expanded 
upon from this work include further development of high-resolution MRI 
assessment of bone; investigation of the underlying mechanisms for muscle 
dysfunction in CD; prospective assessment of musculoskeletal outcomes in young 
and older populations with CD; and further exploration of the feasibility and utility 
of exercise for the management of muscle-bone deficits and other secondary 
complications of CD. 
This work and previously published studies have highlighted MRI as a promising 
tool for holistically assessing the muscle-bone unit at both the macro and 
microstructural level. If MRI is to advance towards a clinically viable method of 
assessing skeletal health, there is a need to develop standardised methods of 
assessment and to explore the utility of commercially available MRI pulse 
sequences. Currently, no accepted standard for MRI assessment of bone exists, 
meaning studies - including those reported here - have implemented custom pulse 
sequences at independently selected ROIs. Here, data are reported from 15% 
distal femur; an area representative of the distal metaphysis that should be 
further developed as a standardised ROI. This ROI provides clear delineation of 
the trabecular microarchitecture and sufficient cortical geometry to make a 
combined assessment of these compartments at the same level. Other studies 
have utilised the growth plate as a reference point, which adds subjectivity to 
analyses and cannot be applied in adults. Furthermore, although uncommon in CD, 
the distal femur is a common site of major osteoporotic fracture and therefore a 
clinically relevant site for skeletal evaluation in populations with severe skeletal 
phenotypes. Further developmental work is required using high field (≥3 Tesla) 
and ultra-high field (≥7 Tesla) MRI scanners to optimise pulse sequences for 
assessment of skeletal micro and macrostructure and to identify the parameters 
that may be the most useful prognostic indicators of skeletal fragility. 
Investigations of the repeatability of longitudinal MRI scanning of bone is also 
required as there is currently no data on the variability between scans taken at 




Muscle function deficits are a consistent problem across the lifespan in CD, even 
in cohorts of mild or well controlled disease managed with contemporary 
therapies. Historically, GC exposure and inflammation have been implicated in CD 
muscle dysfunction as these are known catabolic factors. However, particularly in 
young populations, contemporary management increasingly involves the use of 
anti-cytokine antibodies for induction and maintenance therapy, and very limited 
GC exposure. In these cohorts, therefore, it is unclear whether subclinical 
inflammatory activity contributes to skeletal dysfunction or whether other 
unknown factors are involved. Detailed assessments of skeletal muscle in a range 
of CD populations including young and old, and treated and non-treated, may 
provide insight into potential mechanisms of muscle dysfunction that could 
become therapeutic targets in future.  
The current studies revealed various degree of musculoskeletal abnormality in 
separate cohorts of CD. What remains unknown, is the natural history of 
musculoskeletal development in children diagnosed with CD. Some studies suggest 
a potentially protracted period of skeletal growth in children with well controlled 
CD, potentially facilitating the improvement of any previously incurred 
musculoskeletal deficits. To adequately assess this, a large prospective study of 
muscle-bone assessment in children diagnosed with CD into young adulthood 
would be required. The use of MRI as a repeat assessment tool could be applied 
to such a study due to its lack of ionising radiation and ability to assess multiple 
components of muscle-bone in a single series of scans. This would provide insight 
into the longitudinal changes of bone and muscle in children with CD and how 
these relate to clinical and environmental factors. 
The future projected increases in CD prevalence, particularly older patients, 
underlines the necessity to understand the risk of adverse musculoskeletal 
outcomes and their effects on daily living in this population. The use of population 
databases such as the clinical practice research datalink would provide access to 
prospectively study a non-selected cohort of CD patients with comprehensive 
primary care and linked data, including prescriptions and hospital episode 
statistics. Such studies may be able to provide perspective into clinical risk factors 
of CD that are associated with poor bone and muscle in older adults and how these 
relate to activities of daily living. 
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The preliminary data on exercise feasibility reported here should be built upon in 
future studies. Particularly, the effects of jumping and resistance exercise should 
be explored as a method for augmenting muscle-bone development and function 
in young CD populations. The potential added benefit of PA or exercise for 
improving bone and muscle mass could be assessed in observational or 
intervention studies. For example, a prospective cohort study of paediatric CD 
enrolled at the time of anti-TNF-α induction and followed up for 12 to 24 months 
with periodic assessment of habitual PA by accelerometry. This format of study 
has been successfully implemented previously when assessing the independent 
effects of treatment on muscle-bone outcomes in CD, and the addition of habitual 
PA monitoring could be easily implemented. A more ambitious study may involve 
a randomised controlled trial of resistance and impact exercise versus standard 
care in young people with CD at the point of transitioning to maintenance anti-
TNF therapy. Not only would this provide data on the effects of exercise for 
improving muscle-bone but could also provide insight into the potential 
interactions between exercise and pharmacotherapy. The current lack of data 
regarding the role of exercise in the management of CD means this should be an 
active area of investigation not only for improving muscle-bone outcomes, but 




Appendix 1: Roles and responsibilities within each study/chapter. 
 
Chapter 2: Paediatric MRI study. 
 
- Study design (LS & Dr Jarod Wong)  
- Submission for ethical and R&D approval (LS) 
- Recruitment of CD group (LS & Paediatric IBD Team at RHC, Glasgow) 
- Recruitment of healthy controls (Dr Huda Elsharkasi [for separate MRI 
study]) 
- Study visits and data collection (LS) 
- Blood samples (Research nurses at CRF) 
- MRI Scans (Research radiographers) 
- MATLAB code for MRI analyses (Dr Blair Johnston, Dr Christie McComb & Dr 
John Foster, NHSGGC Medical Physics) 
- All MRI & MRS analyses (LS) 
- Data curation and statistical analyses (LS) 
- Write up (LS) 
 
Chapter 3: Young adult MRI study. 
 
- Study design (Jarod Wong) 
- Ethical & R&D approvals (Jarod Wong) 
- Recruitment (Jan – Sept 2017 = research nurses; Oct 2017 onwards = LS) 
- Study visits and data collection (LS and Research nurses at CRF) 
- Blood samples (Research nurses at CRF) 
- Biochemical analyses of blood samples (LS and Martin McMillan) 
- MRI Scans (Research radiographers) 
- MATLAB code for MRI analyses (Dr Blair Johnston, Dr Christie McComb & Dr 
John Foster, NHSGGC Medical Physics) 
- All MRI & MRS analyses (LS) 
- Data curation and statistical analyses (LS) 
- Write up (LS) 
 
Chapter 4: Associations between IBD and musculoskeletal outcomes. 
 
- UK Biobank study design, approvals, & data collection (UK Biobank) 
- Design and analysis conception (LS) 
- Data curation and cleaning (LS) 
- Statistical analyses (LS) 
- Write up (LS) 
 
Chapter 5: Systematic review of exercise in IBD. 
 
- Study conception and design (LS) 
- Search strategy development (LS) 
- Literature searches (LS) 
- Study assessment and selection for review (LS) 
- Study quality assessment (LS [primary], Jarod Wong [secondary, for 
quality control]) 




Chapter 6: Feasibility questionnaire. 
 
- Study conception and design (LS, Jarod Wong & Stuart Gray) 
- Questionnaire development (LS) 
- Questionnaire content validity check (Paediatric & Adult 
Gastroenterologists) 
- Questionnaire readability (paediatric & adult laypersons) 
- Data collection (LS) 
- Data curation and analyses (LS) 
- Write up (LS) 
 
Chapter 7: Feasibility of jumping based exercise in paediatric CD 
 
- Study conception and design (LS, Jarod Wong & Stuart Gray) 
- Ethical & R&D approvals (LS) 
- Recruitment (LS & Paediatric IBD Research nurse) 
- Study visits & data collection (LS) 
- Data curation and analyses (LS) 




Appendix 2: Systematic Review Search Strategy (Chapter 5) 
 
EMBASE (1996 to 2021 Week 14) 
1. exp inflammatory bowel disease/  
2. exp Crohn disease/  
3. exp ulcerative colitis/  
4. (inflammatory bowel disease or ibd or ulcerative colitis or crohn* disease).tw. 
5. 1 or 2 or 3 or 4  
6. exp exercise/  
7. exp kinesiotherapy/  
8. exp fitness/  
9. exp exercise test/  
10. exp physical activity/  
11. exp sport/  
12. (exercis* or physical activit*).tw.  
13. 6 or 7 or 8 or 9 or 10 or 11 or 12  
14. clinical trial/  
15. exp controlled clinical trial/  
16. exp case control study/  
17. exp pilot study/ 
18. "review"/  
19. intervention.tw.  
20. (randomi* control* trial or RCT).tw.  
21. 14 or 15 or 16 or 17 or 18 or 19 or 20  
22. 5 and 13 and 21 
Results – 605 
 
MEDLINE (1946 to April Week 2 2021) 
1. exp Inflammatory Bowel Diseases/  
2. exp Crohn Disease/  
3. exp Colitis, Ulcerative/  
4. (inflammatory bowel disease* or ibd or ulcerative colitis or crohn* 
disease).tw. 
5. 1 or 2 or 3 or 4  
6. exp EXERCISE/  
7. exp Exercise Therapy/  
8. exp Exercise Movement Techniques/  
9. exp Physical Fitness/  
10. exp Exercise Test/  
11. exp SPORTS/  
12. (exercis* or physical activit*).tw.  
13. 6 or 7 or 8 or 9 or 10 or 11 or 12  
14. exp Clinical Trial/  
15. exp Controlled Clinical Trial/  
16. exp Pilot Projects/  
17. exp Case-Control Studies/  
18. exp "REVIEW"/  
19. intervention.tw.  
20. (randomi* control* trial or RCT).tw.  
21. exp Prospective Studies/  
22. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21  
23. 5 and 13 and 22 
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Results – 233 
 
COCHRANE Database (Issue 3 of 12, March 2021) 
          
#1 MeSH descriptor: [Inflammatory Bowel Diseases] explode all trees  
#2 MeSH descriptor: [Crohn Disease] explode all trees    
#3 MeSH descriptor: [Colitis, Ulcerative] explode all trees   
#4 (inflammatory bowel disease* or IBD or crohn* disease or ulcerative 
colitis):ti,ab            
#5 #1 or #2 or #3 or #4         
#6 MeSH descriptor: [Exercise] explode all trees     
#7 MeSH descriptor: [Exercise Movement Techniques] explode all trees 
#8 MeSH descriptor: [Exercise Test] explode all trees    
#9 MeSH descriptor: [Exercise Therapy] explode all trees   
#10 MeSH descriptor: [Physical Fitness] explode all trees    
#11 MeSH descriptor: [Sports] explode all trees     
#12 (exercis* or physical activit*):ti,ab       
#13 #6 or #7 or #8 or #9 or #10 or #11 or #12      
#14 #5 and #13           
Results – 270 
 
CINAHL (Searched 18/04/2021) 
1. (MH "Inflammatory Bowel Diseases+") 
2. (MH "Crohn Disease") 
3. (MH "Colitis, Ulcerative") 
4. TI(inflammatory bowel disease* or ibd or ulcerative colitis or crohn* disease) 
OR AB(inflammatory bowel disease* or ibd or ulcerative colitis or crohn* disease) 
5. S1 OR S2 OR S3 OR S4 
6. (MH "Exercise+") 
7. (MH "Therapeutic Exercise+") 
8. (MH "Exercise Test+") 
9. (MH "Physical Fitness+") 
10. (MH "Exercise Physiology+") 
11. (MH "Sports+") 
12. (MH "Physical Activity") 
13. TI exercis* OR AB exercis* 
14. TI physical activit* OR AB physical activit* 
15. S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 
16. S5 AND S15 




Appendix 3: Questionnaires for feasibility of high-impact exercise (Chapter 6) 
 
Survey on Exercise and Crohn’s Disease 
(Young people with Crohn’s [13 – 17 years]) 
 
 
People with Crohn's disease are at risk of poor bone and muscle health. We know that 
exercise is good for bone and muscle health, but we don't know if exercise has the same 
benefits for people with Crohn's disease. 
 
We hope to design some research studies investigating the effects exercise in people 
with Crohn's disease. Before we do this, we would like to know the opinions of people 
with Crohn's towards taking part in this type of exercise. These opinions will be very 
helpful when designing our research. 
 
Q1. Do you have Crohn’s disease?   
 
Yes  
No   (if you answered ‘no’, please do not complete this survey) 
 
 
Q2. How old are you? (e.g. 14 years, 7 months)   
 
____________________ years ___________ months 
 
 
Q3. At what age were you diagnosed with Crohn’s disease? (e.g. 11 years, 6 
months) 
 
 ____________________ years ___________ months 
 
 
Q4.  Are you:   
 
Male    
Female   
 
Q5.  What medications are you currently taking for your Crohn’s disease? (Tick all 
that apply. If you are taking a medication that is not listed, write it in the box below.) 
 
Prednisolone      
Mercaptopurine/Azathioprine   
Methotrexate      
Infliximab      
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Adalimumab      
Mesalasine (e.g. Pentasa, Salofalk)   
Nutritional Supplements    
Other (please specify)    
 
___________________________________________________ 
    
 
Q6. How many surgeries have you had for your Crohn’s disease? 
 
None     
One     
Two     
More than two   
 
 
Q7. How would you rate your general wellbeing? 
 
Very well    
Slightly below average  
Poor     
Very poor    
Terrible    
 
 
Q8.  How would you rate the overall control of your Crohn’s disease in the past 
3 months? 
 




Q9.  How concerned are you about your bone health? 
 
Not concerned   
Slightly concerned   
Very concerned   
 
 
Q10. We will now ask some questions about your exercise habits, and how 
exercising makes you feel. Please answer as honestly as possible. 
 
Not including during school time, in a typical week which of the following 
exercises do you do? (Tick all that apply. If you do a type of exercise that is not listed, 




   Walking/Hiking for leisure     
   Jogging/Running      
Cycling       
   Team sports (i.e. football, hockey, rugby etc.)  
   Resistance training (i.e. lifting weights)   
   I don’t do any exercise     
Other (explain below)     
 
   ________________________________________________________ 
 
 
Q11. Does your Crohn’s disease make it harder for you to exercise? 
 
   Yes      if yes, go to Q12 
   No     if no, go to Q13 
   
 
Q12.  If you answered ‘Yes’ to Q11, is it harder for you to exercise because of any 
the following reasons? (Tick all that apply. If you think of a reason that is not listed, 
please write it below.) 
 
   Joint pain     
   Muscle weakness    
   Tiredness/fatigue    
   Embarrassment    
   Lack of access to toilet   
   Painful stomach/abdomen   




Q13.  When you take part in exercise, does it make you feel BETTER in any of the 
following ways? (Tick all that apply. If you think of something not listed, please write it 
below.) 
 
I have more energy       
I feel stronger/fitter       
I feel less tired/fatigued      
I have less joint pain      
I have less abdominal pain     
It improves my mood     
Exercise doesn’t make me feel any better   







Q14. When you take part in exercise, does it make you feel WORSE in any of the 
following ways? (Tick all that apply. If you think of something that is not listed, please 
write it below.) 
 
   I feel more tired      
   I feel weak       
I have more joint pain     
   I have increased need for the toilet    
   I have more stomach/abdominal pain   
   It makes me embarrassed     
   Exercise doesn’t make me feel any worse   
   Other (explain below)      
 
   ____________________________________________________________ 
    
 
Q15.  We are investigating whether exercise may be a useful treatment for 
people with Crohn’s disease. We are going to carry out come research studies to 
see if certain types of exercise benefit people with Crohn’s. 
 
The following questions will ask your opinions about this type of exercise, and 
your thoughts about taking part in future research studies. 
 
Not including during school time, how many times per week do you think you 
would be able to set aside 30 minutes for exercise? 
    
   None     
   1 or 2 times    
   3 or 4 times    
   More than times   
    
 
Q16. Please follow the link below to watch a short video demonstrating the type 
of exercise we are investigating. Please watch the video then answer the 
following questions. 
 
[VIDEO LINK HERE] 
 
How easy do you think it would be to participate in exercise like this, three times 
per week?  
 







Q17. Do you think the opportunity of improving your health is worth doing this 
type of exercise three times per week? 
 
    Yes     
    No     
 
 
Q18.  Would you be interested in taking part in a research study looking at the 
effects of this type of exercise in people with Crohn’s disease? 
 
    Yes     
    No     
 
 
Q19. Can you think of any problems you might face if you were trying to 







Q20. Do you have any additional comments that you would like to make 














Survey on Exercise and Crohn’s Disease 
(Adults with Crohn’s [18 years+]) 
 
 
People with Crohn's disease are at risk of poor bone and muscle health. We know that 
exercise is good for bone and muscle health, but we don't know if exercise has the same 
benefits for people with Crohn's disease. 
 
We hope to design some research studies investigating the effects exercise in people 
with Crohn's disease. Before we do this, we would like to know the opinions of people 
with Crohn's towards taking part in this type of exercise. These opinions will be very 
helpful when designing our research. 
 
Q1. Do you have Crohn’s disease?   
 
Yes  
No   (if you answered ‘no’, please do not complete this survey) 
 
 





Q3. At what age were you diagnosed with Crohn’s disease? (e.g. 14 years) 
 
 ____________________  
 
 
Q4.  Are you:   
 
Male    
Female   
Transgender   
Gender Neutral  
 
Q5.  What medications are you currently taking for your Crohn’s disease? (Tick all 
that apply. If you are taking a medication that is not listed, write it in the box below.) 
 
Prednisolone      
Mercaptopurine/Azathioprine   
Methotrexate      
Infliximab      
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Adalimumab      
Mesalasine (e.g. Pentasa, Salofalk)   
Nutritional Supplements    
Other (please specify)    
 
___________________________________________________ 
    
 
Q6. How many surgeries have you had for your Crohn’s disease? 
 
None     
One     
Two     
More than two   
 
 
Q7. How would you rate your general wellbeing? 
 
Very well    
Slightly below average  
Poor     
Very poor    
Terrible    
 
 
Q8.  How would you rate the overall control of your Crohn’s disease in the past 
3 months? 
 




Q9.  How concerned are you about your bone health? 
 
Not concerned   
Slightly concerned   
Very concerned   
 
Q10. We will now ask some questions about your exercise habits, and how 
exercising makes you feel. Please answer as honestly as possible. 
 
In a typical week, which of the following exercises do you do? (Tick all that apply. 
If you do a type of exercise that is not listed, please write it below.) 
 
   Walking/Hiking for leisure     
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   Jogging/Running      
Cycling       
   Team sports (i.e. football, hockey, rugby etc.)  
   Resistance training (i.e. lifting weights)   
   I don’t do any exercise     
Other (explain below)     
 
   ________________________________________________________ 
 
 
Q11. Does your Crohn’s disease make it harder for you to exercise? 
 
   Yes      if yes, go to Q12 
   No     if no, go to Q13 
   
 
Q12.  If you answered ‘Yes’ to Q11, is it harder for you to exercise because of any 
the following reasons? (Tick all that apply. If you think of a reason that is not listed, 
please write it below.) 
 
   Joint pain     
   Muscle weakness    
   Tiredness/fatigue    
   Embarrassment    
   Lack of access to toilet   
   Painful stomach/abdomen   




Q13.  When you take part in exercise, does it make you feel BETTER in any of the 
following ways? (Tick all that apply. If you think of something not listed, please write it 
below.) 
 
I have more energy       
I feel stronger/fitter       
I feel less tired/fatigued      
I have less joint pain      
I have less abdominal pain     
It improves my mood     
Exercise doesn’t make me feel any better   







Q14. When you take part in exercise, does it make you feel WORSE in any of the 
following ways? (Tick all that apply. If you think of something that is not listed, please 
write it below.) 
 
   I feel more tired      
   I feel weak       
I have more joint pain     
   I have increased need for the toilet    
   I have more stomach/abdominal pain   
   It makes me embarrassed     
   Exercise doesn’t make me feel any worse   
   Other (explain below)      
 
   ____________________________________________________________ 
    
 
Q15.  We are investigating whether exercise may be a useful treatment for 
people with Crohn’s disease. We are going to carry out come research studies to 
see if certain types of exercise benefit people with Crohn’s. 
 
The following questions will ask your opinions about this type of exercise, and 
your thoughts about taking part in future research studies. 
 
How many times per week do you think you would be able to set aside 30 minutes 
for exercise? 
    
   None     
   1 or 2 times    
   3 or 4 times    
   More than times   
    
 
Q16. Please follow the link below to watch a short video demonstrating the type 
of exercise we are investigating. Please watch the video then answer the 
following questions. 
 
[VIDEO LINK HERE] 
 
How easy do you think it would be to participate in exercise like this, three times 
per week?  
 







Q17. Do you think the opportunity of improving your health is worth doing this 
type of exercise three times per week? 
 
    Yes     
    No     
 
 
Q18.  Would you be interested in taking part in a research study looking at the 
effects of this type of exercise in people with Crohn’s disease? 
 
    Yes     
    No     
 
 
Q19. Can you think of any problems you might face if you were trying to 







Q20. Do you have any additional comments that you would like to make 
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